CLINICAL STUDY PROTOCOL
Study Title: A Phase 2, Randomized, Double- Blind, Placebo- Controlled,
Multi -center Study  to Evaluate the Safety , Tolerability  and Antiviral 
Activity  of G S-9688 in Virally -Suppressed Adult Subjects with 
Chronic Hepatitis B
Sponsor: Gilead Sciences, Inc.
333 L akeside Drive
Foster City , CA 94404
IND Number :
ClinicalTrials.gov 
Identifier:129387
[STUDY_ID_REMOVED]
Indication: Chronic Hepatitis B 
Protocol ID: GS-US-389-2024
Gilead Medical 
Monitor :Name:
Telephone:
Mobile:
Fax:
Protocol Version/Date: Original : 15 January  2018
Amendment 1 13March 2018
Amendment 2 15February 2019
Amendment 2.1 27 August 2019
CONFIDENTIALITY STAT EMENT
The information contained in this document, particularly unpublished data, is the propert y or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review b y you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The information is only  to be used by  you in 
connection with authorized clinical studies of th e investigational drug described in the protocol. 
You will not disclose any of the information to others without written authorization from 
Gilead Sciences, Inc., except to the extent necessary  to obtain informed consent from those 
persons to whom the drug may be administered.
PPD
PPD
PPD
PPD(rJ GILEAiJ 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 2 27 August 2019TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABL ES........................................................................................................................................ 5
LIST OF IN-T EXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 23
1. INTRODUCTION .............................................................................................................................................. 27
1.1. Background ............................................................................................................................................ 27
1.2. GS-9688 ................................................................................................................................................. 28
1.2.1. General Infor mation ............................................................................................................. 28
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 28
1.2.3. Genotoxicity ......................................................................................................................... 30
1.2.4. Safety Pharmacology ............................................................................................................ 30
1.2.5. Nonclinical Pharmacology ................................................................................................... 31
1.2.6. Clinical Trials of GS -9688 ................................................................................................... 32
1.3. Rationale for This Study ........................................................................................................................ 40
1.3.1. GS-9688 for Treatment of Virally -Suppressed Subjects with Chronic 
Hepatitis B ............................................................................................................................ 40
1.3.2. Rationale for the Dose Selection .......................................................................................... 40
1.3.3. Rationale for Treatment Duration ........................................................................................ 41
1.4. Risk/Benefit Assessment for the Study .................................................................................................. 42
1.4.1. .............................................. 43
1.5. Com pliance ............................................................................................................................................ 43
2. OBJECTIVES ..................................................................................................................................................... 44
3. STUDY DESIGN ................................................................................................................................................ 46
3.1. Study Design .......................................................................................................................................... 46
3.2. Study Treatments ................................................................................................................................... 46
3.3. Duration of Treatment ............................................................................................................................ 48
3.4. Pharm acokinetic Assessment ................................................................................................................. 48
3.5. Pharm acody namic Assessments ............................................................................................................. 48
3.6. Biomarker Testing .................................................................................................................................. 48
3.6.1. Biomarker Samples to Address the Study Objectives: ......................................................... 48
3.6.2. Samples for Optional Future Research ................................................................................. 49
3.6.3. Sample for Optional Genomic Research .............................................................................. 49
3.7. End of Study ........................................................................................................................................... 49
4. SUBJECT POPULATION .................................................................................................................................. 50
4.1. Number of Subjects and Subject Selection ............................................................................................ 50
4.2. Inclusion Criteria .................................................................................................................................... 50
4.3. Exclusion Criteria ................................................................................................................................... 51
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 53
5.1. Randomization, Blinding and Treatment Codes .................................................................................... 53
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 53
5.2. Description and Handling of GS -9688 and Placebo to Match ............................................................... 54
5.2.1. Form ulation .......................................................................................................................... 54
5.2.2. Packaging and Labeling ....................................................................................................... 54
5.2.3. Storage and Handling ........................................................................................................... 54
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 3 27 August 20195.3. Dosage and Administration of GS -9688 ................................................................................................ 55
5.4. Fasting State Dosing .............................................................................................................................. 55
5.5. Concomitant Medications ...................................................................................................................... 55
5.6. Accountability for GS -9688 ................................................................................................................... 57
5.7. Investigation Medicinal Product Return or Disposal ............................................................................. 58
6. STUDY PROCEDURES .................................................................................................................................... 59
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 59
6.2. Pretreatment Assessments ...................................................................................................................... 59
6.2.1. Screening Visit (Window of -30 Days) ................................................................................ 59
6.3. On-Treatment Assessments (All Visits Have Window  of ± 1 Days) ..................................................... 60
6.3.1. .............................................. 62
6.4. Post-Treatment Assessments (All Visits Have Window  of ± 3 Days except Week 24 ± 1 Day) ........... 63
6.5. Treatment Free Follow -up (TFFU) Visit Assessments ( ± 7 Days) ........................................................ 64
6.5.1. ............................................ 65
6.6. Unscheduled Visits ................................................................................................................................. 65
6.7. Pharm acokinetic Assessments ................................................................................................................ 65
6.7.1. ............................................... 65
6.8. Pharm acody namic Assessments ............................................................................................................. 66
6.8.1. ............................................ 67
6.8.2. TruCulture Samples .............................................................................................................. 68
6.9. Safety Assessments ................................................................................................................................ 69
6.9.1. Electrocardiogram Assessment ............................................................................................ 69
6.9.2. Holter Monitoring ................................................................................................................ 69
6.9.3. Physical Examination ........................................................................................................... 70
6.9.4. Vital Signs ............................................................................................................................ 70
6.9.5. Clinical Laboratory Tests/Assessments for Safety Evaluations ........................................... 70
6.9.6. Creatinine Clearance ............................................................................................................ 71
6.9.7. Ophthalmic Examination ...................................................................................................... 71
6.9.8. Adverse Events/Concomitant Medications/Protocol Restrictions ........................................ 72
6.10. Sample Storage ....................................................................................................................................... 72
6.11. Assessments for Premature Discontinuation from Study ....................................................................... 72
6.12. Criteria for Discontinuation of Study Treatment .................................................................................... 72
6.13. Resistance Surveillance .......................................................................................................................... 73
6.14. End of Study ........................................................................................................................................... 73
6.15. Post Stu dy Care ...................................................................................................................................... 73
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 74
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 74
7.1.1. Adverse Events ..................................................................................................................... 74
7.1.2. Serio us Adverse Events ........................................................................................................ 74
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 75
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 75
7.2.2. Assessment of Severity ........................................................................................................ 76
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 76
7.3.1. Adverse Events ..................................................................................................................... 76
7.3.2. Serious Adverse Event s........................................................................................................ 76
7.4. Gilead Reporting Requirements ............................................................................................................. 78
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events .......................................................................................................................... 78
7.6. Toxicity Management ............................................................................................................................ 79
7.6.1. ALT Elevation or Flare Management ................................................................................... 79
7.6.2. Management of Dose Limiting Toxicities ............................................................................ 80
CCI
CCI
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 4 27 August 20197.6.3. Management of Neutropenia ................................................................................................ 80
7.6.4. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 81
7.6.5. Grades 3 and 4 Laboratory Abnormality or Clinical Event .................................................. 81
7.7. Other Criteria for Discontinuation of Study Drug .................................................................................. 81
7.8. Subject Withdraw al Criteria ................................................................................................................... 82
7.9. Study Specific Stopping Criteria ............................................................................................................ 82
7.9.1. Laboratory Abnormalities and Treatment -Emergent Adverse Events .................................. 82
7.9.2. Virologic Criteria ................................................................................................................. 83
7.10. Special Situations Reports ...................................................................................................................... 83
7.10.1. Definitions of Special Situations .......................................................................................... 83
7.10.2. Instructions for Reporting Special Situations ....................................................................... 84
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 86
8.1. Analysis Objectives and Endpoints ........................................................................................................ 86
8.1.1. Analysis Objectives .............................................................................................................. 86
8.1.2. Primary Efficacy Endpoint ................................................................................................... 87
8.1.3. Secondary Efficacy Endpoints ............................................................................................. 87
8.2. Analysis Conventions ............................................................................................................................. 87
8.2.1. Analysis Sets ........................................................................................................................ 87
8.3. Data Handling Conventions ................................................................................................................... 88
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 88
8.5. Efficacy Analysis ................................................................................................................................... 88
8.5.1. Primary Analysis .................................................................................................................. 88
8.5.2. Secondary Analyses ............................................................................................................. 89
8.5.3. Analysis of Other Endpoints of Interest ............................................................................... 89
8.6. Safety Analysis ....................................................................................................................................... 89
8.6.1. Extent of Exposure ............................................................................................................... 89
8.6.2. Adverse Events ..................................................................................................................... 89
8.6.3. Laboratory Evaluations ........................................................................................................ 90
8.6.4. Other Safety Evaluations ...................................................................................................... 91
8.7. Pharm acokinetic Analysis ...................................................................................................................... 91
8.8. Exploratory Analysis .............................................................................................................................. 91
8.9. Sample Size ............................................................................................................................................ 92
8.10. Data Monitoring Committee .................................................................................................................. 92
8.11. Internal Data Review Team .................................................................................................................... 92
9. RESPONSIBILITES ........................................................................................................................................... 93
9.1. Investiga tor Responsibilities .................................................................................................................. 93
9.1.1. Good Clinical Practice .......................................................................................................... 93
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... 93
9.1.3. Informed Consent ................................................................................................................. 93
9.1.4. Confidentiality ...................................................................................................................... 94
9.1.5. Study Files and Retention of Records .................................................................................. 94
9.1.6. Case Report Forms ............................................................................................................... 95
9.1.7. Study Drug Accountability and Return ................................................................................ 96
9.1.8. Inspections ............................................................................................................................ 96
9.1.9. Protocol Compliance ............................................................................................................ 96
9.2. Sponsor Responsibilities ........................................................................................................................ 96
9.2.1. Protocol Modifications ......................................................................................................... 96
9.2.2. Study Report and Publications ............................................................................................. 97
9.3. Joint Investigator/Sponsor Responsibi lities ........................................................................................... 97
9.3.1. Payment Reporting ............................................................................................................... 97
9.3.2. Access to Information for Monitoring .................................................................................. 97
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 5 27 August 20199.3.3. Access to Information for Auditing or Inspections .............................................................. 97
9.3.4. Study Discontinuation .......................................................................................................... 97
10. REFERENCES ................................................................................................................................................... 98
11. APPENDICES .................................................................................................................................................. 102
Appendix 1. Investigator Signature Page .................................................................................................. 103
Appendix 2. Study Procedure Table(s) ..................................................................................................... 104
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 110
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............. 112
LIST OF IN -TEXT TABL ES
Table 1-1. GS-US-389-2021: GS -9688 Plasma Pharmacokinetic Parameters by Treatment 
Follow ing Single -Dose Adm inistration of GS -9688 in the Fasted State (Cohorts 1 to 
4) (GS -9688 PK Analysis Set) ................................
................................................................ 33
Table 1-2. GS-US-389-2021: GS -9688 Plasma Pharmacokinetic Parameters by Treatment 
Follow ing Single -Dose Adm inistration of GS -9688 in the Fasted and Fed States 
(Cohort 6) (GS -9688 PK Analysis Set) ................................
.................................................. 34
Table 1-3. GS-US-389-2022: Summary Statistics of GS -9688 Plasma Pharmacokinetic 
Parameters by Treatment Follow ing Single -or Multiple -Dose (2 or 4 Doses QW) 
Administration of GS -9688 in Subjects Who WereVirally Suppressed or Viremic 
(PK Analysis Set). ................................
.................................................................................. 36
Table 1-4. GS-US-389-3979: Statistical comparison of GS -9688 Pharmacokinetic Parameters 
following single dose administration of GS -9688 in the presence of probe drug (Day 
8) and GS -9688 alone (Day 1). ................................
............................................................... 39
Table 5-1. List of Agents Disallowed ...................................................................................................... 56
LIST OF IN -TEXT FIGU RES
Figure 3-1. Study Schema ......................................................................................................................... 46
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 6 27 August 2019PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title: A Phase 2, Randomized, Double- Blind, Placebo- Controlled, 
Multi -center Study  to Evaluate the Safety , Tolerability  and Antiviral 
Activity  of GS -9688 in Virally -Suppressed Adult Subjects with 
Chronic Hepatitis B
IND Number:
ClinicalTrials.gov 
Identifier:129387
[STUDY_ID_REMOVED]
Study Centers 
Planned:Approximately  6 centers in New Zealand and the United States
Objectives: The primary objectives of this study are as follows:
To evaluate the safet y and tolerability  of multiple oral doses of
GS-9688 at Week 24 in virally  suppressed chronic hepatitis B 
(CHB) adult subjects on oral antivirals (OAV)
To evaluate the antiviral activity  of GS -9688 as measured b y the 
proportion of subjects with ≥1 log 10IU/mL  decline from baseline 
in serum quantitative hepatitis B surface antigen (qHBsAg)
at
Week 24
The secondary objectives of this study are as follows:
To evaluate the antiviral activity  of GS -9688 at Weeks 4, 8, 
12
and 48 as measured by  the proportion of subjects with 
≥1log 10IU/mL decline from baseline in serum qHBsAg
To evaluate the change in serum qHBsAg (log10 IU/mL) from 
baseline to Weeks 4, 8, 12, 24 and 48
To evaluate the proportion of subjects with HBsAg loss at 
Weeks 12, 24 and 48
To evaluate the proportion of subjects with Hepatitis B e- Antigen 
(HBeAg) loss and seroconversion at Weeks 12, 24 and 48
To characterize the pharmacokinetics (PK) of GS -9688 
To evaluate the proportion of subjects experiencing Hepatitis B 
virus (HBV) virologic breakthrough (2 consecutive visits of HBV 
DNA ≥69 IU/mL)
To evaluate the incidence of drug resistance mutations
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 7 27 August 2019The exploratory objectives of this study are as follows: 
Study Design: This is a multicenter, randomized, double -blind, placebo -controlled 
Phase 2 study  of GS -9688 in virally  suppressed CHB subjects on 
OAV.
Approximately  50 virall y suppressed subjects currently being treated 
with a commerciall y available OAV for CHB will be enrolled into 
two cohorts within this study  (1:1) that will run in parallel. 
Cohort 1
: HBeAg -positive CHB subjects
Cohort 2: HBeAg -negative CHB subjects
Within each cohort, approximately  25 subjects will be randomized in 
a 1:2:2 in ratio to one of the three treatment arms (A: B: C). All 
subjects will remain on their current commercially available OAV 
therap y for 48 weeks, in addition to the following treatments:
Treatment Arm A: Approximately  5 subjects will be administered 
placebo- to-match (PTM) orally  on th e same day  once a week 
(every 7days) for 24 doses 
Treatment Arm B: Approximately  10 subj ects will be administered 
GS-9688 1.5 mg orally  on th e same day  once a week (every  7days) 
for 24 doses
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 8 27 August 2019Treatment Arm C: Approximately  10 subjects will be administered 
GS-9688 3 mgorally  on th e same day  once a week (every  7days) for 
24 doses
All GS-9688 study  drug doses will be administered in fasted state.
Subjects should take their OAV treatment and other commercially  
available medications n
o earlier than 2 hours after GS- 9688/PTM 
dosing. Ondansetron dosing is allowed around GS -9688/PTM dosing; 
dosing of other antiemetics should be discussed with the Gilead 
medical monitor ( MM) forapproval. 
After the 24thdose (Week 23 visit), GS -9688/PTM will be 
discontinued. Subjects will continue being treated with their original 
commerciall y available OAV and will be followed until 
Week 48/ED . The total study  duration for each subject will be 
48weeks with up to an additiona l 48weeks if continued i nto the 
Treatment Free Follow -
up (TFFU) phase .
Following comp
letion of the 48 -week stud y period the I nvestigators 
will be responsible for assessing the need to continue study  subjects 
on treatment for CHB. At Week 48, at Principal Investigator (PI) 
discretion, subjects will be managed in one of two ways:
1)Continue in the study  for 48weeks following the discontinuation
of OAV (ie,TFFU phase ) 
2) C ontinue current standard of care CHB therapy with Week 48 
representing the last study  visit . 
At the PI ’s discretion, subject(s) in the TFFU phase may  restart 
commerciall y available CHB OAV tre atment at any  time per local 
treatment guidelines. If a subject restarts OAV therapy  for their CHB, 
TFFU visits will continue for 2 more TFFU visits or until the end of 
the TFFU phase ( Study  Week 96), whichever comes first.
The primary  anal ysis will occur after all subjects have completed 
Week 24 assessment post last dose of GS -9688/PTM or prematurely  
discontinued with the primary endpoints being the safet y and 
tolerability  of GS -9688, as well as assessment of the antiviral activit y 
of GS -9688 at Week 24 as measured b y the proportion of subjects 
with ≥1 log 10(IU/mL) decline from baseline 
in serum qHBsAg.
The study  will be unblinded to appropriate Gilead Sciences Inc. (GSI) 
study  team personnel at the time of primary  anal ysis(Week 24 
assessment) . An Internal Data Review , external to the study  team,
may be unblinded at Week 12 assessment visit to review the 
unblinded safet y and efficacy data in order to guide strategic 
decisions regarding the future of the program. Investigators and 
subjects will remai n blinded through Week 48. 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 9 27 August 2019Sample for Optional Genomic Research
 
 
Samples for Optional Future Research
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
CCI
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 10 27 August 2019Pharmacokinetic (PK) Assessments
Sparse ( pre-identified ) PK plasma sampl ingwill occur on Day  1 and 
Week 23 at pre -dose, 1, 4, and 24 hours post -dose and at Week 11 at 
pre-dose, 1, and 4 hours post -dose. 
Sparse (timed) plasma PK samples will be obtained on any  two of the 
following visits: Weeks 2, 4, 8, 12, 16, and/or 20 at pre-dose and an y 
time between 30 minutes to 4 hours post-dose.
 
 
 
All available PK data may be used fo r population PK.
Number of Subjects 
Planned:Approximately  50 subjects
Each Cohort will enroll approximately  25 subjects ( PTM: GS-9688 
1.5 mg : GS
-9688 3 mg at a ratio of 1:2:2 )
Target Population: Adult subjects with CHB who are virally  suppressed on trea tment 
with a 
commerciall y available nucleos(t)ide HBV poly merase 
inhibitor (tenofovir alafenamide, tenofovir disoproxil fumurate, 
entecavir, adefovir, lamivudine, telbivudine, either as single agents or 
in combination) for at least 6 months.
Duration of 
Treatment:GS-9688 or PTM will be administered once a week (every  7 day s) for 
24 treatment doses. Subjects will remain on their current 
commerciall y available HBV OAV for the entire 48 week duration of 
study .
At W eek 48, per PI’s discretion, subjects can continue in the TFFU 
phase for up to an additional 4 8weeks.
Diagnosis and Main 
Eligibility  Criteria:Inclusion Criteria 
Subjects must meet all of the following inclusion criteria to be 
eligible for participation in this study :
1)Must have the ability  to understand and sign a written informed 
consent form, which must be obtained prior to initiation of study  
procedures
2)Adult male and non -pregnant, non -lactating female subjects, 
18-65 years of age inclusive based on the date of the Screening 
visit
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 11 27 August 20193) Documented evidence of chronic HBV infection 
(e.g. HBsAg positive for more than 6 months) with detectable 
HBsAg levels at Screening
4)Females of childbearing potential (as defined in Appendix 3) 
must have a negative serum pregnancy  test at Screening and a 
negative urine pregnancy test at baseline prior to enrollment.
5)
Male and female subjects of childbearing potential who e ngage in 
heterosexual intercourse must agree to use protocol specified 
method(s) of contraception as described in Appendix 3.
6)Have been on 
commercially  available HBV OAV treatment(s) 
(tenofovir alafenamide, tenofovir disoproxil fumurate, entecavir, 
adefovir, lamivudine, telbivudine, either as single agents or in 
combination) for at least 6 months with no change in regimen for 
3 months prior t o screening.
7)HBV Deox yribonucleic acid (DNA) ≤ 20 IU/mL (lower limit of 
quantitation [LLOQ];  measured at least once by  local laboratory  
assessment) for 6 or more months prior to Screening
8)HBV DNA < 20 IU/mL  at Screening
9)Screening Electrocardiogram (ECG) without clinically  significant 
abnormalities and with QTcF interval (QT corrected using 
Fridericia’s formula) ≤450 msec for males and ≤ 470 msec for 
females.
10)Must be willing and able to comply  with all study  requirements
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to 
be enrolled in this study :
1)Extensive bridging fibrosis or cirrhosis as defined clinically , by 
imaging or b y the following:
a)Metavir ≥ 3 or Ishak fibrosis score ≥ 4 by  a liver biopsy  
within 3 y earsof screening, or, in the absence of an 
appropriate liver biopsy , either:
b)Screening FibroTest score of > 0.48 and APRI  > 1, or
c)Historic FibroScan with a result > 9 kPa within ≤ 6 months of 
screening (if available)
If liver biops y is available, the liver bi opsy result 
supersedes (b) and/or (c, if available)
If an appropriate liver biopsy  is not available, fibrosis will 
be evaluated b y (b) and/or (c, if available). In the event of 
discordance between (b) and (c), the FibroScan results 
will take precedence
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 12 27 August 20192)Subjects meeting an y of the following laboratory  parameters at 
screening:
a)Hemoglobin < 12 g/dL (for males) or <11 g/dL  (for females)
b)White Blood cell count < 2500 cells/mm3
c)Neutrophil count < 1500 cell s/mm3(or < 1000 cell s/mm3if 
considered a ph ysiologica l variant in a subject of African 
descent)
d) A lanine aminotransferase (ALT) >3x Upper Limit of Normal 
(ULN) 
e)International normalized ratio (INR)> ULN unless the subject 
is stable on an anticoagulant regimen affecting INR
f)Albumin < 3.5 g/dL
g)Direct bilirubin >1.5x ULN
h) Platelet Count < 100,000/ L
i)Estimated creatinine clearance (CrCl) < 60 mL/min (using the 
Cockcroft -Gault method) based on serum creatinine and 
actual bod y weight as measured at the screening evaluation, 
i.e.,
Male: (140 –Age [y ears]) (Weight [kg]) CrCl (mL /min)
72(Serum Creatinine [mg/dL ])
Female: (140 –Age [y ears]) (Weight [kg])  0.85 CrCl (mL/min)
72(Serum Creatinine [mg/dL ])
3)Co-infection with human immunodeficiency  virus (HIV), 
hepatitis C virus (HCV) or hepatitis D virus (HDV)
Subjects who are HCV Ab positive, but have a documented 
negative HCV RNA, are eligible
4)Prior history  of hepatocellular carcinoma (HCC) (e.g. as 
evidenced b y prior imaging) or screening alpha -fetoprotein 
(AFP) ≥ 50 ng/mL without imaging to rule out HCC
5)Malignancy  within 5 y ears prior to screening, with the exception 
of specific cancers that are cured b y surgical resection (e.g. basal 
cell skin cancer). Subjects under evaluation for possible 
malignancy  are not eligible
6) Significant cardiovascular, pulmonary , or neurological disease in 
the opinion of the investigator
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 13 27 August 20197)Diagnosis of autoimmune disease (e.g., s ystemic lupus 
erythematosus, rheumatoid arthritis, inflammatory bowel disease, 
autoimmune hepatitis, sarcoidosis, psoriasis of greater than mi ld 
severit y, autoimmune uveitis), poorly controlled diabetes 
mellitus, significant psy chiatric illness, severe chronic obstructive 
pulmonary  disease (COPD), hemoglobinopathy , retinal disease, 
or are immunosuppressed
8) Chronic liver disease of a non- HBV etiol ogy (e.g. Wilson’s 
disease, hemochromatosis, alpha -
1-antitry psin deficiency , 
cholangitis
, nonalcoholic steatohepatitis ), except for 
non-alcoholic fatty  liver disease
9)
Received solid organ or bone marrow transplant 
10)Received prolonged systemic therap y with immunomodulators 
(e.g. corticosteroids) or biologics (e.g. monoclonal antibody , 
interferon) within 3 months of screening
11) Use of another investigational agent within 90 days of screening, 
unless allowed b y the Sponsor
12)Current alcohol or substance abuse judg ed by the investigator to 
potentially  interfere with subject compliance
13)Known hy persensitivity  to study  drug or formulation excipients
14)Women who are breastfeeding, pregnant or who wish to become 
pregnant during the course of the study
15)Female subjects unwil ling to refrain from egg donation and in 
vitro fertilization during and until at least 30 day s after the last 
study  drug dose
16)Male subjects unwilling to refrain from sperm donation during 
and until at least 90 day s after the last study  drug dose
17)Use of an y prohibited concomitant medications as described in 
Section 5.5 andTable 5-1
18)Believed b y the Study  Investigator to be inappropriate for study  
participation for an y reason not otherwise listed
Study  Procedures/
Frequency :All subjects will be required to participate in the following visits:
Screening Visit (up to 
-30days of baseline visit)
On-Treatment Period Visits: Day  1(includes post -dose 1 and 
4 hour assessments), Day 1 + 24 h ours (Day  2), Weeks 2, 4, 8, 
11(includes post -dose 1 and 4 hour assessments), 12, 16, 20, 
23(includes post -dose 1 and 4 hour assessments), and 
23 + 24 hours
Post-Study  Treatment Period: Weeks 24, 28, 36, and 48
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 14 27 August 2019Screening assessments include:
Review of inclusion/exclusion criteria
Obtain medical history  (including HBV disease and treatment 
history ) 
Obtain I nformed 
Consent,  
 
Review concomitant medications 
Complete Phy sical examination (including weight, hei ght, BMI, 
vital signs)
Safety  laboratory  tests ( serum chemistry , hematology , and 
coagulation)
12-lead ECG
Ophthalmologic exam (Day s -10 to -
1)
Qualitative HBV serology  (HBeAg [reflex Hepatitis B e -Antigen 
(HBeAb )if HBeAg is negative] and HBsAg [reflex Hepatitis B 
surface Antigen (HBsAb ) if HBsAg is negative])
HBV DNA levels and resistance surveillance sample
HBV genoty ping by  history  (if known)
Quantitative HBsAg
HCV, HDV and HIV Ab testing (with reflex testing performed if 
positive)
Fibro Test 
AFP (Imaging test required to rule out HCC for subjects with 
AFP ≥50 ng/mL)
Urinaly sis and urine drug screen
For all female subjects of child -bearing potential, serum beta 
human chorionic gonadotropin (β -hCG) 
For female subjects post -menopausal for less than two y ears, 
serum f ollicle -stimulating hormone (FSH) testing (if FSH 
< 40 mIU/mL  a serum pregnancy  test will be required)
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 15 27 August 2019On-treatment assessments
All Day  1 (baseline) tests and procedures must be completed prior to 
the receipt of the first dose of study  drug.
All Treatment Phase Assessm ents (Day  1 through 
Week 23+24hours) should be obtained pre -dose unless otherwise 
indicated:
Review of inclusion/exclusion criteria and confirm medical 
history  on Day  1
Complete pre -dose ph ysical examination (includ es weight, height, 
BMI, vital signs, concomitant medications and adverse events
[AEs]) on Day  1 and Weeks 2, 4, 8, and 12. 
Symptom directed phy sical exam (includes weight, vital signs, 
concomitant medications and AEs) on Day  2, Weeks 11, 16, 20, 
23 and 23 + 24 hours. 
Ophthalmologic exam on Week 12  (Day s -4 to +10)
In clinic GS -9688 study  drug dosing on Day  1 and Weeks 2, 4, 8, 
11, 12, 16, 20, and 23. Self/Home GS -9688 study  drug dosing on 
Weeks 1, 3, 5, 6, 7, 9, 10, 13, 14, 15, 17, 18, 19, 21, and 22.  
Study drug will be taken orally  at approximately  the same time on 
the same day  once a week (every  7 day s) for 24 doses.
Safety  laboratory  tests ( serum 
chemistry , hematology , and 
coagulation) on Day 1 and Weeks 2, 4, 8, 11, 12, 16, 20, and 23
Urinaly sis on Day  1 and Weeks 2, 4, 8, 11, 12, 16, 20, and 23
Fibro Test on Day  1
Serum β -hCG, for all female subjects of child -bearing potential 
on Day  1 and Weeks 4, 8, 12, 16, and 20
Urine Pregnancy  Test, for all female subjects of child -bearing 
potential on Day  1 and Weeks 2 and 11
HBV DNA and resistance surveillance on Day  1 and Weeks 2, 4, 
8, 11, 12, 16, 20, and 23
Qualitative HBV serology  (HBeAg [reflex HBeAb if HBeAg is 
negative] and HBsAg [reflex HBsAb if HBsAg is negative])
on 
Day 1 and Week 12
Quantitative HBsA g on Day  1 and Weeks 2, 4, 8, 11, 12, 16, 20, 
and 23
Quantitative HBeAg, HBV RNA and HBV core- related antigen 
(HBcrAg) on Day  1 and Weeks 4, 8, 12, 16, and 20
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 16 27 August 2019  
Serum and plasma PD biomarkers on Day s 1 Pre -dose, 
1 + 4 hours, 1 + 24 hours and Weeks 2, 8, 11, 11 + 4 hours, 12, 
16, 20, 23, 23 + 4 hours and 23 + 24 hours
TruCulture sample on Day 1 pre-dose
Whole blood gene expression (Paxgene RNA) samples on Day s 1
Pre-dose, 1+4hour,1 + 24 hours and  Week s 11 Pre-dose, 
11+4 hours, 12, 23, 23 +4 hours, and 23 + 24 hours
PBMC samples will be collected on Day s 1,
1 + 4 hours, 
1 + 24 hours and Weeks 11, 11 + 4 hours, 12, 23, 23 + 4 hours, 
and 23 + 24 hours
Toll-like receptor ( TLR8)SNP genot yping on Day 1 but may be 
collected at an y time during the stud y or at an y unscheduled visit
Sparse ( pre-identified ) PK plasma sampl ingwill occur on Day 1 
and Week 23 at pre -dose, 1, 4, and 24 hours post- dose and
Week 11 at pre -dose, 1, and 4 hours post -dose.
Sparse (timed) plasma PK samples will be obtained on an y two of 
the following visits: Weeks 2, 4, 8, 12, 16, and/or 20 at pre -dose 
and an y tim e between 30 minutes to 4 hours post -dose.
Holter Monitoring : 
Day 1: Pre-dose (≤ 5 minutes of dose) through 4hours, and 
24hours
Week 11: Pre -dose ( ≤ 5minutes of dose) through 4hours
Week 23: Pre -dose (≤ 5minutes of dose) through 4 hours, and 
24 hours 
  
HRQoL  Survey s (SF -36, CL DQ, and WPAI ) on Day  1 and 
Week 12
Randomization on Day  1
If a subject chooses to terminate the study  anytime during the 
treatment period, all subjects should complete allof the above 
assessments at the ED visit except for the sparse ( pre-identified )
plasma PK sample.
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 17 27 August 2019 
 
 
 
 
 
Post-study treatment assessments include the following, performed 
at all visits from Week 24 through Week 48, or in event of ED , unless 
specificall y noted:
Complete phy sical examination (includes weight, height, BMI, 
vital signs, concomitant medications and AEs)
Ophthalmologic exam on Week 24 (Day s -4 to +10
Safety  laboratory  tests ( serum chemi stry, hematology , and 
coagulation)
Urinaly sis
Fibro Test on Weeks 24 and 48/ED
Serum β -hCG, for all female subjects of child -bearing potential
HBV DNA levels and resistance surveillance samples
Qualitative HBV serology  (HBeAg [reflex HBeAb if HBeAg is 
negat ive] and HBsAg [reflex HBsAb if HBsAg is negative]) on 
Weeks 24, 36, and 48/ED
Quantitative HBsAg
Quantitative HBeAg, HBV RNA and HBcrAg 
  
Serum and plasma PD biomarkers on Weeks 24 and 28
Whole blood gene expression (PAXgene RNA) samples on 
Weeks 24 and 48/ED
PBMC samples will be collected on Weeks 24 and 48/ED
HRQoL  Survey s (SF -36, CL DQ, and WPAI ) on Weeks 24 
and48/ED
If a subject chooses to terminate the study  anytime during the 
post - treatment period, all subjects should complete all of the above 
assessments at the ED visit.
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 18 27 August 2019Test Product, Dose, 
and Mode of 
Administration:GS-9688 will be supplied as tablets in strengths of 1.5 mg. 
Treatment Arm A (PTM) : No GS -9688 tablets
Treatment Arm B ( GS-9688 1.5 mg) : 1 x GS -9688 1.5mg tablet
Treatment Arm C ( GS-9688 3 mg) : 2 x GS -9688 1.5mg tablets 
Study  drug(s) will be administered at approximately  the same time, 
on the same day , once weekl y, following an overnight fast (no food 
or drinks, except water, for at least 8 hours with no food or drinks, 
including water, for the 1 hour before dosing). After dosing, subjects 
will continue to fast (no food or drinks, including water) for 2 hours. 
After 2 hours postdose, water is a llowed and after 4 hours postdose, 
patients are allowed to eat any food or drinks. Subjects should take 
their other prescribed medications n o earlier than 2 hours after 
GS-9688/PTM dosing or, if medications require dosing with food, no 
earlier than 4 hours after GS-9688/PTM dosing. Ondansetron dosing 
is allowed around GS -9688/PTM dosing; dosing of other antiemetics 
should be discussed with the Gilead MM for approval.
Reference Therapy, 
Dose, and Mode of 
Administration:PTM GS -9688 tablets will also be supp lied and will be identical in 
size, shape, color and appearance to the active GS -9688 tablets.
Treatment Arm A ( PTM) : 2x PTM tablets
Treatment Arm B ( GS-9688 1.5 mg) : 1 x PTM tablet
Treatment Arm C ( GS-9688 3 mg) : No PTM tablets 
All study  treatments will be administered in the same manner, as 
describ ed above.
Criteria for 
Evaluation:
Safety : Safety  will be evaluated by  assessment of clinical laboratory  tests, 
ECGs /Holter monitoring , periodic phy sical examinations including 
vital signs at various time points during the stud y, including the 
TFFU Phase, and b y documentation of AEs and concomitant 
medications.
An independent, external 
Data Monitoring C ommittee (DMC) will 
review the prog ress of the study  and perform safety  data review after 
20 subjects have completed randomization. Subsequent meetings may  
be held approximately  every  3 months until the last subject enrolled 
has completed the stud y drug dosing period. The DMC will provide 
recommendations as needed regarding study  conduct and the need for 
additional meetings or an alternative meeting schedule. The DMC 
will be immediately  notified in the event of an y dose limiting 
toxicities (DL T)or virologic study  stopping criteria . 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 19 27 August 2019Grade 3 and 4 clinicall y significant laboratory  abnormalities, AL T 
elevations meeting definition of AL T flare or dose -limiting flare, and 
Grade 2 neutropenia should be confirmed b y repeat testing within 
7calendar day s of receipt of results. 
ALT Elevation or Flare Management
Subjects with on- treatment A LT flare defined as serum ALT 
> 2BL and≥ 5ULN (with or without associated symptoms) 
should be managed according to the guidance below. 
All on -treatment ALT flares should be confirmed within 3 day s of
receipt of results. During the visit, a clinical assessment of the subject 
should be performed. The assessment should include a complete 
physical examination, evaluation of the subject’s mental status and 
the following laboratory  tests: 
Laboratory  parameters: serum ALT and aspartate 
aminotransferase (AST ), alkaline phosphatase, total and 
fractionated bilirubin, gamma -glutam yl transferase (GGT), INR 
and serum albumin
If the ALT elevation/flare is confirmed, the central clinical 
laboratory  will conduct reflex testing for HBV DNA, qualitative 
HBV serology  (HBeAg [reflex HBeAb if HBeAg is negative] and 
HBsAg [reflex HBsAb if HBsAg is negative]), Hepatitis A Virus 
(HAV) immunoglobulin M (IgM), HCV RNA, HDV RNA, and 
Hepatitis E Virus ( HEV) IgM
Management of Dose Limiting Toxicities
In the event of an y DLT, the investigator should discuss with the 
Gilead Medical Monitor the subject’s status until the DLT has 
resolved.
GS-9688/PTM dosing for a subject will be held if the subject 
experiences at lea st one of the following DLTs:
A confirmed, clinically  significant lab abnormality (other than 
ALT) ≥ Grade 3 considered drug -related b y the investigator or 
Sponsor
Dose -limiting ALT flare defined as confirmed ALT ≥ 10x ULN
If a subject experiences any  of the above DLT s, then GS -9688/PTM 
will be held until repeat labs demonstrate that the lab abnormalit y 
returns to 
≤ Grade 2 levels. Once t he lab abnormality  returns to 
≤Grade 2, GS -9688/PTM can be restarted with Gilead Medical 
Monitor consultation. Subjects who experience a dose interruption 
DLT will continue to be monitored at least once a week, or more 
frequentl y as clinically needed, until resolution.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 20 27 August 2019GS-9688/PTM dosing for a subject will be permanently  discontinued
if the subject experiences at least one of the following DLTs:
A confirmed ALT increase (i.e. grade shift or 2x previous value) 
with evidence of worsened hepatic f unction (e.g. Total Bilirubin 
>2mg/dL above BL, elevated INR ≥ 1.7 or > 0.5 over BL, 
abnorm al serum albumin > 1g/dL decrease from BL)
Prolonged (2 sequential), confirmed, clinically  significant lab 
abnormality  (other than AL T) ≥ Grade 3 considered drug -related 
by the investigator
Any confirmed recurrence of study  drug -related Grade 3 or 
4clinically  significant laboratory  adverse event following dose 
interruption mandates permanent discontinuation of study  drug.
A confirmed ≥ Grade 3 AE (excluding ALT) considered 
drug-related b y the investigator
Subjects who experience a permanent discontin uation DL T will 
be monitored at least once a week, or more frequently  as 
clinically  needed, until resolution .
Other Criteria for Discontinuation of Study Drug
Intercurrent illness that would, in the judgment of the 
investigator, affect assessments of clini cal status to a significant 
degree
Unacceptable toxicity  or toxicity  that, in the judgment of the 
investigator, compromises the ability  to continue study -specific 
procedures or is considered to not be in the subject’s best interest 
Subject requests to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study  
Investigator discretion
Discontinuation of the study  at the request of Gilead, a regulatory  
agency  or an institutional review board (IRB) or independent 
ethics committee (IEC)
Contin uation of dosing will be suspended if three or more 
Grade 3 or two or more Grade 4treatment- emergent, drug related 
AEs or laboratory  abnormalities occur. Decisions to reinitiate 
continuation of dosing will be made by  the Sponsor upon review 
of all safet y data generated by  subjects dosed to date.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 21 27 August 2019Efficacy: The primary efficacy endpoint is:
Proportion of subjects with ≥ 1 log 10IU/mL  decline in serum 
qHBsAg from baseline at Week 24
The secondary efficacy endpoints are: 
Proportion of subjects with ≥ 1 log 10IU/mL  decline in serum 
qHBsAg from baseline at Weeks 4, 8, 12 and 48
Change in serum qHBsAg (log 10IU/mL) from baseline at 
Weeks 4, 8, 12, 24 and 48
Proportion of subjects with HBsAg loss at Weeks 12, 24 and 48
Proportion of subjects with HBeAg loss and s eroconversion at 
Weeks 12, 24 and 48
Proportion of subjects with virologic breakthrough (2 consecutive 
visits of HBV DNA ≥ 69 IU/mL )
Proportion of subjects with drug resistance mutations
Statistical Methods: The primary  efficacy  endpoint is the proportion of subjects with 
≥ 1log 10IU/mL decline in qHBsAg from baseline atWeek 24. The 
primary  anal ysis will be performed in all randomized and treated 
subjects after the last subject has completed Week 24 assessments or 
discontinued prematurel y. To compare the GS-9688 1.5 mg group
and the GS -9688 3 mg group to the PTM group for HBeAg positive 
and negative subjects separatel y, the 95% confidence intervals (CI)
on the proportion difference ( 1.5 mg –PTM
, 3mg -PTM) will be 
constructed, b y baseline HBeAg status (positive, negative), based on 
the standardized statistic and inverting 2 1 -sided tests.  
The secondary  endpoints include the proportion of subjects with 
≥ 1log 10IU/mL decline in HBsAg from baseline at Weeks 4, 8, 
12 and 48; the proportion of subjects w ith HBsAg loss; the proportion 
of subjects with HBeAg loss and seroconversion; the change in 
log 10qHBsAg from baseline; the proportion of subjects with 
virologic breakthrough; the proportion of subjects with drug 
resistance mutations; and the PK parameter s. Analy sis of secondary  
efficacy  endpoints will be performed b y treatment group b y baseline 
HBeAg status (positive, negative).  
All continuous efficacy  endpoint s will be summarized using an 
8-number summary  (n, mean, standard deviation (SD) , median, 
Quar tile (Q1, Q3, minimum, and maximum). All categorical 
secondary
 endpoints will be summarized by  number and percentage 
of subjects who meet the endpoint.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 22 27 August 2019Safety  endpoints will be anal yzed by treatment arm by  the number 
and percentage of subjects with AE or laboratory  abnormalities for 
categorical values or b y the 8-number summary  (n, mean, SD, 
median, Q1, Q3, minimum, and maximum) for continuous data.
Due to the exploratory  nature of this study , the sample size was not 
determined b y any formal power calcul
ation. The number of subjects 
in each treatment arm was decided based on clinical experience.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP)
including the archiv alof essential documents.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 23 27 August 2019GLOSSARY OF ABBREVIATIONS AND DE FINITION OF TERMS
λz terminal elimination rate constant, estimated by linear regression of the terminal elimination 
phase of the log concentration versus time curve of the drug
%AUC exp percentage of AUC extrapolated betw een AUC lastandAUC inf
C degrees Celsius
F degrees Fahrenheit
AE adverse event
ALT alanine aminotransferase (previously serum glutamic pyruvic transaminase )
ANOVA analysis of variance
APTT activated partial thromboplastin time
AST aspartate aminotransferase 
AUC area under the concentration versus time curve
AUC inf area under the concentration versus time curve extrapolated to infinite time, calculated as 
AUC last+ (C last/λz)
AUC last area under the concentration versus time curve from time zero to the last q uantifiable 
concentration
AUC tau area under the concentration versus time curve over the dosing interval
BLQ below  limit of quantitation
bpm beats per minute
BUN blood urea nitrogen
CBC complete blood count
CFR Code of Federal Regulations
CHB chronic hepatitis B
CI confidence interval
CK creatine kinase
CL/F apparent oral clearance after administration of the drug:
CL/F = Dose/AUC inf, where “Dose” is the dose of the drug
Clast last observed quantifiable concentration of the drug
CrCl creatinine clearance
Cmax maximum observed concentration of drug
CPN chronic progressive nephropathy
CRF case report form
CRO clinical research organization
CSR clinical study report
Ctau observed drug concentration at the end of the dosing interval
CYP cytochrome
cccDNA covalently closed circular DNA
DDI drug-drug interaction
DLT dose limiting toxicity
DMC Data Monitoring Committee
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 24 27 August 2019DNA Deoxyribonucleic acid
DSPH Drug Safety and Public Health
EASL European Association for the Study of the Liver
ECG electrocardiogram
eCRF electronic case report form
ED early discontinuation
EDC electronic data capture
eGFR estimated glomerular filtration rate
ELISPOT enzyme -linked immunosorbent spot assay
eSAE electronic serious adverse event
ET early termination
EU European Union
FDA Food and Drug Administration
FE food effect
FIH first-in-human
FSH Follicle -Stimulating Hormone
GCP Good Clinical Practice
Gilead Gilead Sciences, Inc.
GLSM geometric least -squares mean
GLP Good Laboratory Practice
GSI Gilead Sciences, Inc.
HAV hepatitis A virus
HBcrAg hepatitis B core- related antigen 
HBeAg hepatitis B e antigen
HBsAg hepatitis B surface antigen
HBeAb hepatitis B e antibody
HBsAb hepatitis B surface antibody
HCC hepatocellular carcinoma
HCV hepatitis C virus
HDV hepatitis D virus
HED human equivalent doses
HEV hepatitis E virus
HDL high-density lipoprotein
HDPE high-density polyethylene
HIV human immunodeficiency virus
HLGT high-level group term
HLT high-level term
HRQoL Health Related Quality of Life
IB investigator’s brochure
ICF informed consent form
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 25 27 August 2019ICH International Conference on Harmonization (of Technical Requirements for Registration of 
Pharm aceuticals for Human Use)
ID identification
IEC independent eth ics committee
IFN interferon 
IgM immunoglobulin M
IL interleukin
IMP investigational medicinal product
IND investigational new drug (application)
IRB institutional review board
IMRS Interactive Mobile Response S ystem
IUD intrauterine device
IWRS Interactive Web Response System
IXRS Interactive R esponse System
LDH Lactic acid dehydrogenase
LDL low-density lipoprotein
LLT lower-level term
LLOQ lower limit of quantitation
MARCO macrophage receptor w ith collagenous structure
MCV mean corpuscular volume
mDC myeloid dendritic cells
MedDRA Medical Dictionary for Regulatory Activities
MM medical monitor
NDA new drug application
NK natural killer
NOAEL no observed adverse effect level
NSAID Nonsteroidal Anti Inflammatory Drug
OAV oral antiviral
PBMC peripheral blood mononuclear cell
PCTFE Polychlorotrifluoroethylene
PD pharmacodynamic(s)
PD-1 programmed cell death protein 1
PEG pegylated interferon -α
PG Pharm acogenomics
PHH primary human hepatocytes
PI principal investigator
PK pharmacokinetic(s)
PR interval electrocardiographic interval occurring betw een the onset of the P w ave and the 
QRS complex representing time for atrial and ventricular depolarization, respectively
PT preferred term
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 26 27 August 2019PTM placebo -to-match
PTT partial thr omboplastin time
PVC Polyvinyl chloride
PVE Pharm acovigilance and Epidemiology
QD One a day
QRS electrocardiographic deflection betw een the beginning of the Q w ave and termination of the 
S wave, representing time for ventricular depolarization
QT electrocardiographic interval betw een the beginning of the Q w ave and termination of the 
Twave, representing the time for both ventricular depolarization and repolarization to occur
QTcF QT interval corrected for heart rate using the Fridericia formulation
RBC red blood cell
RNA Ribonucleic acid
SAD single ascending dose
SADR serious adverse drug reaction
SAE serious adverse event
SNP single nucleotide polymorphism
SOC system organ class
SOP standard operating procedure
SUSAR suspected unexpected serious adverse reaction
TEAE treatment -emergent adverse event
TFFU Treatment F ree F ollow -up
Tlast time (observed time point) of C last
Tmax the time (observed time point) of C max
TG Triglyceride
TLR Toll-like receptor
TNF Tumor necrosis factor
t1/2 estimate of the terminal elimination half -life of the drug, calculated by dividing the natural 
log of 2 by the terminal elimination rate constant (λ z)
UGT UDP glu coronosyl transferase 
ULN upper limit of normal
Vz/F apparent volume of distribution of the drug
WBC white blood cell
WHO World Health Organization
WHV Woodchuck hepatitis virus
WHsAg Woodchuck hepatitis surface antigen
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 27 27 August 20191. INTRODUCTION
1.1. Background
Chronic hepatitis B (CHB) is a major public health care issue worldwide and one of the principal
causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). The hepatitis B
virus (HBV) is easil y transmissible through perinatal, percutaneous, and sexual exposure 
{World Health Organization (WHO) 2015 }. Following acute HBV infection, 5% to 10% of 
adults and up to 90% of children fail to produce an immune response adequa
te to clear the 
infection; these individuals become chronic carriers of the virus {Zuckerman 1996}. I ndividuals 
who develop CHB are at substantial risk of cirrhosis, hepatic decompensation, and HCC, which 
will afflict 15% to 40% of patients with CHB in the absence of effective trea tment 
{World Health Organization (WHO) 2015 , Wright 2006}. L iver cancer is the third leading cause 
of cancer deaths globally, with the highest burden of disease found in regions where HBV is 
endemic {Global Burden of Disease Cancer Collaboration 2015 }. Recent reports estimated that 
250 to 350 million individuals were living with HBV (ie, are hepatitis B surface antigen
[HBsAg] -
positive) in 2010, representing a worldwide prevalence of 3.6%, with considerable
geographic variability  {Schweitzer 2015, World Health Organization (WHO) 2015 }. In 2015, an 
estimated 654,000 deaths were due to 
HBV infection and associated complications, placing it
among the top 20 causes of mortality worldwide { G. B. D. Mortality  Causes of Death 
Collaborators 2016 }.
The loss of HBsAg, accompanied by  seroconversion to anti -HBsAg, is the accepted endpoint for
anti-HBV therap y endorsed by  the American Association for the Study  of Liver Diseas es, the
European Association for the Study  of the Liver, and the Asian Pacific Association for the Study
of the L iver allowing for cessation of therapy  {European Association for the Study  of the Liver 
2017, European Association for the Study  of the Liver (EASL) 2012, Lok 2009, Sarin 2015, 
Terrault 2016}. Clearance of HBsAg has been associated with improvements in liver histology , 
including the reversal of cirrhosis, a decreased risk of HCC, and prolonged survival, and is 
considered evidence of a functional cure {Benias 2011, Fattovich 1998 , Kim 2013 }.
Nucleos(t)ide analogs are the standard -of-care for CHB treatment, p roviding durable suppression
of viral replication that results in long -
term clinical benefits with a reduced risk of liver
complications {Dienstag 2003, Liaw 2011 , Lok 2013}. However, treatment with nucleos(t)ide
inhibitors rarel y results in clearance of HBsAg and seroconversion to anti -HBsAg {Kwon 2011}.
Thus, new treatment options that enhance rates of HBsAg clearance and seroconver sion are
needed; such treatments will allow patients to discontinue life
-long oral antiviral therapy  and
provide a finite -duration treatment option for a functional cure. A finite therapy  is expected to be
applicable to a broader population of those chroni cally  infected with HBV, including
immunotolerant patients who are currently  untreated.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 28 27 August 2019The host immune response to HBV infection plays a pivotal role in whether acute infection is
resolved or becomes chronic. I ndividuals who are able to clear HBV infectio n spontaneously
following an acute infection display  a vigorous, poly clonal, HBV -specific CD8+ and 
CD4+ Tcellresponse {Rehermann 2005}. I n contrast, CHB is associated with a limited and 
dysfunctional CD8+ T cell response, as well as impaired natural killer (NK) cell antiviral 
function {Peppa 2010, Rehermann 2005 }.
Toll-like receptors (TLRs) are a fa mily of membrane
-bound pattern recognition receptors that
play a central role in both innate and adaptive immunity  by recognition of pathogen-associated
molecular patterns from microorganisms {O'Neill 2013}. TL R8 is a transmembrane receptor
located in the endosomal membrane of a subset of immune cells and recognizes single -stranded
RNA. Published studies have demonstrated t hat TLR8 activates innate and adaptive effector cell
immune responses 
{Du 2010 , Gorski 2006, Jo 2014, Lu 2012, Peng 2005, Wille -Reece 2006 }.
Activation of TL R8 by  a selective, oral, small- molecule agonist with good absorption and high
first-pass hepatic clearance to limit sy stemic activation is therefore a rational approach to safel y
induce effective antiviral immunity  in CHB patients and drive functional cure.
1.2. GS-9688
1.2.1. G eneral Information
GS-9688 is a novel, potent, and selective small molecule agonist of TLR8. GS- 9688 directl y 
binds the ectodomain of TL R8 and activates human TL R8 with > 100 -fold selectivity  over 
human TL R7. In human peripheral blood mononuclear cells ( PBMCs ), GS-9688 induces the 
production of the cellular immune mediator interleukin ( IL) -12 and the antiviral cy tokin es tumor 
necrosis factor ( TNF )-α and interferon ( IFN)-γ, but has minimal effects on the levels of IFN- α, a 
TLR7-induced cy tokine. GS -9688 induces cy tokine production in my eloid dendritic cells (mDC)
and monocy tes, but not plasmacy toid dendritic cells ; acti vates natural killer (NK) cells and total 
CD8+T cells in vitro in PBMCs isolated from both healthy  donors and CHB patients; and 
increases IFN -γ production and reduces expression of the inhibitory  receptor programmed cell 
death protein 1 (PD -1) by  HBV -specific CD8+T cells. Collectively , these data de monstrate the 
selectivity  and activity  of GS -9688 for TLR8 in human primary  immune cells.
For further information on GS -9688 refer to the investigator’s brochure (IB).
1.2.2. Preclinical Pharmacology and Toxicology
GS-9688 has been characterized in repeat -dose oral (once weekl y) toxicity  studies of up to 
26-weeks (27 doses) in m ice and 39- weeks (40 doses) in cy nomolgus monkey s, genetic 
toxicology ,and phototoxicity  studies . The mouse was selected based on its PK properties and 
previous experience with TL R agonists . In rodents, TL R8 agonists activate TL R7 but not TL R8, 
and induce a broader immune response than is expected in humans {Hemmi 2002 , Liu 2010}. 
Female mice were used in nonpivotal studies as TLR8 is X -
linked {Chuang 2000}; however, no 
gender -specific toxicities have been observed in repeat -dose toxicity  studies with GS -9688. The 
monkey  is the closest pharmacologically  relevant species to human for TLR8 activity
. Consistent 
with the intended route of administration in humans, in vivo toxicity  studies were conducted by  
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 29 27 August 2019the oral route of administration. Study  designs and parameters evaluated were consistent with 
accepted principles and practices as outlined by  theInternational Conference on Harmonization
(ICH), Organization for Economic Cooperation and Development, and national regulations 
United States (US) Food and Drug Administration [ FDA ]and European Community  Directives). 
Unless otherwise noted, all studies were conducted in accordance with US FDA Good 
Laboratory  Practice ( GLP )regulations.
In the initial dose range- finding study  (2doses, on Day s 1 and 8) studies, m ortality  in mice was 
observed following a single dose at 1000 mg/kg due to general debilitation . In the chronic 
27dose study  in mice, early  mortalit y was observed in 6 mice administered 30 mg/kg/week, 
which correlated to an exposure margin of >1400- fold the projected 3 mg clinically  efficacious 
dose.
Ocular
In the 4 week, 5 dose, study  in monkey s, 
early terminat ion (Day  11) of the 300 mg/kg/week 
group was due to GS -9688 -related ocular toxicity  and clinical signs of pain/distress associated 
with these findings. A dose-related bilateral inflammation of the anterior segment of the ey es 
wasobserved in 2 of 8 animals in each of the 30 and 100 mg/kg/week groups following 
ophthalmic evaluation. Changes were partially  or completely  resolved between each dose at 
30mg/kg/week and in 1 ofthe 2 animals administered 100mg/kg/week. In one male at 
100 mg/kg/week the inflammatory  response progressively  worsened and was considered adverse. 
In the 39 week, 40 dose (30 mg/kg) , study  in monkey s,3 of 20 animals administered 30 mg/kg 
presented with findings consistent with an intraocular inflammatory  resp onse. The findings were 
generall y mild, occurred at a low incidence, and/or were self -limiting . In addition, no findings 
were observed in an y animals after the 13 -week interim necrops y. The no observed adverse 
effect level ( NOAEL ) for ocular findings in th e monkey  was 30 mg/kg/week. Similar findings 
have previousl y been described for another small molecule TL R8 agonist 
(VTX-2337; motolimod ) in non- human primates, but have not been observed clinically  
{Northfelt 2014}.
No ocular findings were noted in mice at an y dose level. 
Immunomodulation
Adverse, GS 9688 -related, histop athology  changes were observed in the kidney , esophagus, 
thymus, spleen, mesenteric ly mph node, mandibular salivary  gland, Harderian gland, and/or 
lacrimal gland of mice administered 30 mg/kg/week in the 27 dose study . Findings with marked 
severit y included: mononuclear cell infiltrates in the kidney , Harderian gland, mandibular 
salivary  gland, and lacrimal gland; fibroplasia in the esophagus; vessel inflammation in the 
mandibular salivary  gland; ly mphoid cellularit y in thymus and spleen; l ymphocy te necrosis in 
the mesenteric l ymph node (males); and moderate and marked severit y ofchronic progressive 
nephropath y
(CPN )in the kidney . In addition, glomerulonephritis was noted in 2 females . With 
the exception of CPN, all findings were partially  reversed or not observed at the end of the 
4-week recovery . As a result of inflammatory  findings in the 27 dose study , the NOAEL was 
10mg/kg/week.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 30 27 August 2019In monkey s,multisy stemic inflammatory  cell infiltrates were noted in the 4- week, 5 dose study  
in the brain and liver at ≥ 30 mg/kg/ week. In the brain, findings of perivascular mononuclear cell 
infiltrates and/or choroid plexus inflammation at 30mg/kg/week were of increased incidence 
and/or severit y compared with vehicle administered animals. I n addition, microgliosis was noted 
in females administered 100 mg/kg/week. These findings were considered adverse in the 
monkey s at ≥ 100 mg/kg/ week. Inflammatory  cellular infiltrates were limited to the liver, 
gastrointestinal tract, and/or thy mus following chronic dosing in the 40 dose study . All changes 
were considered non- adverse and exhibited reversibility  at the end of the recovery  phase. Due to 
the progressive inflammatory  infiltrates in the brain at the 100mg/kg/week in the 4- week stud y 
and the lack of adverse changes in th e 40 dose study , the NOAEL for immumodulation was 
considered to be 30 mg/kg/week.
GS-9688 is intended for oral administration and evaluation of local tolerance for this route was 
conducted during the repeat dose studies. There were no treatment -related gas trointestinal effects 
observed in mice. Emesis was noted at ≥ 10 mg/kg in cy nomolgus monkey s; however these 
observations had no adverse effect on the health of the animals. In addition sporadic findings 
from male monkey s administered 300 mg/kg/week (termin ated early) that were potentiall y 
GS-9688 related included occasional fibrin thrombi in the villus ly mphatics of the duodenum, 
jejunum, and/or ileum.
GS-9688 administration is not considered to result in phototoxicity .
At the projected efficacious clinical dose of 3 mg, the anticipated margin of exposure based on 
the NOAELs in mice and cy nomolgus monkey  compared to the estimated human exposure 
AUC 0
-24(0.56ng•h/mL) in virally  suppressed CHB subjects is 3 32-and 64 - fold, respectivel y.
1.2.3. Genotoxicity 
GS-9688 was negative in the bacterial reverse mutation (Ames ) assay . GS-9688 was considered 
negative for inducing chromosomal aberrations when tested with and without metabolic 
activation up to the limit dose level or limits of cy totoxicity . In addition, G S-9688 was negative 
in the in vivo rat bone marrow micronucleus assay  at exposures of up to 5400- fold the human 
exposure (AUC 0
-24) of 0.5 6 ng•h/mL at the projected 3 mg clinically  efficacious dose; therefore, 
GS-9688 was considered non -genotoxic.
1.2.4. Safety Ph armacology
To support the proposed clinical development plan, the nonclinical safety  profile of GS-9688 
was characterized in studies evaluating the potential pharmacologic effects on specific organ 
systems. Study  designs and parameters evaluated were consi stent with accepted principles and 
practices as outlined by  the I CH and the US FDA Center for Drug Evaluation and Research. All 
studies were conducted in accordance with I CH GLP regulations.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 31 27 August 2019In safet y pharmacology studies, there were no clinically- relevant effects on the central nervous
and respiratory  systems in mice at exposures approximately  2900- fold above the estimated 
human protein -free C maxof 0.015 ng/mL at the projected 3mg clinical efficacious dose.
In telemetered cy nomolgus monkey s, no adverse cardiovascular effects were noted at doses up to 
100mg/kg. A non-dose dependent increase in heart rate (up to 43%) was noted 2-4 hours post 
dose. 
These changes in heart rate can be correlated with elevated inflammatory  biomarkers
associated with TLR8 agon ists{Northfelt 2014} and have been associated with increased resting 
heart rate {Whelton 2014 }.Minimal b ody temperature changes at 100 mg/kg, resulting from a 
lack of decrease during the post dose dark cy cle were noted at 100 mg/kg and are possibl y an 
exacerbation of stress associated with emesis noted at this dose level (2 of 4 animals). Changes 
were not considered adverse and could potentiall y be secondary  pharmacody namic effec ts of 
TLR8 stimulation with GS -9688. Based on the Day 1 protein -free C max(1.0 ng/mL, males) in the 
4-week (5 dose) stud y in cynomolgus monkey s, the NOAEL dose was at least 67 -fold above the 
estimated human protein -free C maxof 0.015 ng/mL at the projected 3 mg dose.
There was no evidence of significant inhibition of the hERG potassium channel current by  
GS-9688.
Pretreatment with anti -emetic agents (ondansetron orcompazine) or a Nonsteroidal 
Anti- Inflammatory  Drug ( NSAID ) (ibuprofen) did not substantially  alter the PD response to 
GS-9688 in healthy  cynomolgus monkey s. 
1.2.5. Nonclinical Pharmacology 
GS-9688 activates NK cells in vitro in PBMCs from healthy  donors and CHB patients. GS -9688 
also increases the expression of the acti vation marker CD40 in human mDCs and monocy tes in 
vitro, suggesting that GS -9688 has the potential to augment antigen- specific CD8+ T cell 
responses b y enhancing antigen presentation. GS -9688 activates total CD8+ T cells in vitro in 
PBMCs from health y dono rs and CHB patients. GS -9688 increases IFN -γ production while 
reducing expression of PD -1 by HBV -specific CD8+T cells in vitro, suggesting that GS -9688 
has the potential to restore the functionalit y of HBV specific CD8+T cells in vivo.
In HBV -infected pr imary human hepatocy tes (PHH), GS -9688 does not have direct antiviral 
activity , consistent with the lack of TLR8 expression in this cell ty pe. In contrast, cy tokines 
produced b y GS -9688- treated PBMCs reduce the levels of HBV DNA, RNA, HBsAg, and 
hepatitis B e antigen (HBeAg ). This antiviral activity  is comparable for all HBV genoty pes 
tested (A, B, and D) and in PHH from multiple donors. GS
-9688 induced cy tokines do not 
reduce viral cccDNA levels in PHH with established HBV infection, but treatment of PHH p rior 
to HBV infection blocks cccDNA establishment. These data suggest that GS -9688 has the 
potential to produce cy tokines that inhibit established HBV infection and prevent HBV infection 
of hepatocy tes in vivo.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 32 27 August 2019GS-9688 is a selective agonist of woodchuck T LR8. Administration of 3 mg/kg GS -9688 to 
woodchucks chronicall y infected with Woodchuck hepatitis virus ( WHV )led to a reduction of 
serum WHV DNA (2.8 to7.4log10) and Woodchuck hepatitis surface antigen ( WHsAg)
(2.2to> 4.6 log10) in 4 of 6 animals. Th is response was sustained in 3 animals until the end of 
the study  (24 weeks after the end of treatment). These 3animals had > 95% reduction in 
intrahepatic WHV covalently  closed circular DNA ( cccDNA ), DNA, and RNA at the end of the 
study . These 3 animals also had detectable anti- WHsAg antibodies and an enhanced 
WHV -specific T cell response upon GS -9688 treatment. Doses of 3 mg/kg GS- 9688 were 
generall y well tolerated in WHV infected woodchucks.
GS-9688 induces a comparable cy tokine response in PBMCs from cy nomolgus monkey s and 
humans, albeit with 10- fold lower potency  in cy nomolgus monkey  PBMCs. I n healthy  
cynomolgus monkey s, oral administration of GS -9688 induces dose -dependent induction of 
serum IL -12p40, as well as whole -blood macrophage receptor with collagenous structure 
(MARCO )mRNA. The minimum pharmacologically  active dose for oral GS -9688 in 
cynomolgus monkey s is 0.3 mg/kg.
GS-9688 exhibits minimal cy totoxicity  (CC50 from 4.6 to > 44 μM) in human MT -4 
lymphoblastoid T -cells, hepatoma -derived Huh7 cells, galactose-adapted HepG2 cells, galactose 
adapted PC -3 prostate cancer cells, normal human fetal lung fibroblast MRC5 cells, primary  rat 
NRVMs, PHHs, and human PBMCs from healthy donors. Thi s corresponds to a selectivity  index 
of 49 -fold to > 473 -fold relative to the IL -12p40 EC 50in PBMCs. GS -9688 did not show any 
mitochondria -specific inhibition.
Molecular target screening studies showed that GS- 9688 had no activity  against a panel of 
87receptors, ion channels, and transporters when tested at a concentration of 10 μM.
In summary , the preclinical pharmacology  profile of GS
-9688 supports its clinical investigation 
as a novel agent for the treatment of CHB.
1.2.6. Clinical Trials of GS -9688
1.2.6.1. GS-US-389-2021
Study  GS
-US-389- 2021 was a first -in-human (FIH), randomized, blinded, placebo -controlled, 
single ascending dose study  of GS -9688 in health y male and female subjects. The primary 
objective of the stud y was to evaluate the safet y, tolerability  and PK o f escalating doses of 
GS-9688 as well as evaluate the effect of food on GS -9688 PK. The effect of GS -9688 on PD 
markers was also explored.
This FIH stud y comprised four single ascending dose cohorts (each cohort with 
12active/3 placebo) and one food effec t cohort that assessed GS -9688 PK administered under 
fasted and fed conditions (N=12 active subjects). Doses evaluated were 0.5, 1.5, 3, and 5 mg 
GS-9688 and the food effect cohort evaluated 1.5 mg GS-9688. For all cohorts, subjects were 
followed for 14 da ys following the last dose of GS -9688 and evaluated for safet y through the 
reporting of AEs, ph ysical examination and clinical laboratory  test findings, and measurement of
electrocardiograms (ECGs), vital signs, and ophthalmologic exams.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 33 27 August 2019The treatment was generally  safe. There were no Grade 3 or 4 AEs or serious adverse events 
(SAEs) reported. No significant alterations in vital signs, ECGs, or ophthalmologic exams were 
noted in any  cohort. No individual subject discontinued due to AEs or laboratory  abnorma lities 
and most AEs were mild (Grade 1). The single treatment
-emergent, treatment-related Grade 2 
AE was exacerbation of intermittent diarrhea in one subject who received GS -9688 1.5 mg as a 
single dose. 
There were no Grade 3 or higher laboratory  abnormalities in any  cohort. In the 0.5 mg single 
dose cohort, there were 3 treatment -
emergent transient Grade 2 lab abnormalities (lipase in a 
single subject and cholesterol and low densit y lipoprotein (LDL )in another subject). In the 
1.5mg single dose cohort, there were 2 treatment -emergent Grade 2 lab abnormalities (LDL and 
cholesterol, all in a single subject). In the 5 mg single dose cohort, there were 2 subjects with 
treatment -emergent transient Grade 2 ALT elevation and 1 subject with treatment -emergent 
transient Grade 1 ALT elevation . 
PK data following administration of single doses of GS -9688 at 0.5 mg, 1.5 mg, 3 mg and 5 mg 
under fasted conditions are shown in Table 1-1. GS -9688 was absorbed quickly  following single 
fasted oral doses with the maximum plasma concentrations (C max) occurring between 0.5 and 
1.25 hours (median T max). Less than dose proportional 
increases in exposure were observed 
between 0.5 and 1.5 mg dose levels; GS- 9688 exhibited dose proportional PK between 1.5 mg 
and 5 mg doses. Median t 1/2at 1.5 mg, 3 mg and 5 mg d oses was approximately  5 hours.
Table 1-1. GS-US- 389-2021: GS -9688 Plasma Pharmacokinetic Parameters by 
Treatment Following Single -Dose Administration of GS -9688 in the 
Fasted State (Cohorts 1 to 4) (GS -9688 PK Analysis Set)
GS-9688 PK 
Param eterMean (%CV)
GS-9688
0.5 m g
(N = 12)GS-9688
1.5 m g
(N = 12)GS-9688
3 mg
(N = 12)GS-9688
5 mg
(N = 12)
AUC last(h•pg/mL) 97.4 (44.4) 152.6 (75.8) 494.9 (53.2) 825.3 (37.6)
AUC inf(h•pg/mL) 124.2 (39.4) 160.3 (72.9) 507.5 (52.2) 847.9 (38.0)
Cmax(pg/mL) 36.4 (111.5) 52.9 (83.0) 165.3 (92.6) 258.1 (55.9)
Tmax (h)a0.50 (0.50, 1.00) 0.75 (0.50, 1.00) 0.75 (0.50, 1.01) 1.00 (0.50, 2.25)
t1/2(h)a11.28 (8.37, 19.94) 4.28 (2.94, 5.03) 4.91 (4.22, 5.55) 5.05 (4.66, 5.81)
a Values are presented as median (Q1, Q3). Means presented are unadjusted arithmetic means. N is the number of subjects in 
the PK Analysis Set.
PK data summarizing the effect of moderate fat meal on the pharmacokinetics of GS -9688 
1.5mg are shown in Table 1-2.
Food slowed the rate of absorption of GS
-9688 (median T max: 05 hours versus 1.5 hours) without 
a substantial change in bioavailability , as evidenced by  comparable plasma exposures (AUC and 
Cmax) upon fed and fasted administration. These results suggest that pharmacokinetics of 
GS-9688 is not substantially  altered by  food.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 34 27 August 2019Table 1-2. GS-US- 389-2021: GS -9688 Plasma Pharmacokinetic Parameters by 
Treatment Following S ingle -Dose Administration of GS -9688 in the 
Fasted and Fed States (Cohort 6) (GS -9688 PK Analysis Set)
GS-9688 PK Param eterMean (%CV)
GS-9688
1.5 m g Fed
(N = 12)GS-9688
1.5 m g Fasted
(N = 12)
AUClast (h•pg/mL) 268.0 (65.0) 220.8 (76.2)
AUCinf (h•pg/mL) 279.0 (62.9) 236.9 (70.2)
Cmax (pg/mL) 87.2 (83.8) 92.5 (129.9)
Tmax (h)a 1.50 (0.75, 1.75) 0.50 (0.50, 1.00)
t1/2 (h)a 5.18 (4.00, 5.78) 4.91 (4.66, 6.84)
a Values are presented as median (Q1, Q3). Means presented are unadjusted arithmetic means. N is the number of subjects in 
the PK Analysis Set.
IL-12p40, IL -1RA, and MARCO gene expression were evaluated as PD markers of GS -9688 
pharmacological activity . IL-12p40 and IL -1RA serum concentrations increased after GS -9688 
treatment, with peak c oncentrations occurring approximately  4 hours postdose. Generall y, 
IL-12p40 and IL -1RA concentrations increased with increasin g GS -9688 dose. Increases in 
IL-12p40 and IL -1RA concentrations were smaller following fed-state treatment compared with 
fasted -state treatment. Whole blood MARCO gene expression following administration of 
GS-9688 0.5 mg remained generall y constant, with a transient dose -dependent decrease in 
expression 2 hours postdose.
1.2.6.2. GS-US-389-2022
Study  GS-US-389- 2022 is a randomized, blinded, placebo -controlled, multiple -dose, 
dose-escalation Phase 1b study  evaluating the safety , tolerabilit y, pharmacokinetics and 
pharmacod ynamics of GS -9688 in Patients with CHB . 
This study  consisted of four cohorts: Cohort 1 (evaluating 1.5 mg/placebo to matc h (PTM), 
n=10), Cohort 2 (evaluating 1.5 mg/PTM, n=9) and Cohort 4 (evaluating 3 mg/PTM, n=10), 
GS-9688 or placebo to match was administered in the fasted state once a week (every  7 day s) for 
2 treatment doses; Cohort 5 (evaluating 3 mg/PTM, n=9), GS-9688 or placebo to match was 
administered in the fasted state once a week (every 7 day s) for 4 treatment doses. Cohorts 3 and 
6 were not initiated. For Cohorts 1,2, and 4, subjects were followed for up to 28 day s and for 
Cohort 5 subjects were followed for up t o 21 days following the last dose of GS
-9688 and 
evaluated for safet y by assessment of clinical laboratory tests, electrocardiograms(ECGs), 
periodic ph ysical examinations including vital signs, ophthalmic examinations, and by  
documentation of AEs and conco mitant medications.
Single and multiple doses of GS- 9688 were generally  safe when administered to subjects with 
CHB who were virally  suppressed or viremic. Roughl y half of subjects (20 of 38 subjects, 
52.6%) had at least 1 AE, the majority  of these subject s (15 subjects, 75%) reported onl y Grade 1 
AEs. AEs were observed in all treatment groups except for the viremic (2 doses) placebo group.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 35 27 August 2019Across all subjects, the most commonly  reported AEs (ie, AEs reported in ≥ 3 subjects overall) 
were headache, nausea, dizziness, and chills. More AEs were observed in subjects who received
GS-9688 3 mg compared with GS- 9688 1.5 mg or placebo and more AEs were observed for 
virally  suppressed subjects who received 4 doses of GS -9688 compared with 2 doses.
Six Grade 2 AEs, i ncluding headache, cough, herpes virus infection, nausea, and vomiting, were
reported for 5 subjects (13.2%) who were virally  suppressed (2 subjects, placebo [2 or 4 doses]
and 3 subjects, GS -9688 3 mg [4 doses]). Fifteen of 38 subjects (39.5%) had an AE considered
related to stud y drug b y the investigator; of these treatment- related AEs, 4 subjects who were
virally  suppressed (4 doses) had AEs with severity Grade 2 (herpes virus infection [1 subject,
placebo], nausea and vomiting [reported in 1 subject, GS-9688 3 mg], headache and cough
[1subject each, GS -9688 3 mg]).
No Grade 3 or 4 AEs, SAEs, AEs that led to discontinuation or interruption of study  drug, or
deaths were reported.
Overall, 32 of 38 subjects (84.2%) had a graded laboratory  abnormality ; the majority  of these
subjects (18 subjects, 56.3%) had onl y Grade 1 laboratory abnormalities and 36.8% (14 of 38)
had Grade 2 laboratory  abnormalities, which were observed in all treatment groups. The most
frequentl y reported Grade 2 laboratory abnormalities were increased low -density  lipoprotein
(LDL) cholesterol and h yperglycemia (5 subjects overall for both). All other Grade 2 laboratory
abnormalities were reported for ≤ 2 subjects overall. No Grade 3 or 4 abnormalities were 
observed.
Two of 8 viremic subj ects who received GS -9688 3 mg reported treatment -related Grade 1 AEs
of py rexia; no other notable changes in vital signs (systolic blood pressure, diastolic blood
pressure, pulse, respiration rate, and temperature) or ECGs were reported. One Grade 1
ophth almic AE of anterior cell trace was incidentally  found on ey e exam on Day  9 with no other
corresponding ophthalmic AE; the AE was considered study  drug -related and resolved b y
Day 21.
Table 1-3presents GS -9688 plasma PK parameters following multiple -dose administration 
(2or4 doses QW) of GS -9688 1.5 or 3 mg in subjects who were either virally  suppressed or 
viremic
in the fasted state.
GS-9688 was rapi dly absorbed following single -or multiple -dose administration of GS -9688 
1.5or 3 mg on Day  1 and Day  8. Mean GS -9688 plasma concentrations and exposure 
(asmeasured by AUClast, AUCinf, and Cmax) increased with increasing GS -9688 dose on 
Day 1 and Day  8. Anal ysis using the ANOVA model indicated that exposure was approximately  
dose proportional between the GS
-9688 1.5 mg cohort and the pooled GS- 9688 3 mg cohorts.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 36 27 August 2019Table 1-3. GS-US- 389-2022: Summary Statistics of GS - 9688 Plasma 
Pharmacokinetic Parameters by Treatment Following Single -or 
Multiple -Dose (2 or 4 Doses QW) Administration of GS -9688 in 
Subjects Who WereVirally Suppressed or Viremic (PK Analysis Set).
GS-9688 PK 
Param eterMean (%CV)
Virally Suppressed (2 Doses)
GS-9688
1.5 m gGS-9688
3 mg
Day 1 (N=8) Day 8 (N=8) Day 1 (N=7) Day 8 (N=7)
AUClast
(h•pg/mL)304.9 (35.8) 351.4 (37.7) 624.7 (76.5) 434.0 (44.0)
AUCinf
(h•pg/mL)315.9 (36.1) 364.5 (38.1) 641.5 (74.2) 444.5 (43.5)
Cmax(pg/mL) 105.4 (32.2) 140.3 (34.2) 266.5 (83.2) 234.8 (68.3)
Tmax(h)a1.00 (0.75, 1.00) 0.50 (0.50, 1.00) 0.50 (0.25, 2.00) 0.50 (0.50, 0.50)
t1/2(h)a5.63 (5.16, 6.11) 5.54 (4.64, 6.26) 5.26 (3.86, 6.19) 5.32 (4.60, 6.05)
GS-9688 PK 
Param eterMean (%CV)
Virally Suppressed (4 Doses) Viremic (2 Doses)
GS-9688
3 mgGS-9688
1.5 m g
Day 1 (N=8) Day 8 (N=8) Day 1 (N=8) Day 8 (N=8)
AUClast 
(h•pg/mL)932.4 (53.0) 967.4 (61.1) 944.0 (65.1) 899.9 (61.2)
AUCinf 
(h•pg/mL)950.4 (52.5) 986.4 (60.8) 959.5 (64.5) 918.8 (60.9)
Cmax (pg/mL) 627.8 (84.7) 621.0 (71.0) 627.0 (132.3) 433.4 (79.1)
Tmax (h)a 0.75 (0.50, 1.00) 0.50 (0.50, 0.50) 0.38 (0.25, 1.00) 0.50 (0.50, 1.50)
t1/2 (h)a 4.77 (3.96, 5.73) 5.76 (4.69, 6.00) 4.59 (4.15, 5.05) 4.98 (4.60, 5.95)
a Values are presented as median (Q1, Q3). Means presented are unadjusted arithmetic means. N is the number of subjects in 
the PK Analysis Set.
1.2.6.3. Ophthalmolo gic Evaluation in GS -US- 389-2021 and GS -US- 389-2022
Based on nonclinical ophthalmologic finding in monkey s(Section 1.2.2), multiple, sequential 
ophthalmologic exams were assessed in subjects receiving GS -
9688 in GS- US-389- 2021 and 
GS-US-
389-2022. In the FIH stud y in healt hy volunteer s, GS -US- 389-2021, there were 
3treatment -emergent ophthalm ologic abnormalities (1 each in 1.5 mg, 3 mg, and placebo 
groups) . The subject receiving 1.5 mg had the abnormality  of pupils partially  dilated noted on 
Day 7 and was considered study  procedure related ; the subject had a corresponding TEAE of 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 37 27 August 2019visual impairment ( with reported term of intermittent visual disturbance) starting on Day  4 and 
ending on Day  14. It was in the opinion of the onsite ophthalmologist that the visual impairment 
symptoms were related to the dilated ophthalmic assessments performed during the stud y
. The 
subject in the 3 mg group had a small conjunctival scar noted on Day  2
exam and the placebo 
subject had a slight increase in pigment cells in the left ey e on Day  7. Neither of these 2 subjects 
had a corresponding ophthalmologic TEAE. 
In stud y GS -US-389- 2022, three treatment -emergent ophthalmic abnormalities were reported, all 
Grade 1 in severit y as follows:
One subject (GS -9688 1.5 mg [2 doses], virally  suppressed) reported Grade 1 ey e pruritus 
starting on Day  13 and ending on Day  26; this was assessed by  the clinical investigator as not 
related to stud y drug or study procedures. At screening, the subject was noted to have dry ey e 
signs and there were no changes note d on ophthalmologic exams; on the final visit on 
Day 15, the ophthalmologist noted “punctate epitheliopathy  noted in right cornea [that] was 
seen previousl y”.
The second subject (GS -9688 3 mg [4 doses], virally  suppressed), with a medical history  of 
mild c ataract (L isting 16.2.4.3), had a reported AE term of Grade 1 anterior chamber cell 
trace (L isting 16.2.7.1). At the Day  9 ophthalmologic exam (one day  after the second 
GS-9688 dose), the subject was diagnosed to have trace cells in the anterior chamber, w hich 
was evaluated as stud y drug -related. The subject reported no other corresponding 
ophthalmologic treatment -emergent AE. The subject was started on fluorometholone acetate 
drops and the AE was resolved by  Day  21 at the time of the next ophthalmologic ex am as 
well as on Day  28.
The third subject (GS -9688 3 mg [2 doses], viremic) reported Grade 1 dry  eye on Day  9 that 
resolved on Day  10 with no intervention; this AE was considered not related to study  drug. 
There were no changes noted on any  ophthalmologic exams.
Ophthalmologic exams for all other subjects in Study  GS-US-389- 2022 showed no significant 
abnormalities.
1.2.6.4. GS-US-389-3979
Study  GS
-US-389- 3979 is a Phase 1 study  in healthy  volunteers to evaluate UDP glucoronosy l 
transferase (UGT) and cytochrome (CYP ) P450 
–mediated drug -drug interactions between 
GS-9688 and probe drugs. The primary  objectives were to evaluate the effects of probe inhibitor 
and inducer on the PK of GS -9688. The secondary objective was to assess the safet y of GS -9688 
when administered with probe drugs.  
 
This study  consisted of cohort 1 (CYP3A inhibitor - voriconazole 200 mg BID), cohort 2 
(UGT inhibitor –probenecid 500 mg BID), cohort 3 (CYP1A2/CYP3A inhibitor – ciprofloxacin
500 mg BID), and cohort 4 (CYP450/UGT inducer – rifampin 600 mg QD). For cohorts 1- 3, a 
dose of 1 mg GS -9688 was given on Day  1 followed by  a washout, administration of probe 
CCI-
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 38 27 August 2019inhibitor on Day  7, and coadministration of 1 mg GS -9688 + probe inhibitor on Da y 8. For 
cohort 4, 2 mg of GS -9688 was administered on Day  1, followed b y 600 mg of rifampin on 
Days 2-7 and administration of GS -9688 + rifampin administered (12 hours after GS -9688 dose) 
on Day  8. For all cohorts, subjects were followed for 14 day
s after last doe of study  drug and 
evaluated for safety through the reporting of AEs, physical examination and clinical laboratory 
test findings, and measurement of ECGs and vital signs.
Safety  data from GS -US-389-3979 indicate that GS -9688 was generall y safe. There were no 
SAEs or Grade 4 AEs. There were two discontinuations, both considered study  drug related. 
Both discontinuations were in Cohort 4, one subject with transient neutropenia (Grade 3) and 
onesubject with transient elevated liver function tests (Gra de 1 ALT and AST on Day  7). The 
most common Grade 2 AE observed was nausea in 3 subjects (all in cohort 2) with other Grade 2 
AEs observed in one subject each with headache (cohort 1), s yncope (cohort 4) and vomiting 
(cohort 4). Overall, most treatment
-emergent treatment -related AEs were Grade 1 with the most 
common AE being nausea. No Grade 4 laboratory  abnormalities were observed and Grade 3 lab 
abnormalities included creatine kinase (CK) (one subject in cohort 1), LDL (one subject each in 
cohorts 2 and 4 ), lipase (one subject in cohort 3), cholesterol (one subject in cohort 4), and 
neutropenia (one subject in cohort 4, as discussed previously ).
PD biomarkers IL- 12p40 and IL -1RA showed minimal change (~20 -37% increase in 
cohort 1-3 and ~16% decrease in coh ort 4) when GS -9688 was co -administered in the presence 
of probe inhibitors or inducer compared to administration of GS -9688 alone. PD biomarker 
levels were similar to those observed in stud y GS -398- 2021. PK data ( Table 1-4) for this study  
showed a 3 -
fold increase in AUC infand 8 -fold increase in C maxin GS- 9688 exposure when 
co-administered with a potent CYP3A4 inhibitor voriconazole. Smaller increases in the s ystemic 
exposure of GS -9688 with a pan -UGT inhibitor probenecid or a potent CYP1A2/moderate 
CYP3A4 inhibitor ciprofloxacin were noted. Co -administration with probenecid showed a 
45% and 12% increase in AUC infand C max, respectively. Co -administrati on with ciprofloxacin 
showed a 40% and 77% increase in AUC infand C max, respectivel y, likel y due to CYP3A 
inhibition. The coadministration of the inducer rifampin showed a 47% and 50% decrease in 
AUC inf and C maxof GS -9688, respectivel y. 
The data suggest that GS -9688 metabolism is primarily  mediated by  CYP3A4 with CYP1A2 and 
UGT play ing a less important role. Based on these data, the use of strong inhibitors or inducers 
of CYP3A with GS- 9688 is not currently  recommended. GS -9688 may  be co -administered with
CYP1A2 or UGT inhibitors or inducers.   
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 39 27 August 2019Table 1-4. GS-US- 389-3979: Statistical comparison of GS -9688 Pharmacokinetic 
Parameters following single dose administration of GS -9688 in the 
presence of probe drug (Day 8) and GS -9688 alone (Day 1).
Param eter Cohort 1 (VORI) Cohort 2 (PBC) Cohort 3 (CIPRO)
Cohort 4 (RIF)
AUC inf340.5 
(262.3, 442.0)144.3 
(123.8, 168.2)139.6
(125.2,155.6)47.0
(39.6,55.6)
Cmax801.1 
(583.3, 1100.2)112.8 
(94.5, 134.5)176.77
(142.2,219.8)50.27
(39.6, 63.8)
Data are: GLSM ratio (90% CI). GLSM= geometric least-squares mean; CI = Confidence Interval
GLSM ratio = Day 8 / Day 1, Day 8 = GS -9688+probe, Day 1 = GS -9688
VORI = voriconazole (200 mg BID), PBC = probenecid (500 mg BID), CIPRO = ciprofloxacin (500 mg BID), RIF = rifampin 
(600 mg QD).
1.2.6.5. GS-US-389-4564
Study  GS
-US-389- 4564 is a Phase 1 study  in healthy  volunteers to evaluate the PK, PD, safet y, 
and tolerability  of GS -9688 in smoking and nonsmoking subjects. 
Nonclinical and clinical DDI data (Study  GS-US-
389-3979) suggested that GS- 9688 metabolism 
in humans is mediated primarily  by oxidation via CYP3A4 with minor contribution of 
glucuronidation via UGT, and negligible to no contribution by  CYP1A2. GS -9688 is a lso a 
substrate for human CYP1A1 in vitro (Study  AD-
389-2035). CYP1A1 is expressed in lung tissue 
and is known to be induced by  smoking 
{Ding 2003 , Kim 2004, Thum 2006}. According to the 
Centers for Disease Control and Prevention, the prevalence of cigarette smoking among adults in 
the US has remained approximately  15% to 20% in recent years. Smoking is more prevalent in 
other regions of the world and in certain ethnic populations, and can be even more prevalent in 
HBV infected subjects {Yi 2018}. Therefore, it was important to understand the in vivo impact 
ofsmoking on GS -9688 PK and provide guidance on GS -
9688 administration in smokers. 
Subjects were defined as smokers if they  consumed ≥ 20 cigarettes per day  for at least 6 months 
prior to enrolling in the study  and had a urine cotinine level > 500 ng/mL at screening, and as 
nonsmokers if they  had not smoked during the 6 months prior to dosing and had a urine cotinine 
level ≤ 20 ng/mL at screening. Following single -dose administration of GS -9688, lower GS -9688 
plasma exposures were observed in smoking subjec ts compared with nonsmoking subjects, as 
reflected in the 23% and 26% decrease in GS -9688 AUC infand C max, respectively. The T maxand 
t1/2 were similar in smoking and nonsmoking subjects. These data suggest that CYP1A1 does not 
play an important role in GS -9688 metabolism and are in agreement with the clinical DDI stud y 
results (Study  GS-US-389-3979).
Mean IL- 12p40 and IL -1RA serum concentrations increased following single -dose 
administration of GS -9688 2 mg, with similar concentration profiles observed in smokers and 
nonsmokers. Serum concentrations of IL
-12p40 and IL -1RA reached peaks at 4 hours postdose 
and returned to approximate baseline levels 24 hours postdose. There were numericall y higher 
mean concentration ratios for IL- 12p40 in smokers and for IL -1RA in nonsmokers at all postdose 
time points following GS -9688 administration. The variability in the magnitudes of the PD 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 40 27 August 2019responses, together with the lack of a s ystematically  higher PD response in 1 cohort versus the 
other, led us to conclude that there was no substantive difference in the PD responses when 
GS-9688 was administered in smoking and nonsmoking subjects.
GS-9688 was well tolerated by  smoking and nonsmoking subjects. There were no SAEs, AEs 
that led to premature discontinuation of study  drug, or deaths reported during this study . All AEs 
and the majority  of graded laboratory  abnormalities were Grade 1 or 2 in severity. There were no 
notable trends in vital signs measurements and no clinically  significant ECG abnormalities.
Overall, a slight de crease in GS -9688 plasma exposures and no substantive difference in 
biomarker responses were observed in smoking subjects compared with nonsmoking subjects. 
These data suggest a minimal impact of smoking on GS- 9688 PK/PD and support GS9688 
administration w ithout regard to smoking status.
1.3. Rationale for 
This Study
1.3.1. GS-9688 for Treatment of Virally- Suppressed Subjects with Chronic 
Hepatitis B 
Given the low rate of HBsAg loss/seroconversion with currentl y available therapies and the 
treatment burden associated with life -
long treatment to maintain viral suppression, there is a need 
to identify  new therapies that may  provide durable HBsAg loss/seroconversion with a finite 
treatment duration.  The primary  objective is to evaluate the safet y, tolerability  and effica cy of 
GS-9688 in addition to oral nucleos(t)ide HBV poly merase inhibitors for the treatment of CHB 
subjects, and secondary  objectives include evaluating the changes in HBV specific immune 
responses following treatment with GS -9688.
This Phase 2 study  will be conducted in virally -suppressed CHB subjects to minimize safet y 
risks and maximize efficacy benefits associated with GS -9688. Because they have stable viral 
suppression on treatment with an oral antiviral medication, these subjects have lower levels of 
HBV virions and proteins, including HBsAg, within the serum as well as lower expression of 
HBV antigens within infected hepatocy tes. This lower antigen burden enhances the safet y profile 
of immune stimulating approaches to CHB treatment, including GS -9688. In addition, a virally  
suppressed population may have a higher chance of response to GS -9688, as suggested by  the 
observation that  immune responsiveness of chronic HBV patients is improved in patients who 
are on chronic suppressive antiviral therap y. Of note, only  subjects with sufficient hepatic 
reserve will be included in this study  to further maximize safety .
1.3.2. Rationale for the Dose Selection
Selection of the weekly  administration of 1.5 mg and3 mg is based on preclinical data and the 
safet y, tolerabil ity, PK, and PD data from the single ascending dose first in human (FIH) study  in 
healthy  volunteers (GS- US-389- 2021) and the preliminary  data from theongoing Phase 1b study
(GS-US-389-2022) in virologicall y suppressed (on OAV treatment) patients with CHB .
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 41 27 August 2019From available clinical data, a dose of 1.5 mg was chosen as it has resulted in quantifiable and 
consistent increases in PD biomarkers IL -12 and IL -1RA in both the FIH study  and the ongoing 
Phase 1b study . In the Phase 1b study  with CHB subjects, the 1.5 mg dose was well -tolerated and 
safe as discussed in (Section 
1.2.6.2). 
The highest GS -9688 dose planned to be developed in clinical studies is 3 mg . This maximum
dose has been defined based on the available safety and tolerability data and PK and PD resul ts 
from the 
FIH study  and the ongoing Phase 1b study . The FIH study GS-US-389-2021 showed 
that GS -9688 was generally  safe with single doses up to 5 mg (Section 1.2.6.1 ) . At the highest 
dose evaluated, 5 mg, twosubjects had a grade 2 laboratory  abnormality of elevated ALT . 
Accordingl y, GS -9688 doses of 1.5 mg and 3 mg have been selected for subsequent evalu ation
. 
Further, the FIH study  showed dose dependent sy stemic exposure (AUC and Cmax) and PD 
increases ( IL-
12p40 and IL -1RA )peripheral cy tokine induction with GS -9688 doses ranging 
from 0.5 mg up to 5mg. Dosing with food resulted in smaller increases in IL- 12p40 and IL -1RA 
serum concentration compared with fasted state dosing ; therefore dosing will be in the fasted 
state. 
In GS -US-389-2022, two or four weekl y doses of 1.5 or 3 mg have been evaluated in HBV 
infected patients. Safety data from 
this study demonstrated that GS-9688 is generall y 
well-tolerated as discussed previously (Section 1.2.6.2). There were no SAEs, no treatment 
discontinuations due to AEs, and no Grade 3 or higher treatment
-emergent laboratory  
abnormalities in either cohort. Similar to data from the FIH stud y, data shows evidence of 
biological activity  with dose dependen t induction of IL - 12p40 and IL-1RA and PK data shows a 
similar profile in patients compared to healthy  volunteers in the FIH study , with minimal to no 
accumulation with time (Section 1.2.6.2).
Thus, based on preclinical data, safet y and tolerability  and available PD and PK data from both 
the FIH study  and Phase 1b trial, GS -9688 doses of 1.5 mg and a maximal dose of 3 mg is
supported to explore safety , tolerabilit y and efficacy in virally suppressed (cu rrentl y on OAV) 
CHB patients.
1.3.3. Rational efor Treatment Duration
As no reductions in HBsAg levels were anticipated or observed with 2 once -weekly  doses, a
longer treatment duration of 
24weeks isbeing explored. This duration is based on nonclinical 
data with GS -9688 that demonstrated efficacy  in the woodchuck animal model of CHB . In this
model, 8-12 weeks of exposure induced persistent reduction in WHsAgto undetectable levels in 
a subgroup of animals with response rate increasing over time. Given the preclinical efficacy  
data that suggests longer treatment duration may  be required to achieve higher rates of antiviral 
response, this study  will evaluate a 24 week treatment duration. 
More frequent observation and safet y labs at the start of treatment, along with clear management 
of dose limiting toxicities (Section 7.6.2) will allow an adequate assessment of safet y with 
repeated dosing and a rigorous evaluation of efficacy  based on reductions in serum HBsAg 
levels.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 42 27 August 20191.4. Risk/Benefit Assessment for the Study
GS-9688 is being developed to provide patients wit h CHB w ith a finite duration, curative 
treatment option and for beneficial antiviral response without inducing a significant sy stemic 
immune response. Published studies have demonstrated that TLR 8 activates innate and 
adaptive effector cell immune response s {Du 2010 , Gorski 2006, Jo 2014 , Lu 2012 , Peng 2005, 
Wille -Reece 2006
}.Activation of TL R8 by  a selective, or al, small-molecule agonist with good 
absorption and high first-pass hepatic clearance to limit sy stemic activation is therefore a rational 
approach to safel yinduce effective antiviral immunity  in CHB patients and drive functional cure.
The loss of HBsAg w ith seroconversion is the gold standard endpoint for anti -HBV therap y and 
allows for cessation of treatment {European Association for the Study  of the L iver 2017 , 
Liaw 2012 , Sarin 2015, Terrault 2016 }.Loss of serum HBsAg is associated with improvement in 
both the rates of liver c irrhosis and the development of hepatocellula r carcinoma in patients with 
CHB, and increased survival rate {Idilman 2012, Kim 2013, Moucari 2009 , Simonetti 2010 }. 
While HBsAg loss is the ultimate goal of treatment, it occurs at a very  low rate and after multiple
years: less than 10% of patients achieve clearance of HBsA g with the therapeutic options 
currentl y available. Thus, new treatment options that e nhance rates of HBsAg loss with 
seroconversion are needed. Through effects on both innate and adaptive immune e ffectors 
(including HBV -specific T cell s), agonist -induced activation of TLR8 may provide a novel 
component of treatment for patients with chronic HBV infection. 
In human studies, dose escalation in health y volunteers demonstrated dose -dependenc y of AEs
with the highest evaluated dose of 5mgdemonstrating signi ficant increases in nausea and 
vomiting and with several subjects experiencing transient ALT elevations at the highest dose. 
Importantly , at doses of 1 .5 and 3 mg evaluated in the P hase 1b study in CHB patients 
(GS-US-389-2022), rates of nausea, vomiting, and laboratory  abnormalities have been limited .
Nonclinical data in cy nomolgus monkey s suggest that vomiting AEs ar e sporadic with no 
persistence and no morbidity  or mortalit y associated with vomiting was noted. Currentl y, it is not 
known if there will be any  treatment effects associated with longer treatment duration.
Patients will be required to have adequate hematolog ic function at study  entry  and sufficient 
hepatic reserve (F0 -F2). The protocol will follow patient laboratory  and vital sign changes 
routinely  and allows for more frequent monitoring based on clinicall y significant changes. Also, 
specifi c parameters that would lead to dose interruption or discontinuation are included in
Sections 7.6.2 and 7.9. Based on safety  data from 3 clinical trials (completed or ongoing) , a 
number of dos e limiting toxicities (DLTs), including ALT elevation and neutropenia , are 
identified that would d etermine if treatment should be discontinued in a patient. I n addition, risk 
will be further minimiz ed with the inclusion of a data safety  monitoring committee that will 
periodicall y evaluate the safet y of the entire stud y and verify  independentl y if the benefits of the 
trial continue to outweigh any
 risks observed. In summary , the goal of the GS -9688 program is to 
address a maj or unmet need for CHB patients, namely  to enhance rates of serum HBsAg loss 
with seroconversion with a finite duration treatment regimen. Study  GS-US-389-2024 will
investigate 
the efficacy  of 24 doses of GS - 9688at two dose levels (1 .5and 3mg) administered 
weekl y to virall y suppressed CHB patients currently  being treated with an OAV. 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 43 27 August 2019The risks of treatment with GS -9688 in pregnancy have not been evaluated. Pre-clinical data has 
shown that the potential for GS- 9688 to affect the PK of other drugs via CYP450 ,or UGT
enzy mesor drug transporter (P- gp/BCRP) is low. Oral contraceptives are mainly  metabolized by  
CYP450 enzy mesand may  be substrates for P -gp/BCRP . If females are using hormonal agents 
for contraception ,the likelihood for substantial changes in safet y and/or efficacy  of the 
contraceptive via drug -drug interaction ( DDI)is low. Please refer to the current Investigator’s 
Brochure for additional information about GS -9688.
Based on in vitro data and preliminary  data from the DDI stud y (GS -US-389- 3979), GS -9688 is 
mainly  metabolized by  CYP450 enzy mes. In this study ,the inhibition or induction of CYP3A 
show eda decrease in GS -9688 exposure, thus drugs that are known to be potent CYP3A 
inhibitors/inducers of CYP3A are prohibited in this study .
Further, pre -clinical data showed that GS -9688 is unlikely  to be a 
perpetrator of DDIs (based on 
inhibition and induction studies of CYP450 enzy mes and drug transporters). OAVs used in the 
treatment of HBV are not metabolized CYP450 enzymes. Thus, it is not expected that GS -9688 
will result in DDI s with OAVs used to treat HBV . 
Based on available information, the benefit/risk balance for this study  is considered positive.
1.4.1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5. Compliance
This study  will be conducted in compliance with this protocol, GCP, and all applicable 
regulatory  requirements.
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 44 27 August 20192. OBJECTIVES
The primary objectives of this study are as follows:
To evaluate the safet y and tolerability  of multiple oral doses of GS-9688 a t Week 24 in 
virally  suppressed CHB adult subjects on OAV
To evaluate the antiviral activity  of GS -9688 as measured b y the proportion of subjects with 
≥1 log 10IU/mL decline from baseline in serum quantitative hepatitis B surface antigen 
(qHBsAg) atWeek 24
The secondary objectives of this study are as follows: 
To evaluate the antiviral activity  of GS -9688 at Weeks 4, 8, 12 and 48 as measured b y the 
proportion of subjects with 
≥1 log 10IU/mL  decline from baseline in serum qHBsAg  
To evaluate the change in serum qHBsAg (log 10 IU/m L) from baseline to Weeks 4, 8, 1
2, 
24and 48
To evaluate the proportion of subjects with HBsAg loss at Weeks 12, 24 and 48
To evaluate the proportion of subjects with HBeAg loss and seroconversion at Weeks 12, 
24and 48
To characterize the PK of GS -9688 
To evaluate the proportion of subjects experiencing HBV virologic breakthrough 
(2consecutive visits of HBV DNA ≥ 69 IU/mL)
To evaluate the incidence of drug resistance mutations
The exploratory objectives of this study are as follows: 
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 45 27 August 2019
CCI
GS-9688 
Protoco l GS-US-389-2 024 
Gilead Science s Inc. 
3. STUDY DESIGN 
3.1. Study Design Final 
Amendment 2 .1 
This is a multicenter , randomized , double-blind , placebo -controlled Phase 2 s tudy of GS-9688 in 
virally suppre ssed adult CHB subjects on OA V. 
Figure 3-1. Study Schema 
~= 
HBeAg -positive CHB subJe<ts 
N- 25 HBeAg -negative CHB , ubject• I 
111=25 
We•lt 23 (La,t GS-9688/ W•ek 23 I Lost GS-9G88/ 
Pl""8boDo«> ) Week48/ED Placebo O<>so) Week48/[D 
Arm A 
N=S 
Arm 6 
N=10 
ArmC 
~10 Placebo 
weekly x 24 doses 
GS-9688 1.5 mg 
weekly, 24 dose, 
GS-961!8 3 mg 
weekly • 24 dose., OAVTherapy 
OAVTherapy 
OAVTherapy 
a Coho1 1 1 a nd Coho1t 2 w-ill nm in parallel Arm A 
N=5 
Arm B 
N=10 Placebo 
week fy x 24 do!>es 
GS-9688 1.5 !Tl£ 
weekly x 24 do~s 
GS-96883 mg 
weeklv x 24 dose. 
b At Week 48, per PI's discretion, subjec ts will be managed in one of two ways: OAVTherapy 
OAVThera py 
OAVTherapy 
1. Continue in the study for 48 weeks follo\oving the discontinuation of OA V (ie, TFFU) 
2. Continue current standard of care CHB therapy with Week 48 repre senting the last study visit 
3.2. Study Treatments 
Approximately 50 virally suppre ssed subjects cmTently being treated with a commercially 
available OA V for CHB will be em·olled into two coholi s within this study (1: 1) that will nm in 
parallel. 
• Cohort 1: HBeAg-posi tive CHB subject s 
• Cohort 2: HBeAg-negative CHB subjects 
CONFIDENTIAL Page 46 27 Augus t 2019 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 47 27 August 2019Within each cohort, approximately  25 subjects will be randomized in a 1:2:2 ratio to one of the 
three treatment arms (A: B: C). All subjects will remain on their current commercially  available 
OAV therapy for 48 weeks, in addition to the following treat ments:
Treatment Arm A: Approximately  5 subjects will be administered PTM orally  on the same 
day once a week (every  7days) for 24 doses 
Treatment Arm B: Approximately  10 subjects will be administered GS- 9688 1.5 mg plus 
PTM tablet orally  on the same day  once a week (every  7days) for 24 doses
Treatment Arm C: Approximately  10 subjects will be administered GS
-9688 3 mg orally  on 
the same day  once a week (every  7days) for 24 doses
All GS- 9688 study  drug doses will be administered in fasted state. Subjects should take their 
OAV treatment and other commerciall y available medications n o earlier than 2 hours after 
GS-9688/PTM dosing. Ondansetron dosing is allowed around GS- 9688/PTM dosing; dosing of 
other antiemetics should be discussed with the Gilead MM for approval.
After the 24thdose (Week 23 visit), GS -9688/PTM will be discontinued. Subjects will continue 
being treated with their original commerciall y available OAV and will be followed until 
Week 48/ED . The total study  duration for each subject will be 48 weeks with up to an ad ditional 
48weeks if continued i nto the TFFU phase .
Following completion of the 48 -week stud y period the I nvestigators will be responsible for 
assessing the need to continue study  subjects on treatment for CHB. At Week 48, at Principal 
Investigator (PI) discretion, subjects will be managed in one of two ways:
1)Continue in the study  for 4 8
weeks following the discontinuation of OAV (ie, TFFU phase ) 
2)Continue current standard of care C HB therap y with Week 48 representing the last study  
visit.
At the PI ’s discretion, subject(s) in the TFFU phase may  restart commercially  available CHB 
OAV treatment at an y time per local treatment guidelines . If a subject restarts OAV therap y for 
their CHB, TFFU visits will continue for 2 more TFFU visits or until the end of the TFFU phase 
(Study  Week 96), whichever comes first.
The primary  anal ysis will occur 
after all subjects have completed Week 24 assessment post last 
dose of GS -9688/PTM or premature ly discontinued with the primary  endpoints being th e safet y 
and tolerability  of GS -9688, as well as assessment of the antiviral activit y of GS -9688 at
Week 24 as measured b y the proportion of subjects with ≥1 log 10(IU/mL) decline from baseline 
in serum qH BsAg.
The study  will be unblinded to appropriate Gilead Sciences Inc., ( GSI)study  team personnel at 
the time of primary  analysis (Week 24 assessment) . An Internal Data Review , external to the 
study  team, may be unblinded at Week 12 assessment visit 
to review the unblinded safet y and 
efficacy  data in order to guide strategic decisions regarding the future of the program . 
Investigators and subjects will remain blinded through Week 48. 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 48 27 August 20193.3. Duration of Treatment
The total study  duration for each subject will be 4 8 weeks with up to an ad ditional 48 weeks if 
continued i nto the TFFU phase .Cohort 1 and 2 consist of 24 doses ( Week 23) of treatment of 
GS-
9688 study  drug/PTM .
3.4. Pharmacokinetic Assessment
Sparse ( pre-identified ) PK plasma sampl ingwill occur on Day  1 and Week 23at pre -dose, 1, 4, 
and 24 hours post -dose and at Week 11 at pre -dose, 1, and 4 hours post -dose. Sparse (timed ) 
plasma PK samples will be obtained on an y two of the following visits : Weeks 2, 4, 8, 12, 16, 
and/or 20 at pre -dose and any  time between 30 minutes to 4 hours post-dose.See details in 
Section 6.7.
 
 
3.5. Pharmacodynamic Asse ssments
Pharmacod ynamic assessments ( serum and 
plasma PD biomarkers and ) 
will be performed throughout the study  as outlined in Section 6.8.
3.6. Biomarker Testing 
3.6.1.
Biomarker Samples to Address the Study Objectives:
The following biological specimens will be collected from all subjects in this study  and will be 
used to evaluate the association of exploratory  systemic and/or tissue specific biomarkers with 
study  drug response, including efficacy  and/or AEs andthe targ eted pathway and/or the 
validation of a diagnostic.  The specific anal yses will include, but will not be limited to, the 
biomarkers and assay s as described within the protocol .  Because biomarker science is a rapidl y 
evolving area of investigation, it is n ot possible to specify  prospectivel y all tests that will be done 
on the specimens provided.  The testing outlined below is based upon the current state of 
scientific knowledge. It may  be modified during or after the end of the study  to remove tests no 
longer indicated and/or to add new tests based upon the growing state of art knowledge. 
Biomarker samples will be collected as described in Appendix 2.
These samples will be destroy ed no later than 15 years after the end of study . 
Blood samples for 
assessing biomarkers related to G S-9688 and its mechanism of action will be collected on the 
assigned stud y day s as outlined in Appendix 2.
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 49 27 August 20193.6.2. Samples for Optional Future Research
 
 
 
 
 
 
 
 
.
3.6.3. Sample for Optional Genomic Research
 
 
 
 
 
 
 
 
 
 
 
 
3.7. End of Study
The end of this study  will be the last subject’s last completed study  visit at Week 48. If the 
subject enrolls in the TFFU phase, the subject will be observ edfor up to an additional 48weeks 
(Study  Week 96).
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 50 27 August 20194. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
A total of a pproximately  50 subjects will be enrolled in the study , aged 18-65 years inclusive, 
with CHB and currentl y ona commercially  available OAV treatment . 
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study :
1)Must have the ability  to understand and sign a written informed consent form, which must be 
obtained prior to initiation of study  procedures
2)Adult male a nd non- pregnant, non -lactating female subjects, 18 - 65years of age inclusive 
based on the date of the Screening visit
3)Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 
6months) with detectable HBsAg levels at Screening
4)Females of childbearing potential (as defined in Appendix 3) must have a negative serum 
pregnancy  test at Screening and a negative urine pregnancy  test at Baseline prior to 
enrollment
5)Male and female subjects of childbearing potential who engage i
n heterosexual intercourse 
must agree to use protocol specified method(s) of contraception as described in Appendix 3.
6)Have been on 
a commercially  available HBV OAV treatment(s) (tenofovir alafenamide, 
tenofovir disoproxil fumurate, entecavir, adefovir, lamivudine, telbivudine, either as single 
agents or in combination) with no change in regimen for 3 months prior to screening.
7)HBV DNA ≤20 IU/mL lower limit of quantitation ( LLOQ )
;(measured at least once by  local 
laboratory  assessment) for 6 or more months prior to Screening
8)HBV DNA < 20 IU/mL  at Screening
9)Screening ECG without clinically  significant abnormali ties and with QTcF interval 
(QT corrected using Fridericia’s formula) ≤450 msec for males and ≤ 470 msec for females.
10)Must be willing and able to comply  with all study  requirements
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 51 27 August 20194.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study :
1)Extensive bridging fibrosis or cirrhosis as defined clinically , by imaging or by  the following:
a)Metavir ≥ 3 or Ishak fibrosis score ≥ 4 by  a liver biopsy  within 3years of screening, or, 
in the absence of an appropriate liver biops y, either:
b)Screening FibroTest score of > 0.48 and APRI  > 1, or
c)Historic FibroScan with a result > 9 kPa within ≤ 6 months of screening (if available)
If liver biops y is available, the liver biops y result supersedes (b) and/or (c, if 
available)
If an appropriate liver biopsy  is not available, fibrosis will be evaluated b y (b) and/or 
(c,if available). In the event of discordance between (b) and (c), the FibroScan results 
will take preced ence
2)Subjects meeting an y of the following laboratory  parameters at screening:
a)Hemoglobin < 12 g/dL (for males) or <11 g/dL  (for females)
b)White Blood cell count < 2500 cells/mm3
c)Neutrophil count < 1500 cell/mm3(or < 1000 cell/mm3if considered a ph ysiolog ical 
variant in a subject of African descent)
d)ALT >3x UL N 
e)INR > ULN unless the subject is stable on an anticoagulant regimen affecting INR
f)Albumin < 3.5 g/dL
g)Direct bilirubin >1.5x ULN
h)Platelet Count < 100,000/uL
i)Estimated creatinine clearance (CrCl) < 60 mL /min (using the Cockcroft -Gault method) 
based on serum creatinine and actual bod y weight as measured at the screening 
evaluation, i.e.,
Male: (140 –Age [y ears]) (Weight [kg]) CrCl (mL /min)
72(Serum Creatinine [mg/dL ])
Female: (140 –Age [y ears]) (Weight [kg])  0.85 CrCl (mL/min)
72(Serum Creatinine [mg/dL ])
3)Co-infection with human immunodeficiency  virus (HIV), hepatitis C virus (HCV) or 
hepatitis D virus (HDV)
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 52 27 August 2019Subjects who are HCV Ab positive, but have a documented negative HCV RNA, are eligible
4)Prior history  of hepatocellular carcinoma (HCC) (e.g. as evidenced b y prior  imaging) or 
screening alpha -fetoprotein (AFP) ≥ 50 ng/mL  without imaging to rule out HCC
5)Malignancy  within 5 y ears prior to screening, with the exceptio n of specific cancers that are 
cured b y surgical resection (e.g. basal cell skin cancer). Subjects under evaluation for 
possible malignancy are not eligible
6)Significant cardiovascular, pulmonary , or neurological disease in the opinion of the 
investigator
7) D iagnosis of autoimmune disease (e.g., s ystemic lupus ery thematosus, rheumatoid arthritis, 
inflammatory  bowel disease, autoimmune hepatitis, sarcoidosis, psoriasis of greater than 
mild severity , autoimmune uveitis), poorly  controlled diabetes mellitus, sign ificant 
psychiatric illness, severe chronic obstructive pulmonary  disease (COPD),
hemoglobinopath y, retinal disease, or are immunosuppressed
8) Chronic liver disease of a non- HBV etiology  (e.g. Wilson’s disease, hemochromatosis, 
alpha -
1-antitry psin deficiency , cholangitis), except for non - alcoholic fatt y liver disease
9) Received solid organ or bone marrow transplant 
10)Received prolonged systemic therap y with immunomodulators (e.g. corticosteroids) or 
biologics (e.g. monoclonal antibody , interferon) within 3 months of screening
11)Use of another investigational agent within 90 days of screening, unless allowed by  the 
Sponsor
12)Current alcohol or substance abuse judged b y the investigator to potentiall y interfere with 
subject compliance
13)Known hy persensitivity  to stu dy drug or formulation excipients
14) Women who are breastfeeding, pregnant or who wish to become pregnant during the course 
of the study
15) Female subjects unwilling to refrain from egg donation and in vitro fertilization during and 
until at least 30 day s after the last study  drug dose
16) Male subjects unwilling to refrain from sperm donation during and until at least 90 day s after 
the last study  drug dose
17)Use of an y prohibited concomitant medications as described in Section 5.5
18)Believed b y the Study  Investigator to be inappropriate for study  participation for an y reason 
not otherwise listed.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 53 27 August 20195. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Randomization, Blinding and Treatm ent Codes
It is the responsibility  of the investigator to ensure that the subject is eligible for the study  prior 
to enrollment. Subjects will be assigned a screening number at the time of consent.
All screening procedures must be completed and reviewed b ythe investigator for eligibility  prior 
to the administration of the first dose of stud y drug on Day 1. Once informed consent is obtained 
subjects will be randomized in a 1:2:2 ratio to receive either PTM (N=5), blinded GS-9688
1.5mg(N=10), or GS-9688 3 mg (N=10) . Once a subject number has been assigned to a subject, 
it will not be reassigned to another subject. If necessary , replacement subjects may  be enrolled 
after discussion and approval from sponsor. A new unique subject number will be assigned to the 
replacement subject. 
The randomization will be performed via an Interactive Mobile Response System (IMRS) or 
Interactive Web Response Sy stem (I WRS), whereby  study  treatment will be assigned to subjects 
according to the randomization schedule. A uniqu e subject number will be provided during 
randomization.
Investigators and subjects will remain blinded thro ugh Week 48 except in instances of
emergency  treatment unblinding.
5.1.1. Procedures for Breaking Treatment Codes
In the event of a medical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator may  obtain treatment assignment directly  from the Interactive 
Response Sy stem ( IXRS )for that subject. In the event of a s ystem or technology  failure, the 
IXRS provider should be contacted via phone. Gilead recommends but does not require that the 
investigator contact the Gilead medical monitor before breaking the blind. Treatment assignment 
should remain blinded unless that know ledge is necessary  to determine subject emergency  
medical care. The rationale for unblinding must be clearl
y explained in source documentation 
and on the case report form/ electronic case report form (CRF/eCRF), along with the date on 
which the treatment a ssignment was obtained. The investigator is requested to contact the Gilead 
medical monitor promptly  in case of any  treatment unblinding.
Blinding of stud y treatment is critical to the integrity  of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued. All subjects will be followed until study  completion unless consent to do 
so is specificall y withdrawn by the subject.
In addition, Gilead Pharmacovigilance and Epidemiolgy  (PVE) may independently  unblind cases 
for expedited reporting of suspected unexpected serious adverse reactions (SUSARs).
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 54 27 August 20195.2. Description and Handling o f GS -9688 and Placebo to Match 
5.2.1. Formulation
5.2.1.1. GS-9688
GS-9688 is provided as 1.5mg strength tablets. GS-9688 tablets are round, plain -faced, 
film-coated white tablets. I n additi on to the active ingredient, GS -9688 tablets contain the 
following inactive ingredients: microcry stalline cellulose, mannitol, crospovidone , and 
magnesium stearat e. 
PTM GS -9688 tablets contain the following inactive ingredients: microcry stalline cellulose, 
lactose monohy drate, croscarmellose sodium, and magnesium stearate. The white tablet 
film-coating contains polyvin yl alcohol, titanium dioxide, poly ethylene gly col (PEG) 3350, and 
talc. PTM GS -9688 tablets areidentical in size, shape, color and appearance to the active 
GS-9688 tablets.
5.2.2. Packaging and Labeling
GS-9688 1.5 mg tablets and PTM tablets are packaged in clear Pol yvinyl chloride
(PVC) /Polychlorotrifluoroethy lene (PCTFE) film blister strips and sealed with aluminum foil 
lidding material. Each blister strip contains 4 round tablets sealed with an aluminum push 
through lidding material. GS-9688 active and placebo b lister strips in the quantity  needed for a 
4week suppl y of GS -9688 (ie, 2 strips/8ct) are placed into a paperboard child resistant wallet 
system in accordance with the dosage strategy .
Study  drug(s) to be distributed to centers in the US and other participating countries shall b e 
labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing 
Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations. 
5.2.3. Storage and Handling
The recommended storage condition for GS-9688 active and PTM tablets packaged in blister 
strips/wallet sy stem is as follows: “Store below 30 °C.” Storage conditions are specified on the 
label.  Until dispensed to the subjects, all study  drugs should be stored in a securel y locked area, 
accessible only  to aut horized site personnel.
To ensure the stability and proper identification, study drug(s) should not be stored in a container 
other than the container in which they  were supplied. 
Consideration should be given to handling, preparation, and disposal throu gh measures that 
minimize drug contact with the body . Appropriate precautions should be followed to avoid direct 
eye contact or exposure when handling.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 55 27 August 20195.3. Dosage and Administration of GS-9688
Approximately  50 virall y suppressed subjects currently being treated with a commerciall y 
available OAV for CHB will be enrolled into two cohorts within this study  (1:1). 
Cohort 1
: HBeAg -positive CHB subjects
Cohort 2: HBeAg -negative CHB subjects
Within each cohort, app roximately  25 subjects will be randomized in a 1:2:2 ratio to one of the 
three treatment arms (A: B: C). All subjects will remain on their current commercially  available
OAV therap y for 48 weeks, in addition to the following treatments:
Treatment Arm A: Ap proximately  5 subjects will be administered PTM orally  on th e same day  
once a week (every  7days) for 24 doses 
Treatment Arm B: Approximately  10 subjects will be administered GS -9688 1.5 mg plus PTM 
tablet orally  on th e same day  once a week (every  7days)for 24 doses
Treatment Arm C: 
Approximately  10 subjects will be administered GS -9688 3 mg orally  on th e 
same day  once a week (every  7days) for 24 doses
For the purpose of the study  all doses will be administered in fasted state. Subjects should take 
their OAV treatment and other commercially  available medications n o earlier than 2 hours after 
GS-
9688/PTM dosing. Ondansetron dosing is allowed around GS- 9688/PTM dosing; dosing of 
other antiemetics should be discussed with the Gilead MM forapproval.
After the 24thdose (Week 23 visit), GS -9688/PTM will be discontinued. Subjects will continue 
being treated with their original commerciall y available OAV and will be followed until 
Week 48/ED . The total study  duration for each subject will be 48 weeks with up to an ad ditional 
48weeks if continued i nto the TFFU phase .
5.4. Fasting State Dosing 
Study  drug will be administered at approximately  the same time each day  following an overnight 
fast (no food or drinks, except water, for at least 8 hours with no food or dr inks, including water, 
for the 1 hour before dosing). After dosing, subjects will continue to fast (no food or drinks, 
including water) for 2 hours. After 2 hours postdose, water is allowed and after 4 hours postdose, 
patients are allowed to eat any  food o r drinks.
5.5. Concomitant Medications
Concomitant medications taken within 30 day s prior to Screening, up to and including 30 day s 
aft
er the last administration of study  drug or at Week 48, whichever occurs last, need to be 
recorded in the source documents andeCRFs. Further, an y concomitant medications taken 
during TFFU should also be recorded in the source documents and eCRFs .  
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 56 27 August 2019The following medications on the list ( Table 5-1) and those listed here are prohibited for a 
minimum of 21 day s prior to the baseline/Day  1 visit through the last dose of GS- 9688/PTM 
study  treatment plus 7 Day s (except where noted) : Hematologic stimulating agents 
(eg,erythropoiesis -stimulating agents; granulocy te colony  stimulating factor [GCSF ]; and 
thrombopoietin [TPO ]mimetics) .
Data from t he drug -drug interaction study  GS-US-389-3979 indicate that CYP3A play s a major 
role in GS -9688 metabolism and therefore the administration of potent CYP3A
inhibitors/inducers is n ot permitted in this study  (see Section 1.2.6.4). This isnot an exhaustive 
list of agents .Systemic i mmunosuppres
sant(except short term use of prednisone as a steroid 
burst [≤ 1 week of use]) and cy totoxic medications are also prohibited as they  could interfere 
with the immunom odulatory effects of GS - 9688.
Any medications not on the list ( Table 5-1) should be reviewed with the Sponsor prior to 
randomization and during the stud y treatment period with GS -
9688/ PTM.
Subjects who are currently taking other prescription or non -prescription medi cations may  still be 
randomized into the study  if, in the judgment of the Sponsor and the Investigator, the medication 
will not interfere with the study  procedures or compromise subject safet y, efficacy ,and/or 
pharmacokinetic assessments. I n instances where an excluded medication is initiated prior to 
discussion with the Sponsor, the Investigator must notify  Gilead as soon as he/she is aware of the 
use of the excluded medication. Vitamins, acetaminophen, ibuprofen and hormonal contraceptive 
medications are allowed during the stud y period.
Table 5-1. List of Agents Disallowed
Drug Class Agents Disallowed
Acid Reducing AgentsaProton -Pump Inhibitors, H2-Receptor Antagonists, Antacids , Sucralfate
Antibiotics clarithromycin, rifabutin, rifampin, rifapentin ,telithromycin, troleandomycin
Anticonvulsants carbamazepine, enzalutamide, o xcarbazepine, phenobarbital, phenytoin
Antidepressants Nefazodone
Antifungals fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole
AntiviralVIEKIRA PAK (ombitasvir/paritaprevir/ritonavir & dasabuvir), telaprevir, 
danoprevir, boceprevir
Cardiac Medications Mife fradil
Diuretics Conivaptan
GI Motility Agentsb Cisapride, metoclopramide, domperidone, mosapride citrate, pruclopride, 
itopride hydrochloride, levosulpiride
Herbal/Natural SupplementsSt. John’s Wort , Echinaccea. Milk thistle (ie, silymarin), 
Chinese herb sho-saiko -to (or Xiao -Shai-Hu-Tang)
Other Avasimive, enzalutamide, idelalisib, lumacaftor, nitotane
a Proton pump inhibitors can be taken up to 7 days before study drug dosing (Day 1). H2 receptor antagonists can be taken up 
to 3 days before study drug dosing (Day 1). Antacids that directly neutralize stomach pH (e.g., Tums, Maalox) are permitted 
but may not be taken within 4 hours (before or after) study drug administration.
b GI motility agents are prohibited starting 2 days prior to GS-9688/PTM dosing and for the 24 hours postdose
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 57 27 August 2019For subjec ts requiring treatment with a concomitant medication (including treatment of an 
adverse event) after starting stud y drug, the subject’s continued participation in the study  should 
be re -evaluated b y the investigator, in consultation with the Gilead Medical Monitor 
(ordesignee) on an ongoing, case- by-case basis. 
The investigator is authorized to administer acetaminophen or ibuprofen for the treatment of 
minor ailments occurring on study  without prior consultation with the Gilead Medical Monitor. 
Acetaminop hen is the preferred agent, followed by  ibuprofen. The Gilead Medical Monitor 
should be consulted before administering acetaminophen at doses > 2 g/day and ibuprofen as a 
single dose of >200 mg or >400 mg/day . Other Protocol Restrictions :
Subjects will be 
required to refrain from consumption of grapefruit juice, grapefruits, Seville 
oranges and Seville orange juice 72 hours prior to the first dose of study  drug and during the 
course of the stud y through the follow -up visit.
Subjects will be encouraged to av oid strenuous or prolonged exercise, as well as saunas, 
steam baths, and sunbathing or other prolonged ultraviolet exposure, eg, in a tanning salon, 
from the screening evaluation until completion of the follow -upvisit, as these activities are 
known to affect certain clinical laboratory  test parameters, (eg, CK) and will provide false 
indicators of a potentially  treatment related toxicity . 
Upon every  admission to the clinic, each subject will be questioned as to their compliance with 
the above protocol restrictions. I f a subject is unable to comply  with an y of the restrictions 
described above, the subject’s continued participation in the study  will be reevaluated by  the 
investigator in consultation with the sponso r.
5.6. Accountability for GS -9688
The investigator is responsible for ensuring adequate accountability  of all used and unused IMP. 
This includes acknowledgement of receipt of each shipment of I MP (quantity  and condition). All 
used and unused IMP dispensed to subjects must be returned to the site.
GS-9688 accountability  records will be provided to each stud y site to:
Record the date received and quantity  of IMP kits
Record the date, subject number, subject initials, the IMP kit number dispensed
Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 58 27 August 20195.7. Investigation Medicinal Product Return or Disposal
At the beginning of the study , the study  monitor will evaluate the study  centers study  drug 
disposal procedures and provide appropriate instruction for return or destruction of unused study
drug supplies. If the site has an appropriate Standard Operating Procedure (SOP) for drug
destruction, the site may  destroy  used and unused study  drug supplies perf ormed in accordance
with the site’s (hospital/pharmacy ) SOP. If the site does not have acceptable procedures in place 
for drug destruction, arrangements will be made between the site and Gilead Sciences
(orGilead Sciences representative) for return of unu sed study  drug supplies. A copy  of the sites
SOP will be obtained for central files. Where possible, study drug will be destroyed at the site.
Upon study  completion, a copy  of the Investigational Drug Accountability records must be filed
at the site. Anoth er cop y will be returned to Gilead Sciences. If drug is destroy ed on site, the
investigator must maintain accurate records for all study  drug kits and/or blister packs destroy ed.
Records must show the identification and quantity  of each unit destroy ed, the method of
destruction, and person who disposed of the drug. All study  drug records must be maintained at
the site and copies must be submitted to Gilead Sciences at the end of the study .
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 59 27 August 20196. STUDY  PROCEDURES
The study  procedures to be conducted for each subje ct enrolled in the study  arepresented in 
tabular form in Appendix 2and described in the text that follows. 
The investigator must document an y deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
Entry  into screening does not guarantee enrollment into the study . In order to manage the total
trial enrollment, Gilead, at its sole discretion, may suspend screening and/or enrollment at an y
site or trial -wide at any  time.
6.2. Pretreatment Assessments
Prior to the conduct of any  screening procedures, each candidate must sign an Informed Consent 
Form. Consent is to be obtained in accordance with regulatory  and local Ethics Committee 
requirements.
6.2.1. Screening Visit (Window of -30Days )
Subjects will be screened within 30days of the baseline visit to determine eligibility  for 
participation in the study .
Review of inclusion/exclusion criteria
Obtain medical history  (including HBV disease and treatment history ) 
Obtain I nformed Consent, 
Review concomitant medications 
Complete p hysical examination (including weight, height, BMI, vital signs)
12-lead ECG – ( ECG must be taken before blood drawn and subjects must rest quietly  in the 
supine position for a minimum of 10 minutes prior to the recording)
Ophthalmologic exam (Day s -10 to -1)
Sample Collection for:
Safety  laboratory  tests ( serum chemistry , hematology , and coagula tion)
HCV, HDV and HIV A b testing (with reflex testing performed if positive)
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 60 27 August 2019Qualitative HBV serology (HBeAg [reflex HBeAb if HBeAg is negative] and HBsAg 
[reflex HBsAb if HBsAg is negative])
HBV DNA levels and resistance surveillance
HBV genoty ping by  history  (if known)
Quantitative HBsAg
Fibro Test
AFP [ An imaging test will be required for subjects with AFP  ≥ 50 ng/mL ]
Urinaly sis, urine drug screen, serum β -hCG (for all female subjects of child- bearing 
potential), and FSH testing (for female subjects post-menopausal for less than two y ears, 
if FSH < 40 mIU/ mL a serum pregnancy  test will be required)
 
 
 
 
 
 
 
 
 
.
6.3. On-Treatment Assessments (All Visits Have Window of ± 1Days)
All Day  1 (baseline) tests and procedures must be completed prior to the receipt of the first dose 
of study drug. 
All Treatment Phase Assessments (Day  1 through Week 23 +24 hours) should be obtained 
pre-dose unless otherwise indicated:
Review of inclusion/exclusion criteria and confirm medical history  on Day  1
Complete pre -dose physical examination on Day  1and Weeks 2, 4, 8, and 12. 
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 61 27 August 2019Symptom directed phy sical exam on Day  2, Week s 11, 16, 20, 23 and23+24 hours. 
Complete phy sical examination should include weight, BM I,height, vital signs, 
concomitant medications and AEs
Sympto m directed phy sical examination should include weight, vital signs, 
concomitant medications and AEs
Ophthalmologic exam on Week 12 (Day s -4 to +10)
In clinic GS -9688 study  drug dosing on Day  1 and Weeks 2, 4, 8, 11, 12, 16, 20, and 23. 
Self/Home GS -9688 st udy drug dosing on Weeks 1, 3, 5, 6, 7, 9, 10, 13, 14, 15, 17, 18, 19, 
21, and 22.  Study  drug will be taken orall y on the same day approximately  at the same time
once a week (every  7 days) for 24 doses.
Safety  laboratory  tests ( serum 
chemistry , hematology , and coagulation) on Day  1 and 
Weeks 2, 4, 8, 11, 12, 16, 20, and 23
Urinaly sis on Day  1 and Weeks 2, 4, 8, 11, 12, 16, 20, and 23
Fibro Test on Day  1
Serum β -hCG, for all female subjects of child -bearing potential on Day 1 and Weeks 4, 8, 12, 
16, and 20
Urine Pregnancy  Test, for all female subjects of child -bearin g potential on Day 1 and 
Weeks 2and11
HBV DNA and resistance surveillance on Day  1 and Weeks 2, 4, 8, 11, 12, 16, 20, and 23
Qualitative HBV serology  (HBeAg [reflex HBeAb if HBeAg is negative] 
and HBsAg 
[reflex HBsAb if HBsAg is negative]) on Day  1and Week 12
Quantitative HBsAg on Day  1 and Weeks 2, 4, 8, 11, 12, 16, 20, and 23
Quantitative HBeAg, HBV RNA and HBV core- related antigen (HBcrAg) on Day  1 and 
Weeks 4, 8, 12, 16, and 20

Serum and plasma PD biomarkers on Days 1 Pre -dose, 1 + 4 hours, 1 + 24 hours and 
Weeks 2,8, 11, 11 + 4 hours,12, 16, 20 , 23, 23 + 4 hours ,and 23 + 24 hours
TruCulture 
sample on Day  1pre-dose
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 62 27 August 2019Whole blood gene expression (Paxgene RNA) samples on Day s 1 Pre -dose, 1+4hour,
1
+ 24 hours and  Weeks 11 Pre-dose, 11+4 hours, 12, 23, 23 +4 hours, and 23 + 24 hours
PBMC samples wil l be collected on Day s 1, 1 + 4 hours, 1 
+ 24 hours and Weeks 11, 
11 + 4 hours, 12, 23, 23 + 4 hours, and 23 + 24 hours
TLR8 SNP genot yping on Day 1 but may be collected at an y time during the study  or at any  
unscheduled visit
Sparse ( pre-identified ) PK plasma sampl ingwill occur on Day  1 and Week 23at pre -dose, 1, 
4, and 24 hours post -dose and at Week 11 at pre -dose, 1, and 4 hours post -dose.
Sparse (timed) plasma PK samples will be obtained on any  two of the following visits :
Weeks 2, 4, 8, 12, 16, and/or 20 at pre- dose and any  time between 30 minutes to 4 hours
post-dose.
Holter Monitoring
Day 1: Pre-dose (≤ 5minutes of dose) through 4hours, and 24 hours
Week 11: Pre -dose ( ≤ 5minutes of dose) through 4hours
Week 23: Pre -dose (≤ 5minutes of dose) through 4hours , and 24 hours
  
Health Related Quality  of L ife (HRQoL) Survey s (SF -36, CLDQ, and WPAI) on Day  1 and 
Week 12
Randomization  on Day  1
If a subject chooses to terminate the study  anytim
e during the treatment period, all subjects 
should complete allof the above assessments at the ED visit except for the sparse (timed )plasma 
PK sample.
6.3.1.
 
 
 
CCI
CCII 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 63 27 August 2019 
 
 
 
 
. 
6.4. Post-Treatment Assessments ( All Visits Have Window of ± 3Days except 
Week 24 ± 1 Day
)
Complete phy sical examination (includes weight, height, BMI, vital signs, concomitant 
medications and AEs)
Ophthalmologic exam on Week 24 (Day s -4 to +10)
Safety  laboratory  tests ( serum chemistry , hematology , and coagulation)
Urinaly sis
Fibro Test on Weeks 24 and 48/ED
Serum β -hCG, for all female subjects of child -bearing potential
HBV DNA and resistance surveillance
Qualitative HBV serology  (HBeAg [reflex HBeAb if HBeAg is ne gative] and HBsAg 
[reflex HBsAb if HBsAg is negative]) on Weeks 24, 36, and 48/ED
Quantitative HBsAg
Quantitative HBeAg, HBV RNA and HBcrAg 

Pharmacod ynamic assessments: 
Serum and plasma PD biomarkers on Weeks 24 and 28
Whole blood gene expression (PAXgene RNA) samples on Weeks 24 and 48/ED
PBMC samples will be collected on Weeks 24 and 48/ED
HRQoL  Survey s (SF -36, CL DQ, and WPAI ) on Weeks 24 and 48/ED
If a subject chooses to terminate the study  anytime during the post-treatment period, all subjects 
should complete allof the above assessments at the ED visit .
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 64 27 August 20196.5. Treatment Free Follow -up(TFFU) Visit Assessments ( ± 7 Days)
Following completion of the 48 -week stud y period the I nvestigators will be responsible for 
assessing the need to continue study  subjects on treatment for CHB. At Week 48, per PI 
discretion, if a subject discontinues OAV treatment, the subject will be followed every  4 weeks 
for the first 24 weeks and thereafter at Week 36 and Week 48 in the TFFU phase . 
The following evaluations will be performed at TFFU visits unless otherwise specified. For more 
details, refer to Appendix 2.
Review of AEs and concomitant medications
Symptom -directed phy sical examination
Vital Signs (blood pressure, heart rate, respiration rate and bod y temperature)
Serum pregnancy  test (for all female subjects of child -bearing potential)
Urinaly sis
Safety  laboratory  tests (serum chemistry , hematology , and coagulation)
HBV DNA levels and resistance surveillance
Quantitative HBsAg
Quantitative HBeAg, HBV RNA, Quantitative HBcrAg
Qualitative HBV serology  (HBeAg [reflex HBeAb if 
HBeAg is negative] and HBsAg
[reflex HBsAb if HBsAg is negative])
PBMC

  
Whole blood gene expression (PAXgene RNA) samples 
HRQoL  Survey s (SF -36, CL DQ, and WPAI ) on TFFU Week 12 (Study  Week 60) ,TFFU 
Week 24 (Study  Week 72) and TFFU Week 48 (Study  Week 96)
At the PI s discretion, subject(s) in the TFFU phase may  restart commercia lly available CHB 
OAV treatment at an y time per local treatment guidelines . If a subject restarts OAV therap y for 
their CHB, TFFU visits will continue for 2 more TFFU visits or until the end of the TFFU phase 
(Study  Week 96), whichever comes first.
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 65 27 August 20196.5.1.  
 
 
 
 
 
 
 
 
6.6. Unscheduled Visits
The assessments at the unscheduled visits are at the investigator’s discretion.
6.7. Pharmacokinetic Assessments
Sparse (pre-identified ) plasma PK Collection:
Day 1: Pre -dose, 1, 4 and 24 hours post -dose 
Week 11: Pre -dose , 1,and4 hours post -dose 
Week 23
:Pre-dose , 1, 4 and 24 hours post -dose 
Sparse (timed ) plasma PK Collection (Any 2 of the 2 collections below) :
Week 2 :Pre-dose  and any  time between 30 minutes to 4 hours post -dose
Week 4 :Pre-dose  and any  time between 30 minutes to 4 hours post -dose
Week 8 :Pre-dose  and any  time between 30 minutes to 4 hours post -dose
Week 12: Pre-dose  and any  time between 30 minutes to 4 hours post -dose
Week 16: Pre-dose  and any  time between 30 minutes to 4 hours post -dose
Week 20: Pre -dose  and any  time between 30 minutes to 4 hours post -dose
6.7.1.  
 
 
CCI
CCII 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 66 27 August 20196.8. Pharmacodynamic Assessments
Serum and plasma PD biomarker s:
Day 1: Pre -dose, 4and 24 hours post-dose
Week 2: Pre -dose 
Week 8 : Pre-dose 
Week 11
: Pre-dose and4 hours post-dose
Week 12: Pre -dose 
Week 16: Pre -dose 
Week 20: Pre -dose 
Week 23: Pre -dose, 4 and 24 hours post-dose
Week 24: Pre -dose 
Week 28: Pre -dose 
TruCulture sample:
Day 1: Pre -dose
Whole blood gene expression (Paxgene RNA) samples:
Days 1
:Pre-dose, 4 hours and 24 hours post -dose
Weeks 11
: Pre-dose and 4hours post -dose
Week 12
Week 23: Pre-dose, 4 hours and 24 hours post -dose
Week 24
Week 48/E D
AllTFFU visit s: Weeks 4, 8, 12, 16, 20, 24, 36 and 48
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 67 27 August 2019PBMC: 
Days 1: Pre-dose, 4 hours, and 24 hours post -dose
Week 11: Pre-dose and 4 hours post -dose
Week 12
Week 23: Pre-dose, 4 hou rs, and 24 hours post-dose
Week 24
Week 48/ED
AllTFFU visit s: Weeks 4, 8, 12, 16, 20, 24, 36 and 48
TLR8 SNP genotyping : 
Day 1
butmay be collected at any time during the study  or at any  unscheduled visit

Optional genomic research : 
6.8.1.
 
 
 
 
 
CCI
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 68 27 August 2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.8.2. TruCulture Samples
TruCulture tubes are customized blood collection tubes manufactured to contain GS -9688 and 
will be used to assess the ex vivo activation of peripheral blood of subjects in the study .
CCII 
I 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 69 27 August 20196.9. Safety Assessments
Assessment of AEs and concomitant medications will continue throughout the duration of the 
study , including TFFU . Laboratory  anal yses, ph ysical examinations including vital signs, and 
ECGs / Holter m onitoring will be performed at defined intervals throughout the study .
Safety  Assessments will be performed through the study  as outlined in Appendix 2.
6.9.1. Electrocardiogram Assessment
Subjects should rest quietly  in the supine position for a minimum of 10 minutes prior to each 
scheduled ECG acquisition and should remain in that position until the recording is complete. 
There should be no environmental distractions (including TV, radio, video games, and 
conversation) while the subjects are resting prior to and during the recordings. 
Electrocardiograms will be recorded prior to any  blood draw 
using the site’s standard ECG 
equipment. All ECGs will be obtained using instruments that analy ze data using the same 
algorithms and produce the same data for interpretation. Electrode placement will be performed 
according to the method of Wilson, Goldberger, and Einthoven with a check to confirm that the 
aVR lead is not inverted. The investigator or other qualified individuals at the study  center will 
review ECGs to assess for changes in ECG intervals and morphology  as compared with 
pretreatment ECGs. ECG int erval measurements output by  the machine will be used for bedside 
safet y monitoring.
Collection of additional ECGs for routine safet y monitoring at additional time points or day s is at 
the discretion of the investigator based on GCP.
6.9.2. Holter Monitoring
For the purposes of this study , time -matched digital 12 -lead ECGs will be collected as 
continuous recordings. ECGs may  be extracted from recorded data at a later time.
Holter recording will be obtained via continuous 12-lead digital recorder. Baseline and 
on-treatment ECGs for all treatments will be measured from the same lead for each subject 
(lead II, when possible). Triplicate ECGs will be extracted at various time points for each 
pre-determined time points as indicated below:
Holter Monitoring
Day 1: Pre-dose (≤ 5minutes of dose) through 4hours, and 24 hours
Week 11: Pre -dose (≤ 5minutes of dose) through 4hours
Week 23: Pre -dose (≤ 5minutes of dose) through 4hours , and 24 hours
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 70 27 August 2019During ECG sampling, subjects will rest in a supine position for 10 minutes before and during 
the 5-minute window for each pre- determined ECG acquisition time point. ECGs should be 
collected in a calm, relaxed environment. Environmental distractions (including TV, radio, video 
games, and conversation) and the use of electr onic devices (including cell phones, tablets, and 
laptops) during both the pre -ECG rest and the ECG recording period must be avoided.
All ECG acquisitions will be carried out before blood sample collections at that time tpoint. 
6.9.3. Physical Examination
Physical examinations conducted throughout the study  will be either a complete phy sical 
examination or sy mptom directed phy sical examination , as outlined in 
Appendix 2. 
The complete ph ysical examination conducted at screening will also include the following 
assessments:
Review medical history , including history  of allergies, prior and current use of ,cigarettes
,
tobacco, or an y smoking products, alcohol and illegal drug use, and prior (within 30 days) and 
current medication use .
6.9.4. Vital Signs 
Vital sign measurements include blood pressure, heart rate, respiration rate, and temperature and 
should be taken once subjects have been seated or in the supine position. Subject position for 
measurement should be kept consistent throughout the study. Refer to Appendix 2for vital signs 
collectio n time points.
6.9.5. Clinical Laboratory Tests/Assessments for Safety Evaluations
Blood and urine samples for safety  evaluations will be collected throughout the study  as outlined 
in Appendix 2.
6.9.5.1. Blood Sampling
Blood samples will be collected for the following laboratory  anal yses:
Hematology : 
Hematocrit, hemoglobin, platelet count, red blood cell (RBC) count, white blood cell
(WBC) count with differential (absolute and percentage), including l ymphocy tes, 
monocy tes, neutrophils, eosinophils, basophils, andmean corpuscular volume (MCV)
,
and coagulation panel (prothrombin time, partial thromboplastin time [PTT] and I NR)
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 71 27 August 2019Chemistry (fasting): 
Alkaline phosphatase, AST, AL T, total bilirubin, direct and indirect bilirubin, total 
cholesterol, high -densit y lipoprotein (HDL), LDL, trigl ycerides (TG) , total protein, 
albumin, lactic acid deh ydrogenase (LDH), CK ,bicarbonate, blood urea nitrogen (BUN), 
calcium, chloride, creatinine (see below), glucose, phosphorus, magnesium, potassium, 
sodium, uric acid, and lipase (reflex amy lase testing is performed in subjects with total 
lipase  >1.5 × ULN)
Serum pregnancy  test (females of childbearing potential only )
FSH testing (For female subjects post- menopausal for less than two years, if FSH 
< 40 mIU/mL a serum pregnancy  test will be required)
HIV, H DV, and HCV testing (screening onl y)
HBV Viral Parameters:
Qualitative HBV Serology , HBV DNA levels , HBV Resistance Surveillance, 
Quantitative HBsAg, Quantitative HBCrAg, Quantitative HBeAg, and HBV RNA
6.9.5.2. Urine Samples
Urine samples will be collected for urinal ysis, alcohol and drug screen assessments and urine 
pregnancy  as applicable.
6.9.6. Creatinine Clearanc e
Weight will be collected at screening and upon admission calculate creatinine clearance ( CrCl ) 
for inclusion criteria.
Estimated CrCl < 60 mL /min (using the Cockcroft -Gault method) based on serum creatinine and 
actual bod y weight as measured at the screening evaluation, i.e.
Male: (140 –Age [y ears]) (Weight [kg]) CrCl (mL /min)
72(Serum Creatinine [mg/dL ])
Female: (140 –Age [y ears]) (Weight [kg])  0.85 CrCl (mL/min)
72(Serum Creatinine [mg/dL ])
6.9.7. Ophthalmic Examination
Ophthalmic Examinations will be performed to assess ophthalmologic findings, including slit 
lamp and fundoscopic examination with retinal photographs (both ey es). An examination of the 
full retinal field should be conducted noting changes or abnormalities. Photographs of the retina 
must be taken at each exam and filed in the subject’s source medical records. A central vendor 
will be used to assess the retinal photographs. Refer to Appendix 2for ophthalmic examination 
collection time points.
A procedural window will be given to accommodate ophthalmic assessments. Refer to 
Appendix 2for details.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 72 27 August 20196.9.8. Adverse Events/Concomitant Medications/Protocol Restrictions
Evaluation for AEs, review of concomitant medications, and review of protocol restrictions will 
occur at the times sh own in Appendix 2. See Section 7.1 for more information regarding AEs 
and Section 5 and Table 5-1for more information about concomitant medications.
6.10. Sample Storage
The stored blood samples may  be used by  Gilead or its research partner for future clinical 
laboratory  testing to provide additional data to answer questions that relate to the main study . At 
the conclusion of this study , the backup PK samples may  be retained in storage by  Gilead at its 
research partner facility  for a period up to 2 y ears. 
6.11. Assessments for Premature Discontinuation from Study
If a subject discontinues study  treatment dosing for example as a result of an AE, every  attempt 
should be made to keep the subject in the study  and continue to perform the required 
study -related procedures until stabilization per the investigator.
If this is not possible or acceptable to the subject or investigator, the subject may  be withdrawn 
from the study . Evaluations indicating abnormal results believed to be possibly  or probabl y 
related to stud y treatment at the EDvisit should be repeated weekly  or as often as deemed 
appropr iate b y the i
nvestigator until the abnormality resolves, returns to baseline visit levels, or 
is otherwise explained.
6.12. Criteria for Discontinuation of Study Treatment
Discontinuation of dosing for individual subjects will be governed b y pre -specified stoppi ng 
rules for safet y and tolerability .
Study medication may be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree
Unacceptable toxicit y, as defined in the toxicity  management Section 7.6of the protocol, or 
toxicity  that, in the judgment of the investigator, compromises the ability to continue 
study -specific procedures or is considered not to be in the subject’s best interest
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 3
Investigator discretion
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 73 27 August 2019Discontinuation of the study  at the request of Gilead, a regulatory  agency  or an institutional 
review board or independent ethics committee (IRB/IEC)
Continuation of dosing will be suspended if three or more Grade 3 or two or more Grade 4 
treatment -emergent, drug related AEs or laboratory  abnormalities occur. Decisions to 
reinitiate continuation of dosing will be made b y the Sponsor upon review of all sa fety data 
generated b y subjects dosed to date.
Refer to Section 7.6for additional discontinuation criteria for Toxicity  Management. HBV will 
be ma naged according to local standard of care if subjects are discontinued from the study . 
Subjects that discontinue all study  drugs will be followed for up to 48weeks if continued into the
Treatment Free Follow -up (TFFU) phase .
6.13. Resistance Surveillance
Sequence anal ysis of the HBV genome may  be attempted for an y subject who is currentl y being 
treated with OAV and experiences viremia (HBV DNA > 69 IU/mL) at an y time point. 
As it may  not be known at the time of the visit whether a patient is viremic or if it will be their 
last study  visit, a separate serum sample for potential resistance surveillance will be collected at 
each stud y visit.
6.14. End of Study
The end of this study  will be the last subject’s last completed study  visit observ edat Week 48. If 
the subject enrolls in the TFFU phase, the subject will be observ ed for up to an additional 
48weeks ( Study  Week 96 ).
6.15. Post Study Care
Once a subject has completed their stud y participation, the long -term care of the participant will 
remain the responsibility  of their primary  treating phy sicians.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 74 27 August 20197. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An AEis an y untoward medical occurrence in a clinical study  subject administered a medicinal 
product ,which does not necessarily  have a causal relationship with th etreatment. An AE can 
therefore be an y unfavorable and/or unintended sign, s ymptom, or disease temporally  associated 
with the use of a medicinal product, wheth er or not considered related to the medicinal product.
AEs may  also include pre -or post-treatment complications that occur as a result of protocol 
specified procedures, lack of efficacy , overdose, drug abuse/misuse reports , or occupational 
exposure . Preexisting events that increase in severity  or change in nature during or as a 
consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, andtransfusion
.
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situa tions where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.10.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A SAE is defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 75 27 August 2019Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contamin ated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs an d SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to IMP 
therap y using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the 
investigational medicinal product.
It should be emphasized that ineffective treatment should not be consid ered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse e vent has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures, (eg., venipun cture )
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 76 27 August 20197.2.2. Assessment of Severity
AE severit y should be recorded and graded according to the modified GSI Grading Scale for 
Severity  of AEs and Laboratory  Abnormalities ( Appendix 4). For AEs associated with laboratory  
abnormalities, the event should be graded on the basis of the clinical severity in the context of 
the underl ying conditions; this may  or may  not be in agr eement with the grading of the 
laboratory  abnormality .
The distinction between the seriousness and the severity  of an adverse event should be noted.
Severity  is a measure of intensity ; thus, a severe reaction is not necessarily  a serious reaction. For 
example, a headache may be severe in intensity
, but would not be classified as serious unless it 
met one of the criteria for serious events.
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underly ing conditions; this may  or may  not be in agreement 
with the grading of the laboratory  abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead 
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the CRF/eCRF: all SAEs and AEs related to protocol
-mandated 
procedures.
7.3.1. Adverse Events
Following initiation of study  treatment, collect all AEs, regardless of cause or relationship, until 
30 day s after last administration of study  drug or at Week 48, whichever occurs last, and report 
to the eCRF database as instructed. Further, an y AEs occurring during TFFU should also be 
reported, regardless of cause or relationship.  
All AEs should be followed up until resolution or until the AE is stable, if possible. Gilead may  
request that certain AEs be followed beyond the protocol -defined follow -up period.
7.3.2. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period and TFFU , must be 
reported to the CRF/eCRF database and Gilead PVE as instructed. This also includes an y SAEs 
resulting from protocol -associated procedures performed after informed consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 30- days of the 
last dose of study  drug, regardless of causalit y, should also be reported. 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 77 27 August 2019Investigators are not obligated to activel y seek SAEs after the protocol defined follow -upperiod ,
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly  document and report 
the event to Gilead PVE .
All AEs and SAEs wil l be recorded in the CRF/eCRF database within the timelines outlined 
in the eCRF completion guideline. 
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
infor mation to Gilead PVE within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If it is not possible to record and submit the SAE information electronicall y, because the 
eCRF databas e cannot be accessed or is not available (including at study  start), record the 
SAE on the paper serious adverse event report form and submit by  e-mail or fax within 
24 hours of the investigator’s knowledge of the event to:
PVE previously  known as Gilead D SPH:Fax:
E-mail:
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary . 
For fatal or life -threatening events, copies of hospital case reports, autops y reports, and other 
documents are also to be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
form.
PPD
PPD
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 78 27 August 20197.4. Gilead Reporting Requirem ents
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, Gilead may  be required to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). I n accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a spec ified designee will notify  worldwide regulatory  
agencies and the relevant I EC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by  Gilead using reference safety  
information specified in the investigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant S
USAR reports associated 
with any  study  IMP. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.5. Clinical Labora tory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are usuall y not recorded as AEs or SAEs. 
However, laboratory  abnormalities (e.g., clinical chemistry , hemat ology , and urinaly sis) 
independent of the underly ing medical condition that require medical or surgical intervention or 
lead to investigational medicinal product interruption, modification or discontinuation must be 
recorded as an AE, as well as an SAE, if applicable. In addition, laboratory or other abnormal 
assessments (e.g., electrocardiogram, X -rays, vital signs) that are associated with signs and/or 
symptoms must be recorded as an AE or SAE if they  meet the definition of an AE (or SAE) as 
described in Sections 7.1.1 and7.1.2. If the laborat ory abnormality  is part of a s yndrome, record 
the sy ndrome or diagnosis (i.e., anemia) not the laboratory  result (i.e., decreased hemoglobin).
Severity  should be recorded and graded according to the modified GSI Grading Scale for 
Severity  of Adverse Events and Laboratory  Abnormalities as described in Appendix 4.The GSI  
Grading Scale for Severity of Adverse Events and Laboratory  Abnormalities has been modified 
to be more appropriate for health y volunteers and patients with inflammatory diseases 
(e.g. rheumatoid arthritis, asthma, psoriasis). For AEs associated wi th laboratory  abnormalities, 
the event should be graded on the basis of the clinical severity  in the context of the underl ying 
conditions; this may  or may  not be in agreement with the grading of the laboratory  abnormality .
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 79 27 August 20197.6. Toxicity Management
All clinical and clinicall y significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3.
All Grade 3 
or greater AEs and laboratory  abnormalities will be reviewed by  the Sponsor to 
determine if the event is at least possibly  treatment- related to determine if the study  drug 
should be held or discontinued
Grade 3 and 4 clinicall y significant laboratory  abnormalities should be confirmed b y repeat 
testing within 3 calendar days of receipt of results and before investigational medicinal 
product discontinuation, unless such a delay  is not consistent with good medical practice.
Clinical events and clinically significant laboratory  abnormalities will be graded according to 
the Table for GSI Grading Scale for Severity  of Adverse Events and Laboratory  
Abnormalities ( Appendix 4).
Whe n restarting investigational medicinal product following resolution of the adverse event,
the investigational medicinal product should be restarted at full dose that is dependent upon 
discussion with the Gilead Sciences Medical Monitor.
Administration of s
tudy drug may  be discontinued due to a clinical or laboratory  event. The
Gilead Medical Monitor should be consulted prior to dose discontinuation of study  drug
unless the investigator believes that immediate action is warranted to ensure the continued
safet y of subject.
Any questions regarding toxicity  management should be directed to the Gilead Sciences
Medical Monitor.
7.6.1. ALT Elevation or Flare Management
Subjects with on- treatment AL T flare defined as serum ALT > 2 BL and≥ 5ULN (with or 
without as sociated sy mptoms) should be managed according to the guidance below. 
All on -treatment ALT flare should be confirmed within 3 day s of receipt of results. During the 
visit, a clinical assessment of the subject should be performed. The assessment should inc lude a 
complete ph ysical examination, evaluation of the subject’s mental status and the following 
laboratory  tests: 
Laboratory  parameters: serum ALT, AST, alkaline phosphatase, total and fractionated
bilirubin, gamma -glutamy l transferase (GGT), INR and se rum albumin .
If the ALT elevation/flare is confirmed, the central clinical laboratory  will conduct reflex 
testing for plasma HBV DNA, qualitative HBV serology (HBeAg [reflex HBeAb if HBeAg 
is negative] and HBsAg [reflex HBsAb if HBsAg is negative]), HAV Ig M, HCV RNA, HDV 
RNA, and HEV IgM.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 80 27 August 20197.6.2. Management of Dose Limiting Toxicities
In the event of an y DLT, the investigator should discuss with the Gilead Medical Monitor the 
subject’s status until the DL T has resolved.
GS-9688/ PTM dosing for a subject will be held if the subject experiences at least one of the 
following DLT:
A confirmed, clinically  significant lab abnormality (other than ALT) ≥ Grade 3 considered 
drug-related b y the investigator or Sponsor
Dose -limiting ALT flare defined as confirmed ALT ≥ 10x ULN (to be confirmed within 
3days from receipt of 
initial laboratory  results)
If a subject experiences any  of the above DLT, then GS -9688/ PTM will be held until repeat labs 
demonstrate that the lab abnormality  returns to ≤ Grade 2 levels. O nce the lab abnorma lity 
returns to ≤ Grade 2, GS -9688/ PTM can be restarted with medical monitor approval. Subjects 
who experience a dose interruption DLT will continue to be monitored at least once a week, or 
more frequently  as clinically  needed, until resolution.
GS-9688/ PTM dosing for a subject will be permanently  discontinued if the subject experiences 
at least one of the following DLTs:
A confirmed ALT increase (i.e. grade shift or 2x previous value) with evidence of worsened 
hepatic function (e.g. Total Bilirubin > 2mg /dL above BL, elevated INR ≥ 1.7 or > 0.5 over 
BL, abnormal serum albumin > 1g/dL decrease from BL)
Prolonged (2 sequential), confirmed, clinically  significant lab abnormality  (other than ALT) 
≥ Grade 3 considered drug -related b y the investigator
Any confirmed recurrence of study  drug -related Grade 3 or 4 clinicall y significant laboratory 
adverse event following dose interruption mandates permanent discontinuation of study  drug.
A confirmed ≥ Grade 3 AE (excluding ALT) considered drug -related b y the investigator
Subjects who experience a permanent discontinuation DLT will be monitored at least once a 
week, or more frequentl y as clinically needed, until resolution.
7.6.3. Management of Neutropenia
If a subject experiences Grade 2 or higher neutropenia while par ticipating in the study , they
should return to the study site the following week (within 7 day s) for retest and result
confirmation from the central lab . If Grade 2 or higher neutropenia is confirmed, GS-9688/ PTM
dosing should be held until the retest results are available and subject followed weekly  until 
neutrophils improves to < Grade 2. At that time, w ithGilead m edical monitor approval, 
GS-9688/ PTM may be rechallenged.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 81 27 August 2019If study  drug is re -challenged followin g a return to < Grade 2, GS -9688/placebo dosi ng should
continue as per the original treatment schedule. If any scheduled dosing of GS -
9688/placebo is
missed due to a Grade 2 neutropenia event, it should be captured in the source documentation
and appropriate CRF.
7.6.4. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study  drug at the discretion of the investigator.
7.6.5. Grades 3 and 4 Laboratory Abnormality or Clinical Event
For a Grade 3 and 4 clinical event or clinicall y significant Grade 3 and 4 laboratory abnormality 
(with the exception of asymptomatic Grade 3 or 4 cholesterol and trigl yceride increases or CK 
elevations unrelated to study
 drug, or hematuria due to menses) confirmed by  repeat testing 
(preferabl y within 3 calendar day s after receipt of the original test results), study  drug should be 
permanentl y discontinued and the subject managed according to local practice. The subject 
should be followed as clinically  indicated until the laboratory  abnormality  returns to baseline or 
is otherwise explained, whichever occurs first. A clinically significant Grade 3 and 4 laboratory 
abnormality  that is not confirmed by  repeat testing should be managed according to the 
algorithm for the new toxicity  grade.
7.7. Other Criteria for Discontinuation of Study Drug
Discontinuation of dosing for individual subjects will be governed b y pre -specified stopping 
rules for safet y and tolerability .
Study medication may be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical statu
s to a significant degree
Unacceptable toxicity , as defined in the toxicity  management Section 7.6of the protocol, or 
toxicity  that, in the judgment of the investigator, compromises the ability  to continue 
study -specific procedures or is considered not to be in the subject’s best interest
Subject requests to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 3
Investigator discretion
Discontinuation of the study  at the request of Gilead, a regulatory  agency  or an IRB or IEC
Continuation of dosing will be suspended if three or more Grade 3 or two or more Grade 4 
treatment -emergent, drug related AEs or laboratory  abnormalities occur. Decisions to 
reinitiate or continuation of dosing will be made by  the Sponsor upon review of all safet y 
data generated b y subjects dosed to date.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 82 27 August 2019Refer to Section 7.6for additional discontinuation criteria for Toxicity  Management. HBV 
disease will be managed according to local standard of care if subjects are discontinued from the 
study . Subjects that discontinue all study  drugs will be followed for up to 24 weeks if continued 
into the Treatment Free Follow -up (TFFU) phase.
An independent, external D ata Monitoring C ommittee (DMC) will review the progress of the 
study  and perform safet y data review after 20 subjects have completed randomization .
Subsequent meetings may be held approximately  every  3 months until the last subject enrolled 
has completed the stud y drug dosing period. The DMC will provide recommendations as needed 
regarding stud y conduct and the need for additional meetings or an alternative meeting schedule.
The DMC will be immediately  notified in t he event of any  dose limiting toxicities (DLT) or 
virologic stud y stopping criteria.
7.8. Subject Withdrawal Criteria
Discontinuation of dosing for individual subjects will be governed b y pre specified stopping 
rules for safet y and tolerability
. A subject will be withdrawn from stud y if they experience one of 
the following:
A confirmed, clinically  significant treatment -emergent ≥ Grade 3 adverse event or laboratory  
abnormality  (with the exception of as ymptomatic Grade 3 or 4 cholesterol and TGincreases 
or CK e levations unrelated to study  drug, or hematuria due to menses) , considered 
treatment -related, defined by  the GSI Grading Scale ( Appendix 4). Subjects should be 
followed as clinicall y indicated until the laboratory abnormality returns to baseline or is 
otherwise explained, whichever occurs first. Grade 3 and 4 laboratory  abnormalities that are 
not confirmed b y repeat testing should be managed according t o the algorithm for the new 
toxicity  grade.
A clinically  significant ECG measurement (e.g., a change from baseline QTcF value of 
>
60msec, 2nd or 3rd degree heart block, or pronounced QRS widening) by  confirmed 
measurement as described in Section 6.9.1.
7.9. Study Specific Stopping Criteria
7.9.1. Laboratory Abnormalities and Treatment -Emergent Adverse Events
If 3 or more subjects in any  cohort experien ce the same or similar Grade 3 or Grade 4 
treatment -emergent adverse event or confirmed laboratory  abnormality  (with the exception of 
asymptomatic Grade 3 or 4 cholesterol and TG increases), unless there is a clear and obvious 
physiologic explanation for t he events (e.g. blood in urine occurring in a menstruating female, 
CK elevation after strenuous exercise, or TG elevation that is non fasting, etc.), then a review of 
all safet y data generated in subjects dosed to date will be initiated. For individuals al ready on 
study  drug, the decision whether or not to complete the full course of study medication will be 
made b y the sponsor with disclosure of new information to the study  subject(s).
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 83 27 August 20197.9.2. Virologic Criteria
If 2 or more subjects in a treatment arm experience an increase in HBV DNA of ≥ 69 IU/mL on 
two consecutive visits , unless there is a clear and obvious explanation for the events 
(e.g. nonadherence to OAV), then a review of all safet y data generated in subjects dosed to date 
will be initiated. During this t ime, further enrollment into that treatment arm will be held and not 
reopened for enrollment until the decision to reinitiate dosing is made b y the Sponsor with input 
from the DMC upon review of all safet y data generated b y subjects dosed to date. For 
individuals alread y on study drug, the decision whether or not to complete the full course of 
study  medicat ion will be made by  the S ponsor. D isclosure of this new information will be 
provided to the study  subject(s). 
7.10. Special Situations Reports
7.10.1. Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose, reports 
of AEs associated with product complaints, occupational exposure with an AE, pregnancy  
reports regardless of an associated AE and AE in a n infant following exposure from 
breastfeeding .  
Medication error is an
y unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing in formation.
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or di stribution of the medicinal product. 
Occupational exposure is defined as exposure to a medicinal product as a result of one’s
professional or non
-professional occupation. 
Infant exposure from breastfeeding that is associated with an AE. 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 84 27 August 20197.10.2. Instructions for Reporting Special Situations
7.10.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the poststudy drug follow - up 
period, to Gilead PVE using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy .
Refer to the eCRF completion guidelines for full instructions on the mechanism of pregnancy  
reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported wit hin 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is alway s considered to be an SAE and w ill be reported as described in 
Section 7.3.2. Furthermore, an y SAE occurring as an adverse pregnancy  outcome post study
must be reported to Gilead PVE .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead 
PVE using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcome should 
be reported directl y to Gilead PVE . Gilead PVE contact informa tion is as follows: 
Email: and Fax: .
Pregnancies of female partners of male stud y subjects exposed to Gilead or other study  drugs 
must also be reported and relevant information should be submitted to Gilead PVE using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the outcome should be reported directl y to Gi lead PVE , fax 
number  or email 
Refer to Appendix 3for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements
.
7.10.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead PVE within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  IMPand/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications. 
PPD
PPD
PPD
PPD
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 85 27 August 2019Special situations involvin g non-Gilead concomitant medications does not need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form. 
Any inappropr iate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to 
Section 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 86 27 August 20198. STAT ISTICAL  CONSIDERA TIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary objectives of this study are as follows:
To evaluate the safet y and tolerability  of multiple oral doses of GS-9688 a t Week 24 in 
virally  suppressed CHB adult subjects on OAV
To evaluate the antiviral activity  of GS -9688 as measured by the proportion of subjects with 
≥1 log 10IU/mL decline from baseline in serum qHBsAg atWeek 24
The secondary objectives of this study are as follows: 
To evaluate the antiviral activity  of GS -9688 at Weeks 4, 8, 12 and 48 as measured b y the 
proportion of subjects with 
≥1 log 10IU/mL  decline from baseline in serum qHBsAg 
To evaluate the change in serum qHBsAg 
(log10 IU/mL) from baseline to Weeks 4, 8, 12, 
24and 48
To evaluate the proportion of subjects with HBsAg loss at Weeks 12, 24 and 48
To evaluate the proportion of subj ects with HBeAg loss and seroconversion at Weeks 12, 
24and 48
To characterize the PK of GS -9688 
To evaluate the proportion of subjects experiencing HBV virologic breakthrou gh 
(2consecutive visits of HBV DNA ≥ 69 IU/mL)
To evaluate the incidence of drug resistance mutations
The exploratory objectives of this study are as follows: 
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 87 27 August 20198.1.2. Primary Efficacy Endpoint
The primary  efficacy  endpoint of this study  is the proportion of subjects with ≥ 1log 10IU/mL  
decline in serum qHBsAg from baseline at Week 24
8.1.3.
Secondary Efficacy Endpoint s
The secondary  endpoints of 
this study  include:
Proportion of subjects with ≥ 1 log10 IU/mL decline in serum qHBsAg from baseline at 
Weeks 4, 8, 12 and 48
Change in serum qHBsAg (log 10IU/mL) 
from baseline at Weeks 4, 8, 12 , 24and 48
Proportion of subjects with HBsAg loss at Weeks 1 2, 24 and 48
Proportion of subjects with HBeAg loss and seroconversion at Weeks 12, 24 and 48
Proportion of subjects with virologic breakthrough (2 conse cutive visits of HBV DNA 
≥
69IU/mL)
Proportion of subjects with drug resistance mutations
8.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. Efficacy  
The primary  anal ysis set for efficacy  anal ysis is the full anal ysis set (FAS), defined as all 
randomized subjects who took at least 1 dose of the study  drug . Subjects will be anal yzed 
according to the randomized treatment assignment .In this study , the study  drugs are GS -9688 
and placebo.
8.2.1.2. Safety
The primary  anal ysis set for safety anal ysis is the safety analysis set (SAS), defined as all 
subjects who took at least 1 dose of the study  drug . Subjects will be analy zed according to the 
treatment actually  received. 
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 88 27 August 20198.2.1.3. Pharmacokinetics
The PK anal ysis set will include all randomized subjects who took at least 1 dose of the study  
drug and have at least 1 nonmissing concentration value reported by  the PK laboratory .
 
 
8.2.1.4. Pharmacod ynamic Biomarkers
The primary  anal ysis set for PD biomarker anal ysis is the biomarker analy sis set, defined as all 
randomized subjects who took at least 1 dose of the study  drug and have at least 1 nonmissing 
biomarker value for each respective biomarker.
8.3. Data Handling Conventions
For the primary  efficacy  endpoint and the categorical secondary  efficacy  endpoints, missing data 
will be handled using a missing = failure approach.
For the drug resistant mutations endpoint, a missing = excluded approach will be employ ed.For
summary  statistics, PK concentration values below the limit of quantitation (BLQ) will be treated 
as zero at pre -dose and one -half of the LLOQ for postdose time points.
8.4.
Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be summarized by treatment group and overall for 
each cohort using standard descriptive methods.
Demographic summaries will include age, sex, race and ethnicit y.
Baseline data will include a summary  of bod y weight, height, bod y mass index, HBsAg 
(log 10IU/mL), HBV DNA ( log 10IU/mL), HBV genoty pe, concomitant HBV OAV, ALT and 
additional endpoints as necessary . 
8.5. Efficacy Analysis
8.5.1. Primary Analysis
The primary  efficacy  analy sis will be performed in FAS after the last subject has completed 
Week 24 assessments or discontinued GS-9688 or placebo prematurel y.
The proportion of subjects with ≥ 1 log 10IU/mL decline in qHBsAg from baseline at Week 24
will be evaluated. To compare the GS -
9688 1.5 mg dose group and the GS -9688 3 mg dose 
group to the placebo group for HBeAg positive and negative subjects separatel y, the 
95%
confidence intervals (CI) on the proportion difference ( 1.5 mg –PTM, 3 mg –PTM) will be 
constructed, b y baseline HBeAg status (positive, negative), based on the standardized statistic 
and inverting 2 1 -sided tests.
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 89 27 August 2019In addition, by  combining the HBeAg positive and negative subjects, the 2- sided 95% CI of the 
proportion difference ( 1.5mg –placebo, 3 mg –placebo) will be constructed by  using 
stratum -adjusted Mantel -Haenszel proportions, stratified by  HBeAg status (positive, negative).
8.5.2. Secondary Analyses
Continuous secondary  endpoints will be summarized using conventional descriptive statistics 
(n,mean, standard deviation, median, Q1, Q3, minimum, and maximum) by treatment group for 
each cohort . 
Categorical secondary  endpoints will be summarized by  number and percentage of subjects that 
meet the endpoint b y treatment group for each c ohort .
8.5.3. Analysis of Other Endpoints of Interest
Continuous endpoints will be summarized using conventional descriptive statistics (n, mean, 
standard deviation, median, Q1, Q3, minimum, and maximum) by  treatment group for each 
cohort. 
Categorical endpoints will be summarized by  number and percentage of subjects who meet the 
endpoint by  treatment group for each cohort.
8.6. Safety Analysis
All safet y data collected on or after the first dose of study drug administration up to 30 days after 
the last dose of study  drug will be summarized by  treatment group according to the study  drug 
received. All safet y data collected during the study will be included in data listings.
8.6.1. Extent of Exposure
A subject’s extent of exposure to study
 drug data will be generated from the s tudy drug 
administration page in eCRF. Exposure data will be summarized by  treatment group.
8.6.2. Adverse Events
Clinical and laboratory  AEs will be coded using the Medical Dictionary  for Regulatory  
Activities (MedDRA). Sy stem organ class (SOC), high -level group term (HLGT), high -level 
term (HLT), preferred term (PT), and lower -level term (LLT) will be attached to the clinical 
database.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
AE will be defined as any  AE wit
h an onset date on or after the study  drug start date and no later 
than 30 day s after permanent discontinuation of the study  drug; or any  AE leading to premature 
discontinuation of the study  drug.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 90 27 August 2019Summaries (number and percentage of subjects) of treatment -emergent AEs (by  SOC and PT) 
will be provided by  treatment group:
All AEs
AEs of Grade 3 or above
AEs of Grade 2 or above
All treatment -related AEs
Treatment -related AEs of Grade 3 or above
Treatment -related AEs of Grade 2 or above
All SAEs
All treatment -related SAEs
All AEs leading to temporary interruption of the study  drug
All AEs leading to premature discontinuation of the study  drug
All AEs collected during the study  will be presented in the data listings. 
8.6.3. Laboratory Evaluations
Selected laboratory  data (using conventional units) will be summarized using onl y observed data. 
Data and the corresponding change from baseline will be summarized by  treatment group at each 
measured stud y visit . 
Graded laboratory  abnormalities will be defined using the grading scheme in Appendix 4
(GSI Grading Scale for Severit y of Adverse Events and Laborator y Abnormalities) for anal ysis 
purpose. 
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase by at 
least one toxicity  grade from baseline at any  time post baseline
,up to and including the date of 
last dose of study  drug plus 30 days, will be summarized by  treatment group . 
Values for missing safety laboratory data will not be imputed; however, a missing baseline result 
will be replaced with a screening result, if available. If no pretreatment laboratory  value is 
available, the baseline value will be assumed to be normal (i.e., no grade [Grade 0] ) for the 
summary  of graded laboratory  abnormalities.
All laboratory  abnormalities will be included in the listings of laboratory  data .
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 91 27 August 20198.6.4. Other Safety Evaluations
Individual data fo rECG and vital sign measurements will be listed by  subject and summarized 
for each treatment group by incidence of events/abnormalities or descriptive statistical 
summaries (n, mean, SD, median, Q1, Q3, minimum, and maximum) , as appropriate.
8.7. Pharmacokinet ic Analysis
 
 
 
 
 
 
. 
8.8. Exploratory Analysis
 
 
 
 
 
 
 
 
.
CCI
CCI
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 92 27 August 20198.9. Sample Size
Due to the exploratory  nature of this study , the sample size was not determined by  any formal 
power calculation. The number of subjects in each treatment group was decided based on clinical 
experience.
8.10. Data Monitoring Committee
An independent, external D ata Monitoring C ommittee (DMC) will review the progress of the 
study  and perform safet y data review after 20 subjects have completed randomization .
Subsequent meetings may be held approximately  every  3 months until the last subject enrolled 
has completed the stud y drug dosing period. The DMC will provide recommendations as needed 
regarding stud y conduct and the need for additional meetings or an alternative meeting schedule . 
The DMC will be immediately  notified in t he event of any  DLT or virologic study  stopping 
criteria .
While the DMC will be asked to advise Gilead regarding future conduct of the study , including 
possible earl y study termination, Gilead retains final decision -making authority  on all aspects of 
the study.
8.11. Internal Data Review Team
The study  will be unblinded to appropriate GSI study  team personnel at the time of primary  
analysis(Week 24 assessment) . An Internal Data Review , external to the study  team, may be 
unblinded at Week 12 assessment visit to r eview the unblinded safet y and efficacy  data in order 
to guide strategic decisions regarding the future of the program . Investigators and subjects will 
remain blinded thro ugh Week 48 except in instances of emergency  treatment unblinding 
(
See Section 5.1.1). 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 93 27 August 20199. RESPONS IBILITES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, 
andSouth Africa), ICH guidelines, or with the laws and regulations of the country  in which the 
research is conducted, whichever affords the greater protection to the study  subject. These 
standards are consistent with the European Union Clinical Trials Directive 2001/20/EC and 
Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of GCP as outlined in 21 CFR 312, 
subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, part
50, 1998, and 21 CFR, 
part56, 1998.
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, 1998, 
providing documentation of their financial interes t or arrangements with Gilead, or proprietary  
interests in the investigational drug under stud y. This documentation must be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator ag
ree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol- defined activities.
9.1.2. Institutional Review Boar d (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, Informed Consent Form ( ICF), and any  accompan ying material to be provided to the 
subject ( such as advertisements, subject information sheets, or descriptions of the study  used to 
obtain informed consent) to an I RB/IEC .The investigator will not begin any  study  subject 
activities until approval letter from the IRB has been documented and sponsor has also provided 
a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC any  modifications made to the protocol or any  accompany ing material to be 
provided to the subject after initial I RB/IEC approval
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the stu dy and before undertaking an y stud y-related procedures. The 
investigator must use the most current IRB/IEC -approved ICF for documenting written informed 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 94 27 August 2019consent. Each ICF will be appropriatel y signed and dated b y the subject or the subject’s legall y 
author ized representative and the person conducting the consent discussion, and also by  an 
impartial witness if required b y IRB/ IEC local requirements. The consent form will inform 
subjects about PG testing and sample retention, and whether they  will receive cli nically  relevant 
PG analy sis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthori zed parties. Only  date of birth, another unique identifier 
(as allowed b y local law), and an identification code will be recorded on any form or biological 
sample submitted to the sponsor, I RB/IEC/EC or laboratory . Laboratory  specimens must be 
labeled in such a way  as to protect subject identity  while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions or in accordance with local 
regulations. NOTE: The investigator must keep a screening log showing codes, names, and 
addresses for all subjects screened and for all subject s enrolled in the study . Subject data will be 
processed in accordance with all applicable regulations.
The investigator agrees that all information received from Gilead, including but not limited to the 
IB, this protocol, eCRF, the study  drug, and an y othe r study  information, remain the sole and 
exclusive property  of Gilead during the conduct of the study  and thereafter. This information is 
not to be disclosed to any third party  (except employ ees or agents directl y involved in the 
conduct of the stud y or as required b y law) without prior written consent from Gilead. The 
investigator further agrees to take all reasonable precautions to prevent the disclosure by  any 
employ ee or agent of the study  site to an y third party or otherwise into the public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study
 data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB/IEC and governmental approval with correspondence, informed con sent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identif ication (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled;
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 95 27 August 2019Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all AEs and other safety  parameters (start and end date, and including causality  
and severit y);
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study completion and reason for ED, if it occurs
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region and until there are no pending or planned marketing applications in an I CH 
region; or, if no application is filed or if the application is not approved for such indication, until 
2years after the investigation is discontinued and regulatory  authorities have been notified. 
Investigators may  be required to retain documents longer if specified by  regulatory  requirements, 
by local regulations, or by  an agreement with GSI. The investigator must notify  GSI before 
destroy ing any  clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, G SImust be notified in advance.
If the investigator cannot provide for this archiving requirement at the study site for any  or all of 
the documents, special arrangements must be made between the investigator and G SIto store 
these records securel y awa y from the site so that they can be returned sealed to the investigator 
in case of an inspection. When source documents a re required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF will be completed by  an authorized study  staff member 
whose training for this functio n is documented according to stud y procedures. eCRF should be 
completed on the day  of the subject visit to enable the sponsor to perform central monitoring of 
safet y data.  The Eligibility  Criteria eCRF should be completed onl y after all data related to 
eligibility  have been received.  Subsequent to data entry , a study  monitor will perform source 
data verification within the EDC system. Original entries as well as any  changes to data fields 
will be stored in the audit trail of the sy stem.  Prior to databa se lock (or an y interim time points 
as described in the clinical data management plan), the investigator will use his/her log in 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 96 27 August 2019credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System -generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  the monitor or internal Gilead staff, 
who routinely  review the data for completeness, correctness, and consistency . The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either b y confirming the data as correct or updating the original en try, and providing the reason 
for the update (e.g. data entry  error). At the conclusion of the trial, Gilead will provide the site 
with a read -only archive copy  of the data entered by  that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5 .
9.1.7. Study Drug Accountability and Return
Gilead recommends that used and unused IMP supplies be returned to the shipping facility  from 
which it came for eventual destruction. The stud y monitor will provide instructions for return. If 
return is not possible, the study  monitor will evaluate each st udy center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. I f the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined b y 
Gilead , the site may  destroy  used (emp
ty or partially  empt y) and unused IMP supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved SOP will be obtained 
for central files. 
If IMP is destroyed on site, the investigator must maintain accurate records for all IMP 
destroyed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the I MP. Upon study  completion, copies of the 
IMP accountability  records must be filed at the site. Another copy  will be returned to Gilead.
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud y monitors , toIRB, or to regulatory  authorit y or health authority 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Spons or Responsibilities
9.2.1.
Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit all protocol modifications to I RB in 
accordance with local requirements and receive do cumented IRB approval before modifications 
may be implemented.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 97 27 August 20199.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency. G SIwill 
ensure that the report meets the standards set out in the I CH Guidel ine for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases.
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings.  If required under the applicable statutory  
and regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including any  clinical trial pay ments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
CRF /eCRF .
The monitor is responsible for routine review of the CRF /eCRF at regular intervals throughout 
the study  to verify  adherence to t he protocol and the completeness, consistency , and accuracy  of 
the data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the CRF /eCRF . The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of G SImay conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the G SImedical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or G SIaccess to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authority, IRBs, and IECs. In terminating the stud y, Gilead and the investigator will 
assure that adequate consideration is given to the protection of the subjects’ interests.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 98 27 August 201910. REFERENCES
Benias P, Min A. Goals of Antiviral Therap y for Hepatitis B: HBeAg Seroconversion, HBsAg 
Seroconversion, Histologic I mprovement, and Possible I mpact on Risk of 
Hepatocellular Carcinoma. Curr Hepatiti s Rep 2011;10.
Chuang TH, Ulevitch RJ. Cloning and characterization of a sub -family  of human toll -like 
receptors: hTL R7, hTLR8 and hTL R9. Eur Cy tokine Netw 2000;11 (3):372 -8.
Dienstag J L, Goldin RD, Heathcote EJ, Hann HWL, Woessner M, Stephenson SL , et al.
Histological outcome during long -term lamivudine therapy . Gastroenterology  
2003;124 (1):105 -17.
Ding X, Kaminsky  LS. Human Extrahepatic Cy tochromes P450: Function in Xenobiotic 
Metabolism and Tissue- Selective Chemical Toxicity  in the Respiratory  and 
Gastr ointestinal Tracts. Annu Rev Pharmacol Toxicol 2003;43:149 -73.
Du J, Wu Z, Ren S, Wei Y, Gao M, Randolph GJ, et al. TL R8 agonists stimulate newl y recruited 
monocy te-derived cells into potent APCs that enhance HBsAg immunogenicity . 
Vaccine 2010;28 (38):6273-81.
European Association for the Study  of the Liver. EASL  2017 Clinical Practice Guidelines on the 
Management of Hepatitis B Virus Infection. J Hepatol 2017;67 (2):370 -98.
European Association for the Study  of the Liver (EASL ). EASL  Clinical Practice Guidelines: 
Management of chronic hepatitis B virus infection [published version]. J 
Hepatology  2012;57:167-85.
Fattovich G, Giustina G, Sanchez -Tapias J, Quero C, Mas A, Olivotto PG, et al. Delay ed 
clearance of serum HBsAg in compensated cirrhosis B: relation to interferon 
alpha therap y and disease prognosis. Am J Gastroenterol 1998;93 (6):896-900.
G. B. D. Mortality  Causes of Death Collaborators. Global, Regional, and National L ife 
Expectancy , All- Cause Mortality , and Cause -Specific Mortalit y for 249 Causes of 
Death, 1980-2015: A S ystematic Anal ysis for the Global Burden of Disease Study  
2015. L ancet 2016;388:1459-544.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, 
Moradi -Lakeh M, et al. The Global Burden of Cancer 2 013. JAMA oncology  
2015;1 (4):505 -27.
Gorski KS, Waller EL , Bjornton -Severson J, Hanten JA, Riter CL , Kieper WC, et al. Distinct 
indirect pathway s govern human NK -cell activation by  TLR -7 and TL R-8 
agonists. International immunology  2006;18 (7):1115-26.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 99 27 August 2019Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti -viral compounds 
activate immune cells via the TL R7 My D88-dependent signaling pathway . Nature 
immunology  2002;3 (2):196 -200.
Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozday i M, et al. Hepatitis B surface antigen 
seroconversion is associated with favourable long- term clinical outcomes during 
lamivudine treatment in HBeAg- negative chronic hepatitis B patients. J Viral 
Hepat 2012;19 (3):220 -6.
Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan -Garcia A, et al. Toll- like receptor 8 agonist 
and bacteria trigger potent activation of innate immune cells in human liver. PL oS 
pathogens 2014;10 (6):e1004210.
Kim GA, L im YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside 
analogue therap y in patients with chronic hepatitis B: clinical outcomes and 
durability . Gut 2013;63:1325 -32.
Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR. Expression of 
Cytochromes P450 1A1 and 1B1 in Human Lung from Smokers, Non-Smokers, 
and Ex -Smokers. Toxicol Appl Pharmacol 2004;199 (3):210 -9.
Kwon H, Lok AS. Hepatitis B therap y. Nature reviews. Gastroenterology  & hepatology  2011;8 
(5):275-84.
Liaw Y -F, Kao J -H, Piratvisuth T, Chan HL Y, Chien R -N, Liu C -J, et al. A sian- Pacific 
consensus statement on the management of chronic hepatitis B: a 2012 update. 
Hepatol International 2012;6:531-61.
Liaw YF. Impact of hepatitis B therapy  on the long -term outcome of liver disease. Liver Int 
2011;31 Suppl 1:117 -21.
Liu J, Xu C, Hsu L C, Luo Y, Xiang R, Chuang TH. A five -amino-acid motif in the undefined 
region of the TLR8 ectodomain is required for species -specific ligand recognition. 
Mol I mmunol 2010;47 (5):1083 -90.
Lok AS. Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet? J 
Hepatol 2009;51 (2):416-8.
Lok AS. Hepatitis: L ong-term therap y of chronic hepatitis B reverses cirrhosis. Nature reviews. 
Gastroenterology  & hepatology  2013;10 (4):199 -200.
Lu H, Dietsch GN, Matthews MAH, Yang Y, Ghanekar S, Inokuma M, et al. VTX- 2337 is a 
novel TL R8 agonist that activates NK cells and augments ADCC. Clin Cancer 
Res 2012;18:499-509.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 100 27 August 2019Moucari R, Korevaar A, Lada O, Martinot- Peignoux M, Boy er N, Mackiewicz V, et al. High 
rates of HBsAg seroconversion in HBeAg-pos itive chronic hepatitis B patients 
responding to interferon: a long -term follow -up study . J Hepatol 2009;50 
(6):1084-92.
Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, et al. A phase 
I dose -finding study  of the novel Toll -like re ceptor 8 agonist VTX -2337 in adult 
subjects with advanced solid tumors or lymphoma. Clin Cancer Res 2014;20 
(14):3683-91.
O'Neill LA, Golenbock D, Bowie AG. The history of Toll -like receptors - redefining innate 
immunity . Nature reviews 2013;13 (6):453 -60.
Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, et al. Toll -Like Receptor 8 –Mediated 
Reversal of CD4+ Regulatory  T Cell Function. Science 2005;309 (5739):1380 -
4.
Peppa D, Micco L, Javaid A, Kenned y PT, Schurich A, Dunn C, et al. Blockade of 
immunosuppressive cy tokines restores NK cell antiviral function in chronic 
hepatitis B virus infection. PL oS pathogens 2010;6 (12):e1001227.
Rehermann B, Nascimbeni M. I mmunology  of hepatitis B virus and hepatitis C virus infection. 
Nature reviews 2005;5 ( 3):215 -29.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian -Pacific clinical practice 
guidelines on the management of hepatitis B: a 2015 update. Hepatol I nt 2015.
Schweitzer A, Horn J, Mikolajczy k RT, Krause G, Ott JJ. Estimations of wor ldwide prevalence 
of chronic hepatitis B virus infection: a sy stematic review of data published 
between 1965 and 2013. Lancet 2015;386:1546- 55.
Simonetti J, Bulkow L , McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of 
hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort 
chronicall y infected with hepatitis B virus. Hepatology 2010;51 (5):1531 -7.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASL D guidelines 
for treatment of chronic hepatitis B. Hepatology  2016;63 (1):261 - 83.
Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, Borlak J. Expression of Xenobiotic 
Metabolizing Enzy mes in Different Lung Compartments of Smokers and 
Nonsmokers. Environ Health Perspect 2006;114 (11):1655-61.
Whelton SP, Narla V, Blaha MJ, Nasir K, Blumenthal RS, Jenny  NS, et al. Association between 
resting heart rate and inflammatory  biomarkers (high- sensitivity  C -reactive 
protein, interleukin -6, and fibrinogen) (from the Multi -Ethnic Study  of 
Atherosclerosis). The American journa l of cardiology  2014;113 (4):644 -9.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 101 27 August 2019Wille -Reece U, Fly nn BJ, L ore K, Koup RA, Miles AP, Saul A, et al. Toll -like receptor agonists 
influence the magnitude and quality  of memory  T cell responses after prime -boost 
immunization in nonhuman primates. J Exp Med 2006;203 (5):1249 -58.
World Health Organization (WHO). Hepatitis B. Introduction. Available at: 
http://www.who.int/csr/disease/hepatitis/whocdscsrly o20022/en/index1.html . 
Accessed: 03 August 2015.
Wright TL . Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006;101:6.
Yi YH, Kim YJ, Lee SY, Cho BM, Cho YH, Lee JG. Health Behaviors of Korean Adults with 
Hepatitis B: Findings of the 2016 Korean National Health and Nutrition 
Examination Survey . World J Gastroenterol 2018;24 (28):3163 -70.
Zuck erman AJ. Progress towards the comprehensive control of hepatitis B. Gut 1996;38 (2):S1.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 102 27 August 201911. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedure Table(s)
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
PPD
PPDGS-9688 
Protocol GS-US-389-2024 Final 
Gilead Sciences , lnc. Amendment 2.1 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the 
Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Subjects with 
Chronic Hepatitis B 
GS-US-389-2024 Protocol Amendment 2.1, 27 August 2019 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to a11 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Princi pal Investigator Name (Print ed) Signature 
Date Site umber 
CONFID ENTIAL Page 103 27 August2019 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTI AL Page 104 27 August 2019Appendix 2. Study Procedure Table (s)
Part A. Study Procedures Required at Screening Visit
Screening Study Procedures –Window (
-30days)
Written Informed Consent
Revie w of Inclusion/Exclusion Criteria
Medical History (including HBV disease and treatment history)
Ophthalmologic Exama
Com plete Physical Exam (Including Height, Weight and BMI)
Vital Signs (blood pressure, heart rate, respiration rate and body temperature)
Safety Labs (hematology, serum chemistry, and coagulation)
HIV, HDV, and HCV Testingb
12-Lead ECG
Fibrotest
Alpha Fetoprotein
Urinalysis 
Urine Drug Screen
Serum Pregnancy Test (for all female subjects of child -bearing potential)
Follicle -stimulating Hormone (FSH, for female subjects post -menopausal for less than two years )
Qualitative HBV Serologyc
HBV DNA levels
HBV Resistance Surveillance
HBV Genotyping (B y history if known)
Quantitative HBsAg
Revie w AEs & Concomitant Medications
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTI AL Page 105 27 August 2019Part B. Study Procedure Table (On and Post GS -9688/PTM Treatment Assessments )
On Treatm ent Post GS -9688/PTM Treatm ent
Days Weeks
Windows (±1 Days) (±3 Days)
Study ProceduresBaseline
(Day 1)Day 2
(Day 1 
+24hrs) 2 4 8 11 12 16 20 2323
+24 hrs 24 28 36 48 EDn
Ophthalmologic 
Exama X X
Health Related 
Quality of Life 
SurveysX X X X X
Com plete Physical 
ExamX X X X X X X X X X
Symptom Directed 
Physical ExamX X X X X X
Vital Signs
(blood pressure, heart 
rate, respiration rate 
and body temperature)X X X X X X X X X X X X X X X X
Safety Labs 
(Hem atology, Serum 
Chemistry, and 
Coagulation) X X X X X X X X X X X X X X
Holter MonitoringfX X X X X
Fibrotest X X X X
Urinalysis X X X X X X X X X X X X X X
Serum Pregnancy Test X X X X X X X X X X X
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTI AL Page 106 27 August 2019On Treatm ent Post GS -9688/PTM Treatm ent
Days Weeks
Windows (±1 Days) (±3 Days)
Study ProceduresBaseline
(Day 1)Day 2
(Day 1 
+24hrs) 2 4 8 11 12 16 20 2323
+24 hrs 24 28 36 48 EDn
Urine Pregnancy Test X X X
Qualitative HBV 
Serologyc X X X X X X
HBV DNA levels, 
HBV Resistance 
Surveillance,  
Quantitative HBsAgX X X X X X X X X X X X X X
Quantitative HBCrAg,  
Quantitative HBeAg,  
HBV RNA X X X X X X X X X X X
Randomization X
In Clinic 
GS-9688 Dosing & 
AccountabilitygX X X X X X X X X
Sparse (pre -identified) 
plasma PKh X X X X X
Sparse (timed) plasma 
PK sample Collectioni X X X X X X
Serum andPlasma PD 
Biomarkersk X X X X X X X X X X X X
TruCulture X
CCII I I 111 I I I I I I I I I I 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTI AL Page 107 27 August 2019On Treatm ent Post GS -9688/PTM Treatm ent
Days Weeks
Windows (±1 Days) (±3 Days)
Study ProceduresBaseline
(Day 1)Day 2
(Day 1 
+24hrs) 2 4 8 11 12 16 20 2323
+24 hrs 24 28 36 48 EDn
PBMC CollectionlX X X X X X X X X
TLR8 SNP Collect TLR8 SNP genotyping sample on Day 1 but may be collected at any time during the study or at any unscheduled visit.
Whole Blood gene 
expression 
biomarkersmX X X X X X X X X
Revie w AEs & 
Concomitant 
MedicationsX X X X X X X X X X X X X X X X
CCI
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTI AL Page 108 27 August 2019Part C . Study Procedure Table ( Treatment Free Follow -up)o
TFFU Week
(Study Week)
Windows (±7Days)
Study Procedures4
(52)8
(56)12
(60)16
(64)20
(68)24
(72)36
(84)48
(96)
Health Related Quality of Life Surveys X X X
Symptom Directed Physical Exam X X X X X X X X
Vital Signs
(blood pressure, heart rate, respiration rate and body 
temperature)X X X X X X X X
Safety Labs (Hematology, Serum Chemistry, and 
Coagulation) X X X X X X X X
Urinalysis X X X X X X X X
Serum Pregnancy Test X X X X X X X X
Qualitative HBV SerologycX X X X X X X X
HBV DNA levels,  HBV Resistance Surveillance,  
Quantitative HBsAgX X X X X X X X
Quantitative HBCrAg,  Quantitative HBeAg,  HBV RNA X X X X X X X X
PBMC CollectionlX X X X X X X X
Whole Blood gene expression biomarkersmX X X X X X X X
Revie w AEs & Concomitant Medications X X X X X X X X
CCI
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTI AL Page 109 27 August 2019a Ophthalmologic Exam window at Screening will be (Days -10 to -1) ,Weeks 12 and 24 (Days -4 to +10) 
b In the event of a positive result and/or antigen testing for HIV, HDV, or HCV serology, reflex tests will automatically be pe rformed
c Qualitative HBV serology consists of HBeAg and HBsAg and reflex HBeAb and reflex HBsAb
d
 
 
e
 
 
 
 
f Holte r Monitoring to be collected prior to blood co llection on Day 1 and Week 23 at  pre-dose ( ≤ 5minof dose )through 4 hours, and 24 hours; Week 11 at pre -dose 
(≤ 5 minof dose )through 4 hours 
g Inaddition to the clinic GS -
9688 study drug dosing , self/home GS-9688 study drug dosing will be on Weeks 1, 3, 5, 6, 7, 9, 10, 13, 14, 15, 17, 18, 19, 21, and 22   
h Sparse (pre -identified ) PK plasma sampl ingwill occur on Day 1 and Week 23at pre -dose, 1, 4, and 24 hours post -dose and at Week 11 at pre- dose, 1, and 4 hours post -dose.
i Sparse (timed ) plasma PK samples will be obtained on any two of the following visits: Weeks 2, 4, 8, 12, 16, and/or 20 at pre-dose and any time between 30 min utesto 
4hourspost-dose.
j  
k Serum/plasma PD biomarkers will be collected on Day 1 and Week 23 at pre -dose, 4 and 24 hours post -dose; Weeks 2, 8, 12, 16, 20, 24 and 28 pre -dose; and Week 11 
pre-dose and 4 hours pose -dose.
l PBMC samples collected on Day s 1 and 1+4 hours,1 + 24 hours, and on Week s11, 11+4 hours, 12, 23, 23 + 4 hours, 23 + 24 hours, 24, 48/ED , and during TFFU.  See also 
footnote d for collection of Leukapheresis samples in lieu of PBMC samples
m Whole blood gene expression (Paxgene RNA) 
samples collected on Days 1 and 1+4 hours, 1 + 24 hours, and on Week s11, 11+4 hours , 12, 23, 23 + 24 hours, 24, 48/ED , and 
during TFFU
n The ED visit should be performed within 1 week if ED occurs before Week 24; after week 24 ED should be performed within 2 weeks from notification of study 
discontinuation 
o At Week 48, at PI discretion, if a subject discontinues OAV treatment, the subject will be followed every 4 weeks for the first 24 weeks and thereafter at Week 36 and Week 
48 (TFFU phase) . At the PI’s di scretion, subject(s) in the TFFU phase may restart commercially available CHB OAV treatment at any time per local treatment guidelines . If 
a subject restarts OAV therapy for their CHB, TFFU visits will continue for 2 more TFFU visits or until the end of the TFFU p hase (Week 96), whichever comes first.
CCI
CCI
CCI
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 110 27 August 2019Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically
 documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause.  In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therap y.
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
b)Definition of Male Fertility
For the purposes of this study, a male born subject i s considered fertile after the initiation of 
puberty  unless the subject is permanently  sterile by  bilateral orchiectomy  or medical 
documentation.
2)Contraception Requirements for Female Subjects
a)Study Drug Effects on Pregnancy and Hormonal Contraceptio n
The risks of treatment with GS -9688 during pregnancy  have not been evaluated. The 
reproductive and developmental toxicity  studies with GS -9688 have not been conducted to date. 
Drug -drug interaction (DDI) with hormones used for contraception is not availa ble. Therefore, 
the use of hormonal contraception with GS- 9688 is not recommended. Pregnancy  must be 
excluded before the start of treatment with study  drug and prevented thereafter by  reliable, 
highl y effective contraceptive methods. Pregnancy tests will b e performed regularl y throughout 
this study .Please refer to the latest version of the IB for additional information.
b)Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential req uires the use of highl y effective 
contraceptive measures. They  must also not rely  on hormone -containing contraceptives as a form 
of birth control during the study . They  must have a negative serum pregnancy test at screening 
and a negative pregnancy test at the baseline/Day -1 visit prior to randomization/enrollment. 
Female subjects must agree to 1 of the following from screening until 30 days following the end 
of relevant sy stemic exposure:
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 111 27 August 2019OR
Consistent and correct use of 1 of the following methods of birth control listed below: 
Intrauterine device with a failure rat e of < 1% per y ear
Tubal sterilization
Essure®microinsert s ystem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 mon ths after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 day s after the end of relevant sy stemic exposure.
3) Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condoms during treatment and until 90 days after the 
end of relevant s ystemic exposure. Additional contraception recommendations should also be 
considered if the female partner is not pregnant.
Male subjects must also refrain from sperm donation during treatment and until at least 90days 
after the end of relevant sy stemic exposure. 
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, 
symptothermal, postovulation methods), withdrawal (coitus interruptus), spermi cides onl y, and 
lactational amenorrhea method. A female condom and a male condom should not be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 30 day s (90 day s for female partners of male 
subjects) of last study  drug dose. Subjects who become pregnant or who suspect that they  are 
pregnant during the study , including TFFU, must report the informa tion to the investigator and 
discontinue study  drug immediately . Subjects whose partner has become pregnant or suspects 
she is pregnant during the study  must report the information to the investigator. Instructions for 
reporting pregnancy , partner pregnanc y, and pregnancy  outcome are outlined in Section 7.10.2.1.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 112 27 August 2019Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 
57Days8.5to10.0 g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 
57Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1 –21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
Absolu te Neutrophil Count 
(ANC)
Adult and Pediatric, 
≥ 7 Months#1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 113 27 August 2019HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/d L 50mg/d L
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60 mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time (APTT) 1.00 to 1.66 ULN 1.66 to 2.33 ULN 2.33 to 3.00 ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0% 
# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the Gilead convention of grading 
any result within the LLN and ULN a 0. 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 114 27 August 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to 130mEq/L 121 to 125mEq/L 121 mEq/L
130 to <LLN mmol/L 125 to 130mmol/L 121 to 125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to  <LLN mEq/L 2.5 to 3.0mEq/L 2.0 to 2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to 3.0mmol/L 2.0 to 2.5mmol/L 2.0 mmol/L
Infant  <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to 3.0mEq/L
2.5 to <3.0 mmol/L2.0 to 2.5mEq/L
2.0 to <2.5 mmol/L2.0 mEq/L
<2.0 mmol/L
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant  <1 Year >ULN to 6.0 mEq/L
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL
3.03 to 3.58 mmol/L40 to 55mg/d L
2.20 to 3.03 mmol/L30 to 40mg/d L
1.64 to 2.20 mmol/L30 mg/dL
1.64 mmol/L
Infant, 1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/d L
2.2 to 2.8mmol/L30 to 40mg/d L
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 115 27 August 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmol/L7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L6.1 to 7.0mg/dL
1.51 to 1.74 mmol/L6.1mg/d L
1.51 mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL
1.74 to <1.94 mmol /L6.1 to  <7.0 mg/dL
1.51 to < 1.74 mmol/L< 6.1 mg/dL
< 1.51 mmol/L
Infant, 7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant, 7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to 2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to 0.74 mmol/L 0.49 to 0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to 1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to 0.58 mmol/L 0.28 to 0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmol/L2.5 to 3.0 mg/dL
0.80 to <0.96 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 116 27 August 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
>513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia
Adult and Pediatric
≥ 1 year
Infant  < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to 1.5 mg/dL
57 to 87 μmol/L0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
Creatinine** 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL 
265 to 530 μmol/L6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to 16.0 mEq/L 8.0 to 11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to 16.0 mmol/L 8.0 to 11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/L to <LLN 8.0 to 11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to 11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 117 27 August 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/d L NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to 6.0 ULN 6.0 to 10.0 ULN 10.0 to 20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs.  Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.  
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 118 27 August 2019ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 119 27 August 2019URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) 
See Note below
Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to 999 mg/24 h >999 to 1999 mg/24 h >1999 to 3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to 499 mg/m2/24h >499 to 799 mg/m2/24 h >799 to 1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
 If the severity of a clinical AE could fall u nder either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 120 27 August 2019CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, 
non-life-threatening AND 
Non-urgent medical 
intervention indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac- ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hem orrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140–159mmH g systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 121 27 August 2019CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secCom plete AV block 
Pediatric 16 Years 1st degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Com plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated 
(eg, anticoagulation, lysis 
filter, invasive procedure) Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Embolic event (eg, pulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms 
OR Worsening symptomat ic 
CHFLife-threatening CHF
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 122 27 August 2019RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respiratory 
DistressDyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities Dyspnea on exertion causing 
greater than minimal 
interference with usual social & 
functional activities Dyspnea at rest causing 
inabilit y to perform usual 
social & functional 
activities Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate for 
ageNasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional 
activities OR Pulse 
oximetry 90%Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional 
activitiesDisabling visual loss in affected 
eye(s)
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 123 27 August 2019SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)Thinning or patchy hair loss 
detectable by health care 
providerCom plete hair loss NA
Cutaneous Reaction –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activities NA
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 124 27 August 2019GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutrition]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)Symptomatic despite 
interventionLife-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
episodes of unformed stools 
OR Increase of 3stools 
over baseline/24 hourPersistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24hours. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicate d OR Hypotensive 
shock
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 125 27 August 2019GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life -threatening 
consequences (eg, aspiration, 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 
24-48hoursPersistent nausea resulting in 
minimal oral intake for 
48hours OR Aggressive 
rehydration indicated 
(eg,IVfluids)Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis 
(functional -symptomatic)
Also see Mucositis/ 
Stomatit is for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg, perforation)
Vom iting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent episodes of vomiting 
with no or mild dehydrationPersistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicatedLife-threatening consequences 
(eg, hypotensive shock)
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 126 27 August 2019NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in 
Personality -Behavior or in 
Mood (eg, agitation, 
anxiety, depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual so cial & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others 
(eg,suicidal/homicidal 
ideation or attempt, acute 
psychosis) OR Causing 
inability to perform basic 
self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activities Disabling ataxia causing 
inability to perform basic 
self-care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability cau sing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 127 27 August 2019NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or
other neurologic function 
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic 
self-care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle 
weak -ness causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social & 
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling se nsory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 128 27 August 2019NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive 
(eg,status epilepticus), or 
difficult to control 
(eg,refractory epilepsy)
Seizure: (pre- existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
LevelsNA Increased frequency of pre-
existing seizures 
(non-repetitive) without 
change in seizure character 
OR infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality 
(eg,severity or focality) Seizures of any kind that are 
prolong ed, repetitive 
(eg,status epilepticus), or 
difficult to control 
(eg,refractory epilepsy)
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
5-20minutes with 
<24hours post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic 
self-care functions
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 129 27 August 2019MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic 
self-care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional 
activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activi tiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0 BMD t -score or z- score –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional 
activitiesDisabling muscle pain causing 
inability to perform basic 
self-care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain 
with radiographic findings 
OR Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic 
self-care functions
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 130 27 August 2019SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR 
Life-threatening 
bronchospasm OR laryngeal 
edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6 C
99.8F to 101.5 F38.7C to 39.3 C
101.6 F to 102.8 F39.4C to 40.5 C
102.9 F to 104.9 F40.5C 
104.9 F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic 
self-care functions OR 
Hospitalization (other than 
ERvisit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated 
[eg,tube feeding or total 
parenteral nutrition]
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 131 27 August 2019INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional 
activitiesPain/tenderness causing inability 
to perform basic self-care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 9 9cm 
(or2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythema OR Induration 
OR Edema present but 
2.5cm diameterErythema OR Induration OR 
Edema > 2.5cm diam eter but 
<50% surface area of the 
extremity segment (eg, upper 
arm/thigh)Erythema OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment 
(eg,upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional 
activitiesNA
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 132 27 August 2019ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious 
changes on casual visual 
inspectionNA
Diabetes Mellitus NA New  onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
controlNew  onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities , 
buttocks)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 133 27 August 2019GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycleHem orrhage with 
life-threatening hypotension 
OR Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing 
life-threatening 
consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic an tiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. Usual Social & Functional Activities: Adaptive tasks
GS-9688
Protocol GS -US-389-2024 Final
Gilead Sciences, Inc. Amendment 2.1
CONFIDENTIAL Page 134 27 August 2019
